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Medulloblastom (MB), der häufigste bösartige pädiatrische Hirntumor, umfasst vier molekular und 
genetisch verschiedene Untergruppen von embryonalen Hirntumoren, die sich im Kleinhirn entwickeln. 
MB betrifft vor allem Säuglinge und Kinder und zeichnet sich durch ein hohes Risiko einer metastatischen 
Verbreitung aus, welcher die Infiltration von Tumorzellen in das Hirngewebe vorausgeht. Die molekularen 
Mechanismen, welche die MB-Tumorzellinfiltration kontrollieren, sind zurzeit noch unklar und es existiert 
bisher keine spezifische Therapie, welche die Verbreitung der Tumorzellen unterbindet. Aktuelle 
Behandlungsstrategien beim MB, insbesondere die kraniospinale Strahlentherapie angewandt zur 
Verhinderung der metastatischen Verbreitung, können langfristige Nebenwirkungen für das sich 
entwickelnde Zentralnervensystem der Patienten verursachen. Daher sind Therapien, welche die 
Tumorzellinfiltration und die metastatische Verbreitung spezifisch verhindern dringend nötig, da diese die 
therapeutische Wirksamkeit erhöhen und langfristige Nebenwirkungen verringern könnten. 
Die Krebszellverbreitung ist stark mit einer abweichenden oder überhöhten Kinaseaktivität assoziiert. In 
der vorliegenden Studie haben wir die Ser/Thr Kinase MAP4K4 als ein Molekül im MB identifiziert, 
welches massgeblich zur Zellmigration beiträgt. Mittels immunhistochemischer Analysen von 
Tumorgewebe und quantitativen PCR Methoden haben wir eine erhöhte Expression von MAP4K4 in einer 
Reihe von primären MB Proben im Vergleich zum normalen Cerebellum festgestellt. Dies deutet darauf 
hin, dass die MAP4K4 das invasive Potenzial der MB Tumorzellen erhöhen könnte. 
Die c-Met Rezeptor Tyrosinkinase ist ein Protoonkogen, welche in vielen soliden Tumoren einschliesslich 
dem MB in erhöhter Menge vorliegt und zur Tumorzellverbreitung beiträgt. Unter Verwendung eines 
zellbasierten dreidimensionalen Zellmotilitätsassays, kombiniert mit lebend-Zell Mikroskopie, fanden wir, 
dass der c-Met Ligand HGF die MB Zellmotilität stark erhöht. Dies ist insbesondere in denjenigen MB-
Zelllinien der Fall, in denen viel c-Met vorliegt. Wir konnten aufzeigen, dass MAP4K4 die c-Met-abhängige 
invasive Zellmigration im MB vermittelt und zwar mittels der Kontrolle des F-Aktin Zellskelettes in 
Lamellipodien, den Strukturen, welche für die Migration und Invasion der MB Zellen erforderlich sind.  
Ionisierende Photonenstrahlen-Therapie ist eine gängige therapeutische Modalität für MB. Allerdings 
fanden mehrere Untersuchungen, dass Photonenstrahlung die Tumorzellmigration verstärken kann. Da 
der Beitrag der Photonenstrahlung zur MB Zellverbreitung umstritten ist, untersuchten wir die 
Auswirkungen von Photonenstrahlung auf das Migrations- und Invasionsverhalten der SHH-MB Zelllinien 
DAOY und UW228. Wir fanden, dass Photonenstrahlung von 1 bis 2 Gray die Zellmigration und die 
Invasion in beiden Linien erhöht. Interessanterweise war dieser Effekt der Photonenstrahlung in den MB 
Zellen stark reduziert, in denen wir die MAP4K4 gezielt eliminiert hatten. Obwohl diese Erkenntnisse die 
Relevanz der MAP4K4 im Rahmen der MB Zellverbreitung weiter hervorhoben, blieben die diesem 
Vorgang zugrunde liegenden molekularen Mechanismen nach wie vor unklar. 
Die Stimulation von MB Zellen mit HGF löst sehr dynamische Membranausstülpungen aus und erhöht die 
endozytotische Aktivität, zwei Prozesse, die ebenfalls mit der Tumorzellmigration einhergehen. Wir haben 
daher die Implikation der MAP4K4 in der HGF-induzierter Endozytose und dem vesikulären Transport 
untersucht. Beide Funktionen hängen von der dynamischen Reorganisation des F-Aktin-Zellskeletts ab. 
Wir entdeckten, dass die MAP4K4 nicht nur die HGF-induzierte Makropinozytose, sondern auch die 
Internalisierung des c-Met-Rezeptors und die Aktivierung dessen Effektors ERK beschleunigt. Wir wiesen 
ferner nach, dass die von HGF angeregte Migration und Invasion von MB Zellen vom Adhäsionsrezeptor 
Integrin β1 (ITGB1) abhängt und mit einer erhöhten ITGB1-Aktivierung in Lamellipodien der MB-Zellen 
korreliert. Wir zeigten, dass die beeinträchtigte Migration und Invasion in MB Zellen mit verminderter 
MAP4K4 Expression nicht nur eng mit der verminderten ITGB1-Endozytose korreliert, sondern auch mit 
der Reduktion der Menge aktiven ITGB1 in den Lamellipodien. 
Zusammengefasst identifizierte diese Studie eine prominente regulatorische Rolle von MAP4K4 im 
Zusammenhang mit der Verbreitung von MB Tumorzellen. Sie wies nach, dass MAP4K4 die Signale von 
Wachstumsfaktorrezeptoren auf die Regulation des Aktin Zellskelett überträgt, sowie die endozytotische 
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Aktivität der Tumorzellen steuert. Dies bedeutet, dass MAP4K4 ein vielversprechendes therapeutisches 
Ziel darstellen könnte, welches zur Behandlung der Wachstumsfaktor-induzierten Verbreitung von MB 
Tumoren weiter untersucht werden sollte. Darüber hinaus identifizierte unsere Studie die 
wachstumsfaktorinduzierte, erhöhte endozytische Aktivität und räumliche Kontrolle der 
Adhäsionsrezeptoraktivierung als neuartige, möglicherweise therapierbare Mechanismen in der MB 
Tumorzelle. Wir zeigen, dass diese durch die proto-onkogene Kinase MAP4K4 vermittelt werden und 
vermuten, dass MAP4K4 dadurch mithilft einen invasiven und bestrahlungsbeständigen Phänotyp in MB 
Tumorzellen zu etablieren. 
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Summary 
 
Medulloblastoma (MB), the most common malignant pediatric brain tumor, comprises four 
molecularly and genetically distinct subgroups of embryonal brain tumors that develop in the cerebellum. 
MB mostly affects infants and children and is characterized by a high risk of metastatic dissemination, 
which is preceded by the infiltration of tumor cells into the brain tissue. The molecular mechanisms that 
control MB tumor cell infiltration are only poorly understood and no specific anti-dissemination therapy 
exists so far. Current MB treatment strategies, in particular the craniospinal radiotherapy to prevent 
metastatic outgrowth, can cause long-term side effects for the developing central nervous system of the 
patients. Therefore, therapies that target tumor cell infiltration and metastatic dissemination specifically, 
are urgently needed to increase efficaciousness of therapy and to decrease late-treatment complications. 
Cancer cell dissemination is strongly associated with aberrant kinase signaling. In the present 
study, we have identified the Ser/Thr kinase MAP4K4 as a pro-migratory kinase in MB. Using tumor tissue 
micro array, immunohistochemistry analyses and quantitative PCR methods, we have revealed increased 
expression of MAP4K4 in a number of primary MB samples compared to normal cerebellum, suggesting 
that MAP4K4 could increase the invasive potential of the MB tumor cells by promoting cell dissemination. 
A well-known promoter of cell dissemination is the proto-oncogene receptor tyrosine kinase c-Met, 
which is aberrantly expressed in many human tumors including MB. Using a cell-based three-dimensional 
cell motility assay combined with live-cell imaging, we found that the c-Met ligand HGF induces cell 
dissemination in MB, especially in cell lines expressing increased c-Met levels. Additionally, we identified 
MAP4K4 as a novel driver of c-Met-dependent invasive cell dissemination in MB. This increased invasive 
motility was attributed to MAP4K4 control of F-actin dynamics in lamellipodia, structures required for 
migration and invasion.  
Ionizing photon radiation (IR) therapy is a common therapeutic modality for MB. However, several 
reports found that IR can increase tumor cell migration. Since IR contribution to MB cell dissemination still 
remains controversial, we investigated its effects on migration and invasion in the SHH MB cell lines 
DAOY and UW228. We found that IR increases cell migration and invasion in both lines and that these 
pro-migratory effects of IR were greatly reduced when MAP4K4 was depleted. Although these findings 
further underscored the relevance of MAP4K4 in the context of MB cell dissemination, the underlying 
molecular mechanisms remained unclear. 
 We found that HGF stimulation of MB cells triggers membrane ruffling and enhances endocytic 
activity, processes that are associated with tumor cell migration. We have therefore examined MAP4K4 
implication in HGF-induced endocytosis and vesicle trafficking, two processes depending on dynamic 
reorganization of the F-actin cytoskeleton. We found that MAP4K4 not only promoted HGF-induced 
macropinocytosis but also accelerated c-Met receptor internalization and the activation of its downstream 
effector ERK. We furthermore found that HGF-driven migration and invasion of MB cells depend on the 
adhesion receptor Integrin β1 (ITGB1), and are associated with increased ITGB1 activation in lamellipodia 
of invading MB cells. We demonstrated that impaired migration and invasion after MAP4K4 depletion 
closely correlated with disrupted ITGB1 endocytosis and reduced levels of activated ITGB1 in lamellipodia 
of collagen-invading MB cells. 
In summary, our findings identified a prominent regulatory role of MAP4K4 towards MB tumor cell 
dissemination, and revealed that it couples growth factor signaling to actin cytoskeleton regulation and 
endocytic activity. This implies that MAP4K4 could present a promising novel target to be further 
evaluated for treating growth factor-induced dissemination of MB tumors. Furthermore, we discovered that 
enhanced endocytic activity and the spatial control of adhesion receptor activation and turnover through 
the proto-oncogenic kinase MAP4K4 is a novel, potentially druggable mechanism, which we suspect to 
sustain an invasive and IR-resistant phenotype in MB. 
 
1. Introduction 
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1.1 Cancer 
 
Cancer is a genetic disease that is caused by the accumulation of mutations and epigenetic 
alterations, which ultimately lead to the growth of a mutant clone. The cells within the entity of the mutant 
clone present uncontrolled proliferation/cell division rates, which subsequently give rise to the formation of 
a tumor or neoplasm. Provided that the neoplastic cells have not yet become invasive, the tumor is 
defined as benign. For the majority of such tumors, surgical resection or/and local irradiation of the mass 
leads to the cure of the patient (Weinberg 1983; Hanahan and Weinberg 2011; Hainaut and Plymoth 
2013).  
However, a tumor is considered to be cancerous provided that it is malignant, that is when the cells 
have acquired the capability to invade the surrounding tissue. Invasiveness is an essential characteristic 
of cancer cells since it allows them to escape from the local tumor, enter the bloodstream or lymphatic 
vessels, and form secondary tumors called metastases at other sites of the body (Fidler 2003) (Fig. 1). 
Malignant tumors are defined according to their tissue of origin. Carcinomas are cancers arising 
from epithelial cells and represent the most common human cancers. Carcinomas account for about 80% 
of cases probably due to the fact that epithelial cells present the highest proliferation rates. In addition, 
epithelial cells are the most likely to be exposed to various forms of physical and chemical damage that 
favor cancer development.  
Sarcomas originate from connective tissue or muscle cells, whereas cancers that do not belong in 
either of these two broad categories include leukemias and lymphomas, derived from white blood cells 
and their progenitors (hemopoietic cells), as well as cancers derived from cells of the nervous system.  
In parallel with the set of names for malignant tumors, there is a corresponding nomenclature for 
benign tumors. For instance, an adenoma, vs. a benign epithelial tumor and the corresponding type of 
malignant tumor is an adenocarcinoma. Similarly, a chondroma and a chondrosarcoma are, respectively, 
benign and malignant cartilage tumors (Weinberg 2014).  
Cancers originating from different cell types consist distinct diseases. Basal-cell skin carcinomas, 
for example, are only locally invasive and rarely metastatic, whereas melanomas are highly invasive and 
often form metastases. Basal-cell carcinomas are usually cured following surgery or local irradiation, 
whereas malignant melanomas, once they have metastasized, are usually fatal (Fidler 1999; Hainaut and 




Figure 1: Benign versus malignant tumors: A benign glandular tumor (pink cells) remains inside the basal lamina (yellow) that 
marks the boundary of a normal duct structure. In contrast, a malignant glandular tumor (red cells) derives from a benign tumor cells 




Estimates of the worldwide cancer incidence and mortality for 2012 reported 14.1 million new cases 
and 8.2 million deaths caused by cancer. Notably, the most frequently diagnosed malignancies were lung 
(1.82 million), breast (1.67 million) and colorectal (1.36 million), whereas the most common causes of 
1.1 Introduction - Cancer 
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cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths) and stomach cancer 




Figure 2: Estimated global numbers of new cases (thousands) with proportions for (a) more developed and (b) less 
developed regions worldwide, both sexes combined in 2012. The area of the pie is proportional to the number of new cases 
(Ferlay, Soerjomataram et al. 2015). 
 
1.1.2 Pediatric cancers 
 
Although cure rates for childhood cancers are higher compared to those for adult malignancies, 
cancer remains the leading cause of disease-caused death among children older than one year of age in 
developed countries. Interestingly, the spectrum of cancers occurring in the pediatric patients is 
considerably different from that seen in adults. For instance, the major brain and solid tumors that arise in 
children, including medulloblastoma, neuroblastoma, rhabdomyosarcoma, Ewing sarcoma and 
osteosarcoma, are exceedingly rare in adults (Fig. 3). This marked difference in the spectrum of cancers 
is not unexpected since the majority of pediatric cancers arise within developing tissues during early organ 
formation, growth and maturation, and are not strongly linked to lifestyle or environmental risk factors. With 
some exceptions, childhood cancers tend to respond better to certain treatments such as chemotherapy, 
whereas children (especially very young children) are more likely to be affected by radiation therapy. The 
unique biology of these developing tissues suggests that the spectrum of mutations that lead to malignant 




Figure 3: The frequency of cancer types in children (left) and adults (right) on the basis of 2012. Each chart is organized with 
cancers listed from the most common to the least common in a clockwise fashion (Downing, Wilson et al. 2012). 
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1.2 Embryonal brain tumors 
 
Embryonal brain tumors consist of a group of biologically heterogenous neuroepithelial tumors that 
comprise 3.3% of all malignant brain tumors and represent 15.7% and 4.3% of brain tumors diagnosed in 
patients between 0-14 and 15-19 years of age respectively (Bernstein, Sethi et al. 2013). Based on the 
histopathological features and genetic aberrations, the World Health Organization (WHO) 2016 classification 
has grouped the embryonal brain tumors into the following groups (Louis, Perry et al. 2016): 
 
• Medulloblastomas  
• ETMR (Embryonal tumors with multilayered rosettes) 
• ETMR NOS (not otherwise specified). 
• Medulloepithelioma. 
• CNS neuroblastoma. 
• CNS ganglioneuroblastoma. 
• CNS embryonal tumor NOS. 
• CNS AT/RT (atypical teratoid/rhabdoid tumor).  
• CNS embryonal tumor with rhabdoid features.  




Medulloblastomas (MBs) arise in the cerebellum (Fig. 4 & 5) and are the most common malignant 
pediatric brain tumors, accounting for 15-20% of all pediatric CNS tumors (Pizer, Donachie et al. 2011). 
Most of the cases occur in children aged up to 14 years old (6.8 per million), whereas the frequency 
decreases in the adult population (0.4-1% of all adult tumors). The median age at presentation of MB is 5-





Since MBs are posterior fossa tumors, a frequent symptom of MBs is hydrocephalus which is 
caused due to the compression of the fourth ventricle, with a consequent increase in intracranial pressure. 
Other common symptoms are vertigo, vomiting, ataxia and headache. Patients with a tumor localized in 
the mid-cerebellum may have symptoms that are related to compression of the cranial nerves (nystagmus, 
diplopia, hearing loss, seventh cranial palsies). On MRI, the appearance of MBs is variable. Typically, MB 
appears as a round, slightly lobulated, and T1-iso-/hypointense mass (Fig. 5) (Koeller and Rushing 2003).  
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Figure 4. Anatomy of the inside of the brain, showing the pineal and pituitary glands, optic nerve, ventricles (with 
cerebrospinal fluid shown in blue), and other parts of the brain. The posterior fossa is the region below the tentorium, which 





Figure 5: Medulloblastoma. Sagittal and axial T2‐weighted (a,b) and axial pre‐ and postcontrast T1‐weighted MR images (c,d) of a 
6‐year‐old boy with classical medulloblastoma. The mass lesion is located in the midline dorsally to the fourth ventricle and pushes 
the fourth ventricle anteriorly (arrow on a). The tumor is moderately T2‐hyperintense to the cerebellar and brainstem gray matter and 
shows a strong contrast enhancement. Mild perifocal T2‐hyperintense edema is seen within the vermis, dorsally to the tumor (white 





Survival rates depend on the age of the presenting patients, as well as on the applied treatment 
strategies. Interestingly, 5-year survival is better for the age group 5-14 years (67%), compared to the age 
group of 1-4 years (47%) (Kohler, Ward et al. 2011). Furthermore, it has been reported that treatment care 
entailing surgical resection followed by craniospinal irradiation and chemotherapy, results in overall cure 
1.2 Introduction - Medulloblastoma 
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rates of 70-75% for patients older than 3-5 years (Gatta, Botta et al. 2014). 
 
1.2.4 MB Histology 
 
According to the latest WHO classification of CNS tumors, MB tumors are classified into the 
following histological subtypes based on histopathological features (Louis, Perry et al. 2016): 
§ Classic MB 
§ Desmoplastic/Nodular MB 
§ MB with extensive nodularity (MBEN) 
§ Large cell anaplastic (LC/A) MB  
Among the above histological variants, large-cell anaplastic MBs occur with a frequency of 10-22%. 
Desmoplastic/Nodular MB and MBEN comprise approximately 7% and 3% of all MBs respectively, while 




Figure 6: Histopathologic subtypes of medulloblastoma: The histopathologic subtypes of medulloblastoma exist along a 
spectrum of differentiation and have been investigated for prognostic value, with some studies suggesting an improved prognosis for 
MBEN and desmoplastic subtypes and other studies showing a worse prognosis for LC/A. (Polkinghorn and Tarbell 2007).  
 
Classic MB is composed of densely packed cells with round-to-oval hyperchromatic nuclei 
surrounded by scanty cytoplasm. Desmoplastic/nodular MB is a variant that contains nodular, reticulin-free 
zones, or “pale islands” which represent zones of neuronal maturation. Classic MB exhibits a reduced 
nuclear to cytoplasmic ratio, a fibrillary matrix, and uniform cells with a neurocytic appearance. These 
nodules are surrounded by densely packed mitotically active cells, which produce a dense intercellular 
reticulin-positive network of fibers (Fig. 6).  
MB with extensive nodularity (MBEN) occurs mainly in infants and is associated with a good 
prognosis. It differs from the related nodular/desmoplastic variant by having an expanded lobular 
architecture (Fig. 6). 
The LC/A MB is composed of monomorphic cells with large, round, vesicular nuclei, prominent 
nucleoli and variably abundant eosinophilic cytoplasm. Groups or sheets of these “large cells” tend to mix 
with cells that have a different morphology characterized by marked nuclear pleomorphism and nuclear 
moulding. The latter phenotype has been labelled as “anaplastic” (Fig. 6). 
Histologic subtypes are associated with different outcome and thus have prognostic relevance for 
the patients. Clinical data have indicated favourable prognosis for the nodular/desmoplastic MB, whereas 
significantly worse prognosis has been evident for the LC/A variant (Massimino, Antonelli et al. 2013; 




Traditionally, MB patients are stratified into standard risk and high-risk groups according to age, 
residual tumor and metastatic disease at diagnosis. High-risk patients include those younger than 3 years 
of age or those having a residual tumor (>1.5 cm
2
) or disseminated disease at diagnosis and/or large 
cells/anaplastic histology (Packer, Rood et al. 2003). In fact, one third of the patients will have metastasis 
1.2 Introduction - Medulloblastoma 
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at the time of diagnosis and two thirds will have leptomeningeal spread by the time of relapse (MacDonald 
2008). Moreover, dissemination is the leading cause of treatment failure and the most powerful factor 
associated with poor survival (Zeltzer, Boyett et al. 1999). Therefore, correct staging is crucial for a reliable 
risk stratification of patients and is increasingly relevant for the selection of the appropriate therapeutic 
approach.  
Metastatic spread has higher incidence in children than adults (13% vs. 8%) (Frost, Laperriere et al. 
1995) and typically follows CSF and leptomeningeal dissemination along the spinal cord. The cerebellum 
and brain are the most common sites of metastases in conjunction with spinal diffusion. The time interval 
between diagnosis of the primary tumor and detection of metastases is usually shorter in children than 
adults (20 months vs. 36 months) (Brandes, Franceschi et al. 2009) 
 
1.2.6 MB treatment strategies 
 
The treatment for standard risk patients includes surgery, craniospinal irradiation and chemotherapy 
with reported 5-year overall survival of 80%. For patients with metastatic disease, the intensified treatment 
regimens including high-dose chemotherapy with autologous stem-cell transplantation and non-
conventional radiotherapy, have improved prognosis and 5-year overall survival rates between 50 and 
70% (Gajjar, Chintagumpala et al. 2006; Sanders, Onar et al. 2008). Among survivors, a major concern is 
the long-term sequelae caused by treatments which include endocrinological, neurocognitive, behavioral, 
motor and sensory deficits (Armstrong, Liu et al. 2009). Therefore, there is a critical need to identify new 




Surgical resection is the standard therapeutic approach for MB and since it is of high relevance of 
the outcome, maximum resection is usually aimed for. However, common complications include 
hemorrhage, meningitis, cervical instability and posterior fossa syndrome (swallowing difficulties, mutism, 




Photon radiotherapy remains the main treatment modality for MB patients older than three years 
old, with an onset of 4-6 weeks postoperatively and a maximum duration of 50 days [33,34]. Given the 
propensity of MB to disseminate via the CSF, current standard photon radiotherapy practices across the 
world involve the use of craniospinal irradiation with a boost to the posterior fossa/primary tumor area, 
which has raised the five-year progression-free (PFS) and overall survival (OS) rates from 0% to 50–60% 
in children older than 3 years. By then, a further increase of survival rates by 10–15% was achieved by the 
addition of maintenance chemotherapy (Fossati, Ricardi et al. 2009).  
Proton beam radiotherapy has evolved into an efficient but less toxic therapeutic modality for MB. 
The advantage of proton beam radiation therapy mainly comes from the difference in depth dose 
distribution as compared to standard photon beam radiation therapy. Furthermore, proton doses are lower 
in the normal tissues proximal to the target, reducing thus damage in the healthy tissue adjacent to the 
tumor. Using normal tissue complication probabilities to predict IQ deficits, proton therapy is expected to 
decrease the neuropsychological morbidity associated with photon irradiation, especially in children 
between 4-8 years of age. Proton therapy may also have the potential to decrease the incidence of 




Reduced dose of craniospinal irradiation is usually combined with chemotherapy provided in a 
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weekly concurrent single-drug (vincristine) dose followed by a multidrug regimen that can include cisplatin, 
lomustine, or cyclophosphamide. Based on this regimen, five-year event-free survival (EFS) is over 80% 
(Packer 1990).  
Favorable results with five-year progression-free survival and overall survival rates of more than 
80% have been obtained using a total craniospinal radiation dose of 23.4 Gy and a boost to the posterior 
fossa up to 54–55.8 Gy (with concomitant vincristine), followed by maintenance chemotherapy with 
cisplatin, vincristine, and either lomustine or cyclophosphamide (Lannering, Rutkowski et al. 2012; Packer, 




Although current treatment advances have significantly improved survival rates of MB patients, it is 
known that a high proportion of survivors eventually suffer from significant sequelae, including cognitive 
decline, impairment of growth and endocrine function, hearing loss, and secondary neoplasms, 
neuropsychological and behavioral deficits, which lead to significant impairment of quality of survival.  
Awareness of these sequelae is required not only for the choice of an adequate tumor treatment 
regimen, but also during aftercare. Quality of survival can be optimized by adequate information of the 
patient and his/her family, by detection and treatment of any sequelae, and by minimization of their 
repercussions on the daily life. Clearly, the development of novel treatment concepts, such as treatment 
de-escalation, alternative radiotherapy modalities and schedules (e.g. proton therapy), and incorporating 
of targeted agents into the treatment protocols aim towards the improvement of the quality of survival 
(Kiehna, Mulhern et al. 2006). 
Neurocognitive impairment is particularly important. Due to the variety of contributing factors (e.g. 
anatomical site of tissue destruction, radiation field and dose, chemotherapy regimens, and patient-related 
factors such as age or still little understood traits), the cognitive outcome of brain tumor patients is highly 
individual and only predictable to a certain degree. Although no homogeneous neuropsychological profile 
exists in MB patients, the most affected cognitive areas are mental processing speed, fine motor skills, 
working memory and concentration, with the magnitude of the effects often increasing over time (Palmer, 
Reddick et al. 2007; Duffner 2010).  
Behavioral and psychological outcomes of MB patients are also often impaired. Internalizing 
problems, higher global distress and depression are mentioned in the literature (Zebrack, Gurney et al. 
2004). Other common sequelae include neurological deficits (e.g. cerebellar dysfunction, posterior fossa 
syndrome) caused by tumor growth or by surgery, (Puget, Boddaert et al. 2009) sensorineural hearing 
deficits due to radiotherapy and ototoxic chemotherapy, and endocrinologic deficiencies due to damage of 
the hypothalamo-pituitary axis by irradiation (i.e. growth hormone deficiency, precocious or delayed 
puberty, hypothyroidism, hypocortisolism) (Packer, Gajjar et al. 2006). 
Considering the severity of the aforementioned treatment-related side effects for MB patients, the 
development of new alternative therapies that target MB dissemination while circumventing therapy-




1.2.7.1 MB Subgroups 
 
One of the most important advances in the increasing knowledge of MB is the discovery of 
molecular patterns allowing the division of MBs into distinct molecular subgroups with different 
cytogenetic, mutational and gene expression signatures, as well as different demographics, histology and 
prognosis. According to the above integrated genomic studies, MB is not considered as a single 
morphologically homogenous entity, but is in fact comprised of several different diseases at the molecular 
level. Large scale studies deciphering the transcriptional landscape of MB have revealed the following 
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distinct MB genetic subgroups, each one including unique survival, age, demographics, and genetic 
aberrations signature (Fig. 7, Table 1) (Northcott, Korshunov et al. 2011; Louis, Perry et al. 2016): 
• MB WNT-activated 
• MB SHH-activated and TP53-mutant 
• MB non-WNT/non-SHH 
• MB group 3 




Table 1: Summary of the most common integrated medulloblastoma diagnoses, with clinical correlates (Louis, Perry et al. 
2016). 
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Fig. 7: MB molecular subgroups (Cho, Tsherniak et al. 2011) 
WNT-activated MB 
 
WNT-activated MB consists the least common group of MB, accounting of 11% of all cases (Kool, 
Korshunov et al. 2012). WNT MB patients are often older children (10-12 years) and unlike in the other 
sugroups, gender ratio presents a female preponderance (Taylor, Northcott et al. 2012). Histology is 
generally classic, and most tumors are non-metastatic. (Gajjar and Robinson 2014), (Salaroli, Ronchi et al. 
2015). 
In the WNT-activated subgroup, over 75% of tumors harbor a point mutation in the CTNNB1 gene 
(encoding beta-catenin) (Fig. 8), leading to hyper-activation of the WNT (Wingless) pathway by rendering 
beta-catenin resistant to degradation and causing nuclear accumulation of the protein and subsequent 
increased transcription of genes involved in cellular proliferation including cyclin D1 and c-Myc (Koch, 
Waha et al. 2001; Gilbertson 2004). Cytogenetically, WNT tumors are characterized by the deletion of one 
copy of chromosome 6 (monosomy 6) in the majority of patients (79% of the tumors) and tetraploidy (14% 




Sonic Hedgehog (SHH) subgroup accounts for about 30% of all MBs and has a bimodal age 
distribution, occurring mostly in infants (< 3 years) and adults (>16 years), and less frequently in patients 
who are 3–16 years old (Gibson, Tong et al. 2010; Taylor, Northcott et al. 2012). The gender ratio is about 
1:1, although there is a slight male predominance among infants (Gajjar and Robinson 2014). Histology is 
typically of the nodular/desmoplastic type with MBEN and confers excellent prognosis rates in infants and 
young children (Zeltzer, Boyett et al. 1999; Rutkowski, von Hoff et al. 2010; von Hoff, Hartmann et al. 
2010; Lannering, Rutkowski et al. 2012). Patients in SHH group rarely have a disseminated tumor at 
diagnosis and generally have an intermediate prognosis, with a 5-year overall survival of approximately 
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75% when treated with standard therapy (Taylor, Northcott et al. 2012).  
The main characteristic of SHH MBs is the activation of SHH signaling (Fig. 8), which is caused by 
mutations in PTCH1, SUFU, SMO, or other components of the SHH cascade. 
Most common genetic aberrations in SHH subgroup include PTCH1 mutations (36–54% of the 
patients). However, SHH amplifications, mutations in SMO, SUFU, GLI2, MYC and MYCN genes also 
occur, with the latter comprising subgroups with a particularly poor prognosis (Eberhart, Kratz et al. 2002). 
Copy number aberrations include amplifications of protein phosphatase ID (PPM1D, chromosome 
17q23.2), IGF1R, IRS2, PIK3C2G, PIK3C2B, and YAP-1 along with PTEN deletion on chromosome 
10q23.31 and mutations in DDX3X (Northcott, Jones et al. 2012). Tetraploidy is present in about 29% of 
patients and it is associated with p53 mutations and chromothripsis (Jones, Jager et al. 2012).  
Notably, TP53 mutations often occur among SHH MBs conferring a poor prognosis, thus SHH-
activated MBs are considered to represent two distinct disease entities, depending on the TP53 genetic 
status. The two genetically distinct entities of SHH MB are ‘’MB SHH-activated and TP53-mutant’’ and 
‘’MB SHH-activated and TP53-wildtype’’. The latter occurs mostly in adolescents and young children and 
has good prognosis rates. On the contrary, TP53-mutant SHH MBs occur in older children and have very 




This MB subtype represents the majority of MBs lacking either WNT or SHH pathway activation 
(non-WNT/non-SHH MBs). These tumors often lack recurrent mutations but show frequent chromosomal 
copy number alterations such as isochromosome 17q. They can be further subdivided with DNA 
methylation profiling or mRNA expression studies in “group 3” and “group 4” MBs. c-Myc amplification is 
frequently found in young children with group 3 tumors, and metastatic disease at diagnosis and is 




Figure 8: SHH and WNT signaling pathways implicated in the formation of MB. SHH signaling is initiated when SHH binds to its 
receptor, PTCH1, which releases SMO from inhibition, resulting in the activation of GLI and MYCN. Upon WNT binding to its 
receptor, FRZ, the APC complex is destabilized, allowing β-catenin to enter the nucleus and activate downstream transcription 
factors. Note the shared mechanisms of inhibition between the two pathways, SUFU and GSK3β. Abbreviations: APC: adenomatous 
polyposis coli, Axin: axis inhibitor protein, β-cat: β-catenin, FRZ: Frizzled, GLI: zinc finger protein GLI1, GSK3β: glycogen synthase 
kinase 3 β, LEF1/TCF1: lymphoid enhancer-binding factor 1/T-cell specific factor 1, MYCN: N-myc proto-oncogene protein, PTCH1: 
Patched 1, SMO: Smoothened, SUFU: Suppressor of Fused (Marino 2005).  
 
Group 3 MB 
 
Group 3 accounts for 25–28% of cases and is found almost exclusively in infants and children and 
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rarely in adolescents, presenting a slight male predisposition. Group 3 MB is the worst prognosis 
subgroup, with patients having a high incidence of metastatic disease at the time of diagnosis and less 
than 50% survival rates (Kool, Korshunov et al. 2012). 
Most of these tumors harbor c-Myc amplifications which are responsible for aberrant MYC 
expression (Northcott, Jones et al. 2012). Genome instability is quite frequent and gains of 1q, 7, and 17q 
(i17q) are observed along with 10q, 11, 16q, and 17p deletions (Northcott, Jones et al. 2012). Tetraploidy 
is seen in 54% of group 3 tumours probably occuring as an early event in tumorigenesis (Jones, Jager et 
al. 2012). In a multivariate analysis, Shih and colleagues showed that the presence of i17q, MYC 
amplification, and presence of metastatic disease account for the poor outcome in this group (Shih, 
Northcott et al. 2014). There also appears to be upregulation of TGFβ signaling due to single copy number 
aberration of the genes involved in this signaling cascade (Northcott, Jones et al. 2012). 
 
Group 4 MB 
 
Group 4 is the highest incidence molecular MB subgroup, accounting for about 35% of all cases. 
Although this tumor type is found in all age groups, it is rarely found in infants, and presents a significantly 
male predominance (3:1) (Northcott, Jones et al. 2012). 
Histologically, the vast majority of Group 4 MB are of classic histology, although cases of LC/A have 
also been observed (Ellison, Gajjar et al. 2011). Shih et al. have identified that loss of chromosome 11 and 
presence of i17q in a subset of patients with group 4 MB confer an excellent prognosis irrespective of 
metastatic disease (Shih, Northcott et al. 2014). However, the underlying biology of Group 4 MB is not well 
understood. Similar to group 3 tumors, tetraploidy occurs as an early change (40% of cases) (Jones, 
Jager et al. 2012). Isochromosome 17q occurs in 80% of cases, as does 17p deletion (Skowron, 
Ramaswamy et al. 2015). Additionally, chromatin-remodelling genes including KDM6A, ZYMYM3, and 
CHD7 are also mutated in this group. It has been reported that these mutations, along with overexpression 
of enhancer EZH2, keep neural stem cells in an undifferentiated state and might be sustaining 
tumorigenesis. 
 
1.2.7.2 Epigenetics in MB 
 
Lately, the unexpectedly high frequency and universality of alterations in the chromatin regulation 
machinery in MB and other malignancies has attracted significant research interest. Interestingly, 
alterations in genes involved in chromatin modifications (point mutations and DNA copy number 
aberrations) are a common characteristic across all MBs (Jones, Jager et al. 2012). Some of the identified 
epigenetic alterations include changes in chromatin-modifying genes, such as amplification of histone 
acetyltransferatses (KAT6A), lysine demethylases (JMJD2B, JMJD2C), deletions of histone 
methyltransferases (EHMT1, SMYD4), as well as H3K9 hypomethylation (Northcott, Nakahara et al. 
2009).  
Notably, there are observations supporting that epigenetic alterations occur in a subgroup-specific 
manner in MB. More specifically, truncating mutations of histone methyltransferases MLL2 and MLL3 have 
been identified in WNT MBs (Parsons, Li et al. 2011; Dubuc, Remke et al. 2013), whereas SHH MBs are 
strongly enriched for alterations in members of the nuclear receptor co-repressor (N-CoR) complex, which 
is associated with histone deacetylation and is thought to repress target genes by inducing chromatin 
condensation (Oberoi, Fairall et al. 2011).  
Interestingly, TP53-mutated SHH MBs are often associated with chromothrypsis, an abnormality 
characterized by the loss of specialized chromatin structures at the telomeres, resulting in chromosome 
end-to-end fusions and subsequent mechanical shearing during mitosis (Tusell, Pampalona et al. 2010; 
Rausch, Jones et al. 2012).  
On the other hand, group 3 and 4 MB subtypes share mutations of histone demethylases KDM6A 
and ZMYM (Lee, Wynder et al. 2005; Robinson, Parker et al. 2012). KDM6A acts in concert with the most 
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commonly mutated chromatin modifier in MB, MLL2, to increase H3K4me3 and remove H3K27me3 marks 
in order to target gene activation (Schuettengruber, Chourrout et al. 2007). 
 
1.2.7.3 miRNAs in MB 
 
miRNAs are short (19-25 nucleotides), evolutionary conserved RNA molecules that bind within the 
3’ untranslated region (UTR) of the messenger RNAs (mRNAs) and repress genes, either by blocking 
translation, or by directing sequence-specific degradation of target mRNAs (Bartel and Chen 2004; 
Chiang, Schoenfeld et al. 2010). 
miRNAs have been proposed to be involved in cancer progression and altered miRNA expression 
profiles have been associated with outcome in several human cancers (Santarpia, Nicoloso et al. 2010). 
Since miRNA expression is deregulated in human malignancies, they may exert a dual function during the 
progression of the disease, acting either as oncogenes (by repression tumor-suppressor genes) or tumor 
suppressor genes (by repressing tumor-suppressor genes) (Zhang, Pan et al. 2007).  
However, despite the importance of miRNAs in tumorigenesis, the first indications that miRNAs are 
implicated in MB pathogenesis emerged nine years ago, with miR124 being the first described miRNA to 
be involved in MB progression. miR-124, a modulator of cell cycle regulation (Pierson, Hostager et al. 
2008), was found to be expressed at lower levels in MB samples compared to normal brain (Griffiths-
Jones, Saini et al. 2008). Since then, there has been extensive research on the role of miRNAs in MB, and 
researchers could detect differential miRNA expression in the different MB molecular subgroups or 
histological subtypes, suggesting specific miRNAs as putative prognostic indicators. 
More specifically, significant downregulation of 28 miRNAs has been demonstrated in SHH MB. 
Some of the identified miRNAs were miR-125b, miR-326, miR-214 and miR-324-5b and function as 
regulators of SMO and GLI1, which in turn are key activators of SHH cascade (Griffiths-Jones, Saini et al. 
2008). 
Furthermore, overexpression of miR-23b, miR-148a, miR-182, miR-193a, miR-224, and miR-365 
was validated in WNT MBs, suggesting that the expression levels of these potential tumor/metastasis 
suppressive miRNAs could be important biomarkers for risk stratification in WNT MBs (Gokhale, Kunder et 
al. 2010).  
Recently, the expression of 663 miRNAs was evaluated in MB primary samples, MB cell lines, 
neural stem cells as well as neural progenitor cells. The analysis revealed 33 differentially expressed (21 
upregulated and 12 downregulated) miRNAs in MB primary samples compared to neural stem cells. 
Further integrative and functional analysis of predicted targets of the identified miRNAs revealed 
aberrations in MB signaling pathways related to neuronal migration, nervous system development and cell 
proliferation (Genovesi, Carter et al. 2011).  
Cumulatively, the above findings indicate that miRNA profiling could be an important tool to support 
risk stratification and molecular classification of MBs and suggest that altering miRNA expression could 
serve as a novel therapeutic strategy for MB treatment. 
 
1.2.7.4 Progenitors of the developing cerebellum  
 
The developing cerebellum is composed of two major germinal zones: the ventricular zone (VZ) 
adjacent to the fourth ventricle, which gives rise to the majority of neurons and glia; and the external 
granule layer (EGL), around the outside of the cerebellum, which generates restricted populations of 
glutamatergic neurons (Fig. 9 & 10).  
During embryogenesis, multipotent stem cells of the VZ undergo active proliferation and then 
differentiate to produce neuronal and glial progenitors. These cells radially migrate into the cerebellum and 
give rise to Purkinje, basket, stellate and Golgi neurons, as well as astrocytes and oligodendrocytes (Leto, 
Carletti et al. 2006). After birth, stem cells from the VZ migrate into the cerebellar white matter. Many of 
these cells become restricted to neuronal, oligodendroglial and astrocytic fates and ultimately give rise to 
mature neurons and glia (Milosevic and Goldman 2002). 
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During mid-gestation, a subset of VZ progenitor cells migrates laterally towards the upper rhombic 
lip (URL), where the expression of the transcription factor Atoh1 (Math1) is initiated under the influence of 
bone morphogenetic protein (BMP) signaling (Alder, Lee et al. 1999), leading thus to the restriction of 
Atoh1 to the neuronal lineage. The majority of URL progenitors then migrates around the outside of the 
cerebellum to form the EGL. Progenitor cells in the EGL (granule neuron precursors, or GNPs) proliferate 
extensively in response to SHH secreted by neighboring Purkinje cells. Ultimately (in response to signals 
that are poorly understood), GNPs exit the cell cycle, migrate inward to the internal granule layer (IGL), 
and differentiate into mature granule neurons, the most abundant type of neuron in the brain (Dahmane 




Figure 9: Granule-cell development and tumorigenesis of medulloblastoma. Under normal development, GCPs undergo 
massive proliferation in the external granule layer upon receiving the SHH signal from the Purkinje cell. GCPs then exit the cell cycle 
and begin to differentiate and migrate downward to form the IGL. Dysregulated granule cell development, including excessive signals 
for GCPs to proliferate or an absence of signals to cease dividing, can result in the formation of medulloblastoma. Abbreviations: 
EGL, external granule layer; GCP, granule cell precursor; IGL, internal granule layer; SHH, sonic hedgehog; PCL, Purkinje cell layer 





Figure 10: Three dimensional diagram of the principal circuitry within the cerebellar cortex. Input enters via the mossy and 
climbing fibers, while the only output is via the Purkinje cell axons (from JC Rothwell, in Physical Management in Neurological 
Rehabilitation (Second Edition), 2004). 
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1.2.7.5 Cells of origin for MB  
SHH MB  
The association between the SHH signaling pathway and MB was first recognized when Gorlin 
syndrome, a hereditary disease characterized by skin tumors, craniofacial abnormalities and an increased 
incidence of MB, was found to originate from mutations in Patched 1 (Ptch1) (Gorlin and Goltz 1960). 
Subsequently, mice with germline mutations in Ptch1 were reported to develop MB (Goodrich, Milenkovic 
et al. 1997), suggesting a causal role for SHH signaling in MB tumorigenesis. Later studies confirmed that 
GNP-specific deletion of Ptch1 or activation of Smoothened (Smo) results in MB formation, indicating that 
SHH-associated tumors arise from GNPs (Schuller, Heine et al. 2008).  
WNT MB  
Magnetic resonance imaging of patients with WNT MB demonstrated that this subtype of MB often 
encompasses the dorsal brainstem (Gibson, Tong et al. 2010). Moreover, WNT-associated tumors have a 
transcriptional profile resembling that of dorsal brainstem progenitors. These observations suggested that 
WNT-associated tumors might arise from the dorsal brainstem rather than the cerebellum. To test this 
hypothesis, Gibson and colleagues generated mice expressing a stabilized form of beta-catenin (Ctnnb1) 
(and lacking p53) in glial cells of the hindbrain. These animals exhibit defects in differentiation and 
migration of dorsal brainstem progenitors, with a subset prone to the development of tumors that 
resembled human WNT MB. Notably, activation of Ctnnb1 in GNPs does not cause increased proliferation 
or lead to tumor formation, suggesting that WNT-associated tumors do not arise from the granule lineage. 
Together these studies support the notion that WNT-associated MBs arise from dorsal brainstem 
progenitors (Wang and Wechsler-Reya 2014).  
Group 3 MB  
Although the cell of origin for these tumors remains unclear, much of current research has focused 
on the origins of group 3 MB characterized by c-Myc overexpression. Recent studies revealed that 
infection of cerebellar stem cells with c-Myc retroviruses and p53 mutants, led to the formation of tumors 
that histologically and molecularly resembled the c-Myc-driven group 3 MB (Pei, Moore et al. 2012). 
Similar results were acquired upon transplantation of cerebellar GNPs overexpressing c-Myc into mice 
cerebellum (Kawauchi, Robinson et al. 2012), suggesting that GNPs and stem cells give rise to group 3 
MB.  
Group 4 MB  
Although group 4 is the most prevalent of the four MB subgroups, the origin of this specific subtype 
still remains unclear. Experiments performed in transgenic mice expressing MYCN in stem cells from the 
postnatal cerebellum, led to the development of tumors that exhibited classic or LC/A histology and 
resembled Group 4 MB at a molecular level (Swartling, Grimmer et al. 2010; Swartling, Savov et al. 2012), 
suggesting that the cell of origin for these tumors may be a primitive progenitor or stem cell. 
 
1.2.8 MB targeted therapies 
 
Genetically engineered models of MB  
 
Genomic data have generated numerous hypotheses regarding the biology and appropriate 
treatments for each of the MB subgroups. One approach to test these hypotheses is by using genetically 
engineered mice (GEM) through which the function of particular genes in cancer development can be 
examined. Regarding MB, many existing GEM that have been created in order to study the function of 
putative MB oncogenes or tumor suppressors in stem cells or GNPs have yielded valuable information 
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about the origins and biology of the disease, and have provided valuable platforms for the evaluation of 
therapies.  
Models representing the different subtypes of MB are described below.  
 
Models of SHH MB 
Among the first GEM models of MB was the heterozygous PTCH1 mice (Ptch1+/-mice). 
Approximately 15-20% of these mice develop cerebellar tumors that resemble human SHH MB (Goodrich, 
Milenkovic et al. 1997; Hahn, Wojnowski et al. 2000).  
Notably, conditional Ptch1-knockout models of MB have also been developed, with mice developing 
MB with an incidence of 100%. In these animals, deletion of Ptch1 is either deleted specifically in GNPs 
(using Math-1-controlled Cre recombinase) or in stem cells (using GFAP-controlled Cre), representing a 
valuable tool for understanding the early stages of tumorigenesis in SHH MB (Yang, Ellis et al. 2008). 
Models of MB have also been generated by targeting downstream elements of the SHH pathway. 
Of those, one of the most widely studied is the ‘Smo-Smo’, which bears activated Smoothened (Smo) in 
neural progenitors or stem cells and confers high incidence, short latency and metastatic MBs, represents 
another important and valuable tool for preclinical studies. Additionally, animals lacking Sufu or 
overexpressing an activated form of Gli2 also develop MB (Tang, Gholamin et al. 2014).  
An important use of SHH-associated mutations relies in defining genes that can cooperate with 
SHH signaling to promote MB formation. For example, crossing Ptch1+/- mice with Tp53-/- mice leads to a 
dramatic increase in tumor incidence, from 15% in Ptch1+/- mice to 100% in Ptch1+/-Tp53-/- mice. This 
penetrance has made the Ptch1+/-Tp53-/- model particularly useful for preclinical studies (Romer, Kimura 
et al. 2004).  
Interestingly, analogous to Tp53, other oncogenes can cooperate with SHH signaling to promote 
MB tumorigenesis. More specifically, it has been reported that co-infection with viruses encoding C-myc, 
N-myc, insulin-like growth factor 2 (IGF-2), Akt, Bcl-2, or hepatocyte growth factor (HGF) leads to 
increased incidence of MB, suggesting that each of these genes is capable of cooperating with SHH 
pathway activation to promote tumor development (Rao, Pedone et al. 2003; Browd, Kenney et al. 2006; 
Binning, Niazi et al. 2008).  
 
Models of WNT MB 
Despite the generation of mouse models specifically expressing Ctnnb1 in the cerebellar VZ and in 
the lower rhombic lip, development of WNT MB was only achieved when the above mice were crossed 
with Tp53flx mice, aiming p53 deletion (which is often mutated in human WNT-associated tumours). 
Subsequent studies revealed that the addition of a phosphoinositide 3-kinase (PI3K) catalytic-α 
polypeptide mutant allele (Pik3caE545K) identified in WNT MB, the resulting mouse model presented 
highly penetrating WNT tumors, forming within 3 months. The above studies indicate that p53 as well as 
PI3K mutations consist hallmarks during WNT MB formation (Ellison, Onilude et al. 2005; Gibson, Tong et 
al. 2011; Bourdeaut, Miquel et al. 2014). 
 
Models of other MB subtypes  
In addition to models of SHH- and WNT-associated tumors, several models of non-SHH-associated 
tumors have recently been developed.  
Studies have shown that deletion of Rb and Tp53 in different cell types leads to tumor formation that 
displays different characteristics of SHH or WNT MBs, express stem cell markers such as Nestin, Sox2 
and Sox9 and is associated with poor outcome (Sutter, Shakhova et al. 2010). 
Notably, transgenic mice with targeted overexpressoin of n-Myc in brain astrocytes as well as 
cerebellum (Glt1-tTA::TRE-MYCN/Luc mouse model) presented aggressive MBs. The tumors were 
classified as group 3 MBs and showed large cell anaplastic histology, highlighting thus the agressiveness 
1.2 Introduction - Medulloblastoma 
  24 
of group 3 MB models and signifying the importance of n-Myc in MB. Furthermore the particular mouse 
model supports the important role of astrocytes in the development of the disease (Weiss, Grimmer et al. 
2007). 
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Receptor tyrosine kinases (RTKs) and MB 
 
Receptor tyrosine kinases (RTKs) serve as cell surface receptors for growth factors and cytokines. 
Upon ligand binding, receptor tyrosine kinases cluster and this leads to the activation of the protein’s 
cytoplasmic domains. Activation can also be reinforced upon RTK dimerization in the case of certain 
RTKs. Trans-autophosphorylation of tyrosine residues within the receptor form binding sites for Src 
homology 2 (SH2) and phosphotyrosine binding (PTB) domains. Phosphorylation of these proteins then 
results in the activation of downstream signaling pathways involved in diverse cellular responses, such as 
cell division, differentiation and motility. Members of the RTK family, specifically neurotrophin-3 receptor 
(TrkC), human epidermal growth factor receptor 2 (HER2/erbb-2), platelet derived growth factor receptor 
(PDGFR), insulin-like growth factor receptor (IGFR), nerve growth factor receptor (NGFR) as well as 
hepatocyte growth factor receptor (c-Met) have been associated with MB pathogenesis (Ng, Tong et al. 
2003; Li, Lal et al. 2005).  
 
1.3 HGF/c-Met signaling pathway  
 
The HGF/c-Met pathway has been associated with normal development, organ regeneration and 
cancer. c-Met is a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF - also known as 
scatter factor). c-Met is generally expressed in epithelial cells and is activated by HGF produced in the 
surrounding mesenchymal cells or released into the circulation (Bladt, Riethmacher et al. 1995; Heymann, 
Koudrova et al. 1996). During embryogenesis, HGF/c-Met signaling is necessary for the development of 
tissues such as placenta, liver, kidney and neuronal tissue as well as for the directional migration of 
skeletal muscle cells (Birchmeier and Gherardi 1998). In adult tissues, the c-Met pathway has been 
implicated in regeneration and wound healing (Chmielowiec, Borowiak et al. 2007). Thus, the HGF/c-Met 
axis plays key role in cell proliferation, survival and migration, and when de-regulated, can give origin to a 
variety of cancers.  
 
1.3.1 Structure of HGF and c-Met  
 
HGF is synthesized as a single-chain inactive precursor and it is converted by serine proteases into 
an active form with two chains (α and β chain), linked by a disulfide bond. HGF consists of six domains: 
an amino-terminal hairpin loop domain (HL), four kringle domains (K1-K4) and a serine protease 
homology (SPH) domain which lacks enzymatic activity (Fig. 11) (Basilico, Arnesano et al. 2008).  
c-Met, the HGF receptor, is extracellularly composed of three domains: the Sema domain, the PSI 
domain and four IPT domains. The intracellular region of c-Met consists of three portions: a 
juxtamembrane sequence that downregulates kinase activity upon phosphorylation of Ser975, a catalytic 
region that activates kinase activity following phosphorylation of Tyr1234 and Tyr1235, and a carboxy-
terminal multifunctional docking site that contains two docking tyrosines (Tyr1349 and Tyr1356) essential 
for downstream signaling (Basilico, Arnesano et al. 2008).  
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Figure 11: Structure of HGF growth factor and its transmembrane receptor c-Met: a) HGF consists of six domains: an amino-
terminal hairpin loop (HL), four kringle domains (K1–K4; each defined by three conserved disulphide bonds) and a serine protease 
homology (SPH) domain that lacks proteolytic activity. b) The HGF receptor MET is a single-pass heterodimer comprising an entirely 
extracellular α-subunit that is linked by a disulphide bond to a transmembrane β-subunit, which contains the intracellular catalytic 
activity. The extracellular region of MET includes three functional domains: the Sema domain (which is also found in the semaphorins 
and plexins) spans the first 500 residues at the N terminus, encompassing the whole α-subunit and part of the β-subunit; the PSI 
domain (which is also present in the plexins, semaphorins and integrins, hence its name) covers approximately 50 residues and 
contains four conserved disulphide bonds; the residual 400 residues connecting the PSI domain to the transmembrane helix are 
organized into four IPT (immunoglobulin-like fold shared by plexins and transcriptional factors) domains. The intracellular segment is 
composed of three portions: a juxtamembrane sequence that downregulates kinase activity following phosphorylation of Ser975, a 
catalytic region that positively modulates kinase activity following trans-phosphorylation of Tyr1234 and Tyr1235, and a carboxy-
terminal multifunctional docking site that contains two docking tyrosines (Tyr1349 and Tyr1356) that are involved in the recruitment of 
several transducers and adaptors. 
 
1.3.2 c-Met signal transduction  
 
Following HGF binding, the kinase activity of Met is switched on. This process starts with receptor 
dimerization and trans-phosphorylation of two tyrosine residues in the catalytic region (Tyr1234 and 
Tyr1235) and is followed by phosphorylation of two additional tyrosines in the carboxy-terminal tail 
(Tyr1349 and Tyr1356) (Fig. 12). These tyrosines create docking sites for a variety of adaptor proteins and 
direct kinase substrates such as the growth factor receptor-bound protein 2 (Grb2), Grb2-associated 
adaptor protein (Gab1), son of sevenless (SOS), SRC homology protein tyrosine phosphatase 3 (Shp2), 
phosphatidylinositol-3-kinase (PI3K) and signal transducer and activator of transcription 3 (STAT3). This 
leads to the activation of downstream signaling pathways that include the mitogen-activated protein kinase 
(MAPK), PI3K/AKT and STAT pathways (Ponzetto, Bardelli et al. 1994; Weidner, DiCesare et al. 1996; 
Lock, Royal et al. 2000). 
The activation of the MAPK cascade will sequentially activate different protein kinases whose 
terminal effectors include extracellular signal-regulated kinases (Erk1 and Erk2), Jun amino-terminal 
kinases (JNK1, JNK2 and JNK3) and p38. These downstream elements activate cell cycle regulators 
leading to cell proliferation and promote alterations in cytoskeletal functions that control cell migration and 
invasion (Rodrigues, Park et al. 1997; Lamorte, Kamikura et al. 2000).  
 
1.3.3 Regulation of c-Met signaling  
 
It has been shown that the signaling network around the RTK c-Met is more complex than the 
known process of recruiting signaling effectors to the plasma membrane and subsequently stimulating 
intermediates in the cytosol. In fact, it has been found that relevant c-Met signals can also originate from 
endosomal compartments. It has been shown that HGF stimulates a rapid endocytosis of c-Met through 
clathrin coated vesicles in a dynamin dependent manner (Hammond, Urbe et al. 2001).  
Upon HGF binding, c-Met is internalized by clathrin-mediated endocytosis and recruited into 
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peripheral early endosomes. This process is mediated by protein kinase Cε (PKCε) that promotes the 
transfer of active Erk to focal adhesions and, subsequently causes HGF-induced cell migration. From the 
peripheral endosomes, c-Met travels along the microtubule network to late perinuclear compartments in a 
process mediated by PKCα. This juxtanuclear accumulation of Met is a determinant step for activation and 
nuclear translocation of STAT3 (Kermorgant and Parker 2005).  
 
1.3.4 HGF, c-Met and cancer  
 
Dysregulated HGF/c-Met signaling has emerged as a key player in several human malignancies, 
particularly in tor cell invasion and metastasis. Human cell lines overexpressing either HGF and/or c-Met 
become tumorigenic and metastatic when implanted into nude mice (Rong, Segal et al. 1994). Moreover, 
transgenic mice expressing either the receptor or the ligand, develop metastatic tumors (Takayama, 
LaRochelle et al. 1997). On the contrary, downregulation of HGF or c-Met expression in human tumor 
xenografts decreases tumor growth (Abounader, Lal et al. 2001).  
There are three biological mechanisms underlying the tumorigenicity of c-Met: a) the establishment 
of HGF/c-Met autocrine loops, b) the overexpression of HGF or c-Met, and c) the presence of activating 
mutations in the c-Met receptor (Ferracini, Direnzo et al. 1995).    
The most frequent mechanism of c-Met deregulation found in human tumors is the overexpression 
of the receptor or its ligand. A large number of studies showed that HGF and c-Met are expressed in a 
wide variety of human tumors as well as in the metastasizing cells, conferring tumor aggressiveness and 
poor prognosis. These include malignancies of breast, colon, lung, pancreas and prostate, sarcomas, and 
glioblastomas (Direnzo, Olivero et al. 1995; Olivero, Rizzo et al. 1996; Tuck, Park et al. 1996; 
Koochekpour, Jeffers et al. 1997; Ramirez, Hsu et al. 2000; Tokunou, Niki et al. 2001; Tsao, Yang et al. 
2001; Lengyel, Prechtel et al. 2005; Knowles, Stabile et al. 2009). 
 
1.3.5 HGF/c-Met pathway in cerebellar development  
 
The HGF/c-Met pathway also plays a critical role in cerebellar development. Comparing the regional 
expression of HGF and c-Met in both developing and adult rat brains, Achim and colleagues showed that 
HGF is expressed in the parietal cortex, striatum and cerebellar deep gray matter in the developing but not 
in the adult brain. Abundant expression of c-Met was also detected in the newborn cortex, thalamus and 
brainstem (Achim, Katyal et al. 1997). Leraci et al. described the expression of c-Met in the proliferating 
cells of the external granule layer of the cerebellum. In addition, transgenic mice with partial loss of c-Met 
function had a smaller cerebellum with abnormal foliation and balance impairment (Ieraci, Forni et al. 
2002). Exploring the neuroprotective role of HGF, different groups showed that HGF treatment of primary 
cerebellar granule neurons prevents apoptotic cell death through activation of the PI3K/AKT pathway 
signaling (Zhang, Himi et al. 2000; Hossain, Russell et al. 2002). 
 
1.3.6 HGF/c-Met pathway in MB formation  
 
HGF/c-Met signaling has an important role in tumorigenesis and metastatic behavior in several 
human malignancies but its role in MB pathogenesis was only recently described.  
Comparative genomic hybridization in a series of 14 human MB samples revealed amplification of 
the c-Met oncogene on chromosome 7q in 38.5% of cases (Tong, Hui et al. 2004). Further studies 
revealed that stimulation of MB cells with HGF increased activation of downstream effectors, evidenced by 
c-Met, MAPK and AKT phosphorylation. Up-regulation of the pathway was also able to induce cell 
proliferation, cell cycle progression, anchorage-independent growth and resistance to chemotherapy-
induced apoptosis in MB cell lines. In vivo models overexpressing HGF also showed increased tumor 
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growth and invasion. Additionally, authors reported a positive correlation between the expression of HGF 
and c-Met in human MB samples and poor clinical outcome (Li, Lal et al. 2005).  
Binning et al. showed that HGF and Shh cooperate to transform cerebellar neural progenitors in 
transgenic mice, leading to MB initiation and growth (Binning, Niazi et al. 2008). Last but not least, recent 
studies support the role of c-Met as a marker of SHH-driven MB. More specifically, based on the analysis 
of several large nonoverlapping cohorts of MB patients, active c-Met was correlated with increased tumor 
relapse and poor survival (Faria, Golbourn et al. 2015). 
The above findings highlight the importance of the HGF/c-Met cascade in MB malignancies, further 
suggesting this pathway as a target for new promising therapies using small molecule inhibitors or 
antibodies.  
 
1.3.7 Targeting HGF/c-Met pathway in cancer  
 
Due to its pleiotropic role in cellular processes important in oncogenesis and cancer progression, 
HGF/c-Met cascade is considered to be a major target in anticancer therapy (Migliore and Giordano 2008; 
Trusolino, Bertotti et al. 2010). Several molecules targeting HGF/c-Met have been evaluated in early 
phase clinical trials. Most of them are small kinase inhibitors, while others include antagonists and 
monoclonal antibodies that target either the ligand or the receptor (Comoglio, Giordano et al. 2008; Eder, 
Woude et al. 2009). Based on the mechanisms of action, the HGF/c-Met agents can be classified into 
agents that either target HGF ligand, or those that target c-Met receptor.  
 
HGF Regarding the agents targeting HGF, they are further categorized into either HGF activation 
inhibitors (preventing the cleavage of pro-HGF into the active form of HGF), or HGF inhibitors that block 
the direct binding of HGF to the c-Met receptor (Fig. 12 & 13). The activation of HGF from its inactive 
precursor pro-HGF is a critical step for HGF function (Gak, Taylor et al. 1992). This process is regulated 
by many proteases, including HGF activator (HGFA), matriptase, hepsin, and urokinase-type plasminogen 
activator (uPA), all of which convert inactive pro-HGF to active HGF. Two recently identified HGF 
activation inhibitors (HAIs), HAI-1 and HAI-2, have been shown to block HGF activation (Owen, Qiu et al. 
2010; Fang and Lee 2014). HGF inhibitors bind and neutralize HGF, preventing thus HGF from binding to 
the c-Met and blocking the downstream signaling pathway. Some of the monoclonal antibodies that 
directly bind against HGF and have been studied in clinical trials include ficlatuzumab, HuL2G7, and 
rilotumumab (Tan, Park et al. 2011; Patnaik, Weiss et al. 2014). Of note, HuL2G7 (TAK-701) was one of 
the earliest mAbs developed which was shown to neutralize HGF (Jones, Cohen et al. 2010). 
 
c-Met  For agents targeting the c-Met receptor, they are classified into either c-Met antagonists that bind 
the receptor preventing thus the activation of downstream signaling components, or c-Met tyrosine kinase 
inhitors (TKIs) that target the ATP-binding site of the receptor and block receptor trans-
autophosphorylation (Fig. 12 & 13). Although therapeutic strategies targeting c-MET should in principle be 
similarly efficacious to those targeting HGF, c-Met antagonists have been difficult to develop since many 
of them are bivalent (two-arm) antibodies that induce receptor crosslinking and subsequent downstream 
signal activation, thereby mimicking HGF ligand. Onartuzumab, the only monovalent MET antibody that 
has been tested in clinical studies, showed good tolerance when administered alone or in combination 
with bevacizumab in cancer patients (Salgia, Patel et al. 2014). Another approach towards the inhibiting of 
c-MET pathway is through c-MET kinase inhibitors, which target c-MET intracellularly. Interestingly, 
several small-molecule c-MET kinase inhibitors have entered clinical trials, including selective c-MET 
kinase inhibitors (e.g., tivantinib (ARQ 197) and nonselective c-MET kinase inhibitors (e.g., crizotinib 
(PF02341066), cabozantinib (XL 184), and foretinib). Notably, tivantinib (ARQ 197) has been the first non-
ATP-competitive agent that selectively targets the c-MET RTK. In clinical trials, treatment with tivantinib 
has been generally well tolerated and has shown clinical activity in cancer patients (Feldman, Einhorn et 
al. 2013; Santoro, Simonelli et al. 2013; Kang, Muro et al. 2014; Pant, Saleh et al. 2014). INC 280 is 
another highly selective, small-molecule MET inhibitor which was well tolerated in a phase I study in 
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patients with advanced c-Met-dependent solid tumors such as non-small cell lung cancer, hepatocellular 
carcinoma etc (Bang, Su et al. 2014). Some of the c-MET nonselective, multikinase inhibitors include 
crizotinib that targets c-MET and ALK (Rodig and Shapiro 2010), cabozantinib targeting c-MET and 
VEGFR2 (Yakes, Chen et al. 2011), and foretinib that targets c-MET, VEGFR2 as well as PDGFR (Qian, 
Engst et al. 2009). Among the above compounds, cabozantinib strongly inhibited the self-renewal potential 
and in vivo growth of a c-MET-positive tumorigenic subpopulation of Giant cell tumor of bone (GCTB), 
suggesting that it could be an effective therapeutic option in patients with GCTB (Liu, Aleksandrowicz et al. 
2014). Similar to cabozantinib, foretinib (GSK1363089) has also been tested in vitro and in vivo as to 
whether it could be used as a new therapeutic approach in SHH-driven MBs. Interestingly, foretinib 
suppressed MET activation, decreased tumor cell proliferation, and induce apoptosis in SHH 
medulloblastomas in vitro and in vivo. In established mouse transgenic or xenograft models of metastatic 
SHH, foretinib administration suppressed primary tumor growth, decreased the incidence of metastases, 
and increased host survival, suggesting that this compound should be clinically evaluated as an effective 
therapy for patients with SHH-driven MB (Faria, Golbourn et al. 2015). 
 
Interestingly, current research regarding HGF/c-Met targeted cancer therapies seems to be inclined 
towards small molecule inhibitors compared to mAbs due to certain advantages of small molecules 
compared to mAbs. For instance, even though mAbs present high levels of specificity, their size restricts 
their ability to penetrate the cell membrane. Hence they are limited to targeting HGF or c-Met receptor only 
extracellularly. on the other hand, small molecules can cross the cell membrane and target intracellular 
targets. Furthermore, mAbs molecular weight varies significantly compared to small molecule inhibitors 
(150 kDa for mAbs vs. ~500 Da for small molecules). Thus mAbs present limited tissue distribution in 
comparison with small molecules, which can be extensively distributed into tissues due to their different 
chemical- and protein-binding properties. Thus, theoretically small molecules seem to have a therapeutic 
advantage for treatment of solid tumors possibly because they can be delivered into tumors relatively 
more easily than mAbs. Notably, to date the only US FDA-approved c-MET pathway-related agents, 
crizotinib and cabozantinib, are dual- or multi-tyrosine kinase inhibitors, indicating that blocking c-MET 




Figure 12: Major signaling pathways activated through c-Met, interactions between c-Met and other membrane receptors, 
and c-Met signaling inhibition strategies: HGF binding results in c-Met autophosphorylation of tyrosines Y1234 and Y1235 within 
the activation loop of the kinase domain and subsequent phosphorylation of tyrosines Y1349 and Y1356 near the -COOH terminus. 
Important adaptor proteins and direct kinase substrates activated downstream in the c-Met pathway include growth factor receptor-
bound protein 2 (GRB2), Grb2-associated adaptor protein 1 (GAB1), phosphatidylinositol 3-kinase (PI3K), son of sevenless (SOS), 
rat sarcoma oncogene homolog (RAS), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3/5 
(STAT 3/5), SRC, SRC homology protein tyrosine phosphatase 2 (SHP2), SRC homology domain c-terminal adaptor homolog (SHC), 
1.3 Introduction – HGF/c-Met signaling 
  30 
phospholipase c-γ (PLC), Ras-related C3 botulinum toxin substrate 1 (RAC1), p21-activated kinase (PAK), focal adhesion kinase 
(FAK), AKT, and mammalian target of rapamycin (mTOR). Crosstalk between c-Met and various membrane protein partners, 
including the epidermal growth factor receptor (EGFR), the plexin B family, α6β4 integrin, and CD44, results in additional signaling 







Figure 13: Representative examples of different mechanism classes of HGF and MET inhibitors (Zhang, Jain et al. 2015). 
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1.4 Radiation therapy  
 
Conventional radiation therapy is usually applied with a beam composed of x-rays (photons) and 
leads to ionizations upon interaction of irradiation photons with biological matter. Subsequently, ionizing 
radiation (IR) produces high energy secondary particles (electrons), which can then trigger ionizations in 
the critical target molecules (e.g. DNA). The series of reactions that will follow take place in the cellular 
environment (due to its aquatic nature) and are known as ‘’Radiolysis of water’’, leading to the production 
of free radicals. In the presence of oxygen, the free radicals will produce organic peroxides (reactive 
oxygen species – ROS), which are highly reactive. Therefore, IR may damage almost every cellular 
component, including proteins and lipids in the cell membrane (Stadtman 1993; Mishra 2002).  
DNA damage, however, is the most relevant for cell killing (Hall 2006). DNA damage is classified 
into DNA dimers, oxidative base damage, intra- and inter-strand crosslinks, and single and double-strand 
breaks (DSBs). In order to repair the DNA damage, a cell has developed mechanisms for DNA damage 
sensing, that activate signal transduction pathways, which in turn orchestrate multiple cellular functions for 
successful damage repair (Wilson 2004). 
Notably, among the different ways through which IR can lead to cell death, apoptosis is the one that 
can be induced with even low doses in some interphase cells. Apoptosis is an active process 
characterized by programmed cell death in which a defined cascade of events takes place. Various factors 
may modulate the apoptotic response to DNA damage, including the p53 status of the cell and levels and 
activity of the pro- and anti-apoptotic proteins. The ability to evade apoptosis is one of the hallmarks of 
cancer, however, there seems to be no direct correlation of apoptosis and radiosensitivity. A basic 
principle in the tumor radiobiology is the essential difference between cell death and loss of reproductive 
integrity of tumor cells, so-called clonogenicity, which is the most important read-out for the efficiency of 
curative radiation therapy (Kim, Emi et al. 2006). If cells do not undergo apoptotic death in interphase, 
they may become arrested in G1 and/or G2 phases of the cell cycle and then, as soon as the repair 
processes are accomplished, continue to proliferate. However, if the DNA damage was not sufficiently 
repaired during the arrest, the fate of the cell develops according to different scenarios that lead either to 
cell death or to the loss of clonogenicity: 
I. Mitotic catastrophe: A result of aberrant mitosis, characterized by formation of nuclear envelopes 
around individual clusters of misaggregated chromosomes. 
II. Senescence: A state when cells lose their ability to proliferate but keep on metabolizing.  
III. Autophagy: Another type of programmed cell death which is characterized by the appearance of 
autophagic vacuoles in the cytoplasm.  
Radiotherapy (RT) is one of the most prevalent cancer treatments. The goal of radiotherapy is to 
increase the total radiation dose to tumor tissue, while minimizing the toxicity in surrounding normal 
tissues. This goal can be best achieved by high accuracy conformal techniques and a sensitive 
fractionation schedule, where the total dose is applied in multiple (up to 35) small daily fractions. 
Fractionation helps to reduce dose limiting toxicities, by employing the major differences between cancer 
and normal cells: Most cancer cells are DNA damage repair (DDR)-impaired and proliferate more rapidly 
than most normal cells. It has been speculated that DDR inhibition might enhance the effectiveness of 
radiotherapy and DNA-damaging chemotherapies. Indeed, various DDR-inhibitory drugs are in preclinical 
and clinical development to test this premise (Dumont, Altmeyer et al. 2009). 
 
1.4.1 Irradiation (IR): Friend or foe of antimetastatic therapy? 
 
In spite of the continuous efforts to improve the accuracy of modern radiation therapy, normal tissue 
toxicity still has to be taken into consideration. Nowadays, acute side effects of RT are generally clinically 
manageable but late side effects (such as secondary tumors at the irradiated site) remain an important 
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issue especially for the treatment of childhood cancers including Medulloblastoma (Seehusen, Baird et al. 
2010).  
Another aspect, which is regularly reported in literature, is the potential pro-metastatic effect of IR. 
Although experimental evidence suggests that ionizing radiation can upregulate metastasis-related 
processes (Dumont, Altmeyer et al. 2009), however, there are no comprehensive studies of this problem 
and it is difficult to draw a firm conclusion from the existing reports because of the heterogeneity of patient 
cohorts (age, race and gender, tumor sites, staging), treatments applied (dose and fractionation of RT, 
target of RT, combination with surgery and chemotherapy), response to treatment (local failure or local 
control) and diagnosis of metastasis. However, the current consensus remains that under certain -still 
undetermined-circumstances, RT promotes metastasis.  
Iradiation-induced malignant behavior is often represented by altered protein expression and 
activation profiles, therefore, various groups have tried to investigate possible links between radiation 
therapy and the activation of signaling cascades that lead to dissemination in different types of cancer. 
 
The role of integrins 
 
Integrin-mediated cell adhesion to ECM proteins is an essential mechanism of cell survival 
regulation in normal but also transformed cells (Cordes and Meineke 2003). Cordes et al. have examined 
whether β1 integrin-mediated adhesion confers resistance to radiation- or drug- induced genotoxic injury 
in A-172 glioma cells. They found that β1 integrin-mediated adhesion promotes cell survival post IR in an 
Akt-, p130Cas- and paxillin- dependent manner. Interestingly, IR-induced cell survival levels were reduced 
in cells expressing signaling-incompetent β1 integrin variants, or cells in which β1 integrin was 
downregulated. This suggested that the protein expression as well as the activity/phosphorylation 
signatures of adhesion proteins with low turnover, is highly critical and provides a basis for better 
understanding the mechanisms to cope with IR-genotoxic stress (Cordes, Seidler et al. 2006). 
 
The role of c-Met 
 
Due to the fact that c-Met is a known promoter of invasive growth, studies have focused on its 
function in IR-induced aggressive cell behavior. More specifically, De Bacco et al. have examined c-Met 
transcription and activation status after IR in human breast cancer and glioma cells. Notably, authors 
revealed that IR increased c-Met expression via activation of ATM and NF-kB. Furthermore, this IR-
induced c-Met overexpression promoted ligand-independent c-Met phosphorylation and signal 
transduction, sensitizing thus the cells to HGF. Additionally, IR increased cell invasion in a c-Met 
dependent manner, since c-Met silencing by siRNA or pharmacological blockage using PHA665752 or 
JNJ-38877605 inhibitors counteracted radiation-induced increase of proliferation and invasiveness in vitro 
and in vivo and promoted apoptosis. The above results indicate that IR promotes the acquisition of a 
metastatic cellular phenotype and propose that combination of radiotherapy with c-Met inhibition can 
radiosensitize cancer cells. This finding is particularly relevant for clinical cases like glioblastoma and MB, 
where IR dosages are limited due to radiotoxicity (De Bacco, Luraghi et al. 2011). 
 
IR and pancreatic cancer 
 
Another type of cancer that presented IR-induced aggressive cellular behaviour is pancreatic 
cancer, therefore, numerous studies have been focused on the underlying molecular mechanisms (Qian, 
Mizumoto et al. 2002; Qian, Mizumoto et al. 2003). It has been shown that while coculture of pancreatic 
cancer cells with nonirradiated fibroblasts significantly increases the invasive ability of pancreatic cancer 
cells, the increased invasiveness is further accelerated when cancer cells are cocultured with irradiated 
fibroblasts. Interestingly, although irradiation did not affect fibroblast-induced HGF secretion, exposure of 
pancreatic cancer cells to supernatant from irradiated fibroblasts resulted in increased phosphorylation of 
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c-Met and MAPK activity, partially via increased expression of c-Met. In the same study, in vitro cell 
invasion assays revealed that scattering of pancreatic cancer cells was accelerated by the supernatant 
from irradiated fibroblasts, suggesting that invasive potential of certain pancreatic cancer cells is 
enhanced by soluble mediators released from irradiated fibroblasts, possibly through up-regulation of c-
Met expression/phosphorylation and MAPK activity in pancreatic cancer cells (Ohuchida, Mizumoto et al. 
2004). Furthermore, IR-enhanced invasiveness of pancreatic cancer cell lines has also been associated 
with increased expression and activity of MMP-2. Interestingly, MMP inhibitor CGS27023A, blocked the 
irradiation-induced invasive potential, suggesting that the concomitant use of MMP inhibitors during 
radiotherapy could potentially improve the efficacy of radiotherapy in pancreatic cancer (Qian, Mizumoto et 
al. 2002).  
 
IR and breast cancer 
 
Recent studies have revealed that irradiation-induced aggressive behavior of breast cancer cells is 
linked to tissue stiffness alterations. Asparuhova and colleagues have shown that tumors grown in pre-
irradiated mammary glands were highly enriched in transcripts encoding collagens and other important 
components of the ECM, such as laminin, tenascins and MMPs. Notably, they identified the pro-metastatic 
megakaryoblastic leukemia-1 (Mkl1) protein (tenascin-C transcription regulator) to be a key mediator of a 
signaling cascade leading to the aggressive progression of mammary tumors locally relapsing after 
radiotherapy (Asparuhova, Secondini et al. 2015). 
 
IR and endometrial carcinoma 
 
EMT transition has been reported to be another consequence of irradiation in endometrial carcinoma. It 
has been shown that irradiation resulted in increased levels of invassiveness of endometrial carcinoma 
cells. Additionally, after irradiation cells exhibited changes resembling to EMT phenotype. These 
alterations included morphological changes as well as changes of the molecular level such as decrease in 
the expression of epithelial adhesion molecules (E-cadherin, β-catenin), or the increased expression of 
mesenchymal markers (fibronectin, vimentin), suggesting that radiation therapy can potentially promote 
EMT transition (Wild-Bode, Weller et al. 2001). 
 
IR and Medulloblastoma 
 
However, although radiation therapy is one of the most common MB therapeutic modality, little is 
known about potential irradiation-induced dissemination mechanisms in MB cells. 
uPAR: Urokinase-type plasminogen activator receptor (uPAR) is another transmembrane receptor that is 
implicated in promoting signals related to cell survival, adhesion and migration (Smith and Marshall 2010). 
uPAR is known to form an active complex with integrins through the ligand uPA as well as vitronectin, 
playing thus a crucial role in activating integrin-mediated downstream signaling related to cell adhesion 
and migration (Yebra, Parry et al. 1996; Nguyen, Hussaini et al. 1998; Blasi 1999). Therefore, the 
contribution of the uPA/uPAR system in irradiation-induced MB cell aggressive behavior has also been 
examined. More specifically, it has been shown that irradiation enhances the invasiveness of MB cell lines 
and this correlates with increased uPAR proteolytic activity, increased expression levels of uPAR, uPA, 
FAK, N-Cadherin and α3, α5, β1 integrin subunits. Furthermore, uPAR co-localizes with β1 integrin at the 
migratory front of irradiated cells. Interestingly it has been reported that irradiation enhances uPAR 
association with β1 integrin and this leads to the activation of β1 integrin downstream signaling through 
FAK Tyr397 phosphorylation, which in turn leads to the activation of signals that enhance cell adhesion 
and invasion. Notably, FAK inhibition as well as uPAR downregulation abolished irradiation-induced 
invasiveness of MB cells, indicating that uPAR / β1 integrin / FAK axis control the increased irradiation-
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induced cell invasion and migration of MB cells (Nalla, Asuthkar et al. 2010). 
 
The role of radiation treatment in metastatic processes is a matter of great debate and seems to be 
strongly dependent on the tumor type and the experimental system that was used in the study. However, 
the pro-metastatic action of RT may explain why the better local control achieved by this treatment 
modality fails to be translated into longer survival, free of distant metastasis, and that the better 
radiotherapeutic strategies must aim at a better metastasis control (Dumont, Altmeyer et al. 2009). 
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1.5 Endocytosis 
 
The routes that lead inward from the cell surface start with the process of endocytosis, by which 
cells take up plasma membrane components, fluid, solutes, macromolecules, and particle substances. 
Endocytosed cargo includes receptor-ligand complexes, a spectrum of nutrients and their carriers, 
extracellular matrix components, cell debris, bacteria, viruses, and even other cells. Through endocytosis, 
the cell regulates the composition of its plasma membrane in response to changing extracellular 
conditions (Conner and Schmid 2003; Doherty and McMahon 2009). 
In endocytosis, the material to be ingested is progressively enclosed by a small portion of the 
plasma membrane, which first invaginates and is then pinched off to form an endocytic vesicle containing 
the ingested substance or particle. Endocytic vesicles form at the plasma membrane by multiple 
mechanisms that differ in both the molecular machinery used and how that machinery is regulated 
(Bonifacino and Traub 2003). 
Once generated at the plasma membrane, most endocytic vesicles fuse with a common receiving 
compartment, the early endosome, where internalized cargo is sorted: Some cargo molecules are 
returned to the plasma membrane, either directly or via a recycling endosome, and others are designated 
for degradation by inclusion in a late endosome. Late endosomes form from a bulbous, vacuolar portion of 
early endosomes by a process called endosome maturation (Fig. 14). This conversion process changes 
the protein composition of the endosome membrane, patches of which invaginate and become 
incorporated within the organelles as intralumenal vesicles, while the endosome itself moves from the cell 
periphery to a location close to the nucleus. As an endosome matures, it ceases to recycle material to the 
plasma membrane and irreversibly directs its remaining contents towards degradation: Late endosomes 
fuse with one another and with lysosomes to form endolysosomes, which degrade their contents 




Figure 14: Endosome maturation: Endocytic processes initiating from the plasma membrane towards the lysosomes: Endocytic 
vesicles fuse near the cell periphery with   an early endosome, which is the primary sorting station. Tubular portions of the early 
endosome bud off vesicles that recycle endocytosed cargo back to the plasma membrane—either directly, or indirectly   via recycling 
endosomes. Membrane proteins destined for degradation are internalized  in intralumenal vesicles. The developing   late endosome, or 
multivesicular body, moves on microtubules to the cell interior. Fully matured late endosomes no longer send vesicles to the plasma 
membrane, and they fuse with one another and   with endolysosomes and lysosomes to degrade their contents. Each stage of 
endosome maturation is connected via transport vesicles with the TGN (Trans Golgi Network), providing  a continuous supply of 
newly synthesized lysosomal proteins (Alberts, Johnson et al. 2015). 
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1.5.1 Intracellular trafficking routes  
 
Once cargo is internalized, the nascent vesicles are trafficked to various intracellular compartments 
for further sorting. In this way, the cell decides whether the cargo will be recycled back to the plasma 
membrane, or targeted for degradation (Maxfield and McGraw 2004). Independently of the entry route, the 
initial sorting compartment is often the early endosome. Upon sorting at the early endosome, cargo to be 
recycled can be trafficked back rapidly to the plasma membrane. Alternatively, cargo destined to be 
recycled may be trafficked through the perinuclear recycling endosome before being recycled to the 
plasma membrane. Instead of being recycled, some cargo protein and/or lipids are targeted for 
degradation. In this case, after sorting at the early endosome, these cargo molecules are trafficked to the 
late endosome or multivesicular body (MVB) and subsequently to the lysosome, where the cargo is 
ultimately degraded (Brown and Goldstein 1986).  
Regarding the fate of the internalized cargo, it appears that it might depend on the cellular context. 
For example, ligand concentration may play a role in determining the fate of the receptor: low epidermal 
growth factor (EGF) concentrations favor recycling, while high ligand concentrations target EGFRs for 
degradation (Sigismund, Woelk et al. 2005; Sigismund, Confalonieri et al. 2012). Furthermore, over the 
past years it has been revealed that ubiquitination plays an important role in regulating the trafficking of 
growth factor receptors. While poly-ubiquitination through long chains of lysine 48-linked ubiquitin is well 
known to target proteins for degradation by the proteasome, modification of cargo proteins via mono-
ubiquitination or short chain lysine 63-linked poly-ubiquitination, sometimes at multiple sites within the 
cargo, serves as a signaling module to target proteins for lysosomal degradation (Grant and Donaldson 
2009; Clague, Liu et al. 2012) 
 
1.5.2 Rab proteins  
 
To ensure an orderly flow of vesicle traffic, transport vesicles need to display surface markers that 
identify them according to their origin and type of cargo. Furthermore, target membranes need to present 
complementary receptors that recognize the appropriate markers. This crucial process occurs in two 
steps: First, Rab proteins and Rab receptors direct the vesicle to specific spots on the correct target 
membrane. Second, SNARE proteins and SNARE regulators mediate the fusion of the lipid bilayers 
(Martens and McMahon 2008; Pfeffer 2013).  
Rab proteins play a central part in the specificity of vesicle transport. With over 60 known members, 
the Rab family is the largest of the monomeric GTPase subfamilies. Each Rab protein is associated with 
one or more membrane-enclosed organelles of the secretory or endocytic pathways, and each of these 
organelles has at least one Rab protein on its cytosolic surface (Table 2). Their highly selective distribution 
on these membrane systems makes Rab proteins ideal molecular markers for distinguishing membrane 
type and trafficking vesicles between them (Pfeffer 2013; Pfeffer 2017) (Grosshans, Ortiz et al. 2006).  
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Figure 15: Rab cascade model for the establishment and maintenance of the polarity of the secretory and endocytic 
pathways. (A) In the first scenario, a Rab GEF specific for Rab A generates active Rab A. That Rab recruits a second GEF, which 
activates Rab B. Similarly, Rab B recruits a GEF to activate Rab C. In this model, a membrane could have Rabs A–C intermingled or 
at least on a single compartment. (B) Here GAP proteins are included to remove a previous-acting Rab from a specific membrane 
domain. The presence of the GAP will sharpen the boundaries between individual Rab domains. (Pfeffer 2017).  
 
Protein Organelle 
Rab1 ER and Golgi complex (Batoko, Zheng et al. 2000) 
Rab2 Cis Golgi network (Short, Preisinger et al. 2001) 
Rab3A Synaptic vesicles, secretory vesicles (Vadlamudi, Wang et al. 2000) 
Rab4/Rab11 Recycling endosomes (Li, Li et al. 2008) 
Rab5 Early endosomes, plasma membrane, clathrin-coated vesicles  
(Jovic, Sharma et al. 2010) 
Rab6 Medial and trans Golgi (Storrie, Micaroni et al. 2012) 
Rab7 Late endosomes (Vanlandingham and Ceresa 2009) 
Rab8 Cilia (Lu, Insinna et al. 2015) 
Rab9 Late endosomes, Trans Golgi (Barbero, Bittova et al. 2002) 
 
Table 2: Subcellular Locations of certain Rab proteins 
 
1.5.3 Rab protein effectors 
 
Rab proteins can function on transport vesicles and on target membranes, or both. Rab proteins 
cycle between a membrane and the cytosol and regulate the reversible assembly of protein complexes on 
the membrane. In their GDP-bound state, they are inactive and bound to another protein (Rab-GDP 
dissociation inhibitor, or GDI) that keeps them soluble in the cytosol (Fig. 15). In their GTP-bound state, 
they are active and tightly associated with the membrane of an organelle or a transport vesicle. 
Membrane-bound Rab-GEFs activate Rab proteins on both transport vesicle and target membranes. Once 
in the GTP- and membrane-bound state, Rab proteins bind to other proteins, called Rab effectors, which 
are the downstream mediators of vesicle transport, membrane tethering, and membrane fusion. The rate 
of GTP hydrolysis sets the concentration of active Rab and, consequently, the concentration of its 
effectors on the membrane (Zerial and McBride 2001; Grosshans, Ortiz et al. 2006).  
In contrast to the highly conserved structure of Rab proteins, the structures and functions of Rab 
effectors vary greatly, and the same Rab proteins can often bind to many different effectors. Some Rab 
effectors are motor proteins that propel vesicles along actin filaments or microtubules to their target 
membrane. Others are tethering proteins, some of which have long, threadlike domains that serve as 
“fishing lines” that can extend to link two membranes more than 200 nm apart. Other tethering proteins are 
large protein complexes that link two membranes that are closer together and interact with a wide variety 
of other proteins that facilitate the membrane fusion step. Coupling uncoating to vesicle delivery helps to 
ensure directionality of the transport process and fusion with the proper membrane. Rab effectors can also 
interact with SNAREs to couple membrane tethering to fusion (Jahn and Scheller 2006; Harrison and 
Kirchhausen 2010; Jin, Pahuja et al. 2012). 
 
1.5.4 Rab implication in the generation of different membrane domains 
 
The assembly of Rab proteins and their effectors on a membrane is cooperative and results in the 
formation of large, specialized membrane patches. Rab5, for example, assembles on endosomes and 
mediates the capture of endocytic vesicles arriving from the plasma membrane. The experimental 
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depletion of Rab5 causes disappearance of the entire endosomal and lysosomal membrane system, 
highlighting the crucial role of Rab proteins in organelle biogenesis and maintenance (Zeigerer, Gilleron et 
al. 2012). The assembly of a Rab5 domain on endosomal membranes begins when a Rab5-GDP/GDI 
complex encounters a Rab-GEF. GDI is released and Rab5-GDP is converted to Rab5-GTP. Active Rab5-
GTP is anchored to the membrane and recruits more Rab5-GEF to the endosome, thereby stimulating the 
recruitment of more Rab5 to the same site (Zerial and McBride 2001). In addition, active Rab5 activates a 
PI3-kinase, which locally converts PI to PI(3)P, which in turn binds some of the Rab effectors including 
tethering proteins and stabilizes their local membrane attachment (Jean and Kiger 2012). This type of 
positive feedback greatly amplifies the assembly process and helps to establish functionally distinct 
membrane domains within a continuous membrane.  
The endosomal membrane provides a striking example of how different Rab proteins and their 
effectors help to create multiple specialized membrane domains, each fulfilling a particular set of functions. 
Thus, while for instance the Rab5 membrane domain receives incoming endocytic vesicles from the 
plasma membrane, distinct Rab11 and Rab4 domains in the same membrane organize the budding of 




Figure 16: Pathways of endocytosis: Large particles can be taken up by phagocytosis, whereas fluid uptake occurs by 
macropinocytosis. Both processes appear to be triggered by and are dependent on actin-mediated remodelling of the plasma 
membrane at a large scale. Compared with the other endocytic pathways, the size of the vesicles formed by phagocytosis and 
macropinocytosis is much larger. Numerous cargoes can be endocytosed by mechanisms that are independent of the coat protein 
clathrin and the fission GTPase, dynamin (Mayor and Pagano 2007). 
 
1.5.5 Mechanisms of endocytosis 
 
The two general mechanisms by which extracellular material enters the cell are clathrin-mediated 
endocytosis (CME) and the clathrin-independent endocytic process, CIE (Fig. 16) (Cooper and Shaul 
2006; Doherty and McMahon 2009). CME is well known for its role in the internalization of growth factor 
receptors and is dependent on clathrin coat formation as well as the recruitment of accessory proteins that 
recognize specific cytoplasmic sorting sequences. In contrast, CIE appears to be responsible for 
mediating the internalization of a variety of substrates, is less well defined and most importantly, lacks the 
requirement for clathrin or specific internalization signals. CIE includes phagocytosis, micropinocytosis, 
caveolae-dependent endocytosis and clathrin/caveolae-independent endocytosis (CCI) (Maxfield and 
McGraw 2004; Schmid and McMahon 2007; Doherty and McMahon 2009; McMahon and Boucrot 2011; 
Reider and Wendland 2011; Schroeder and McNiven 2014). 
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1.5.5.1 Clathrin-Mediated Endocytosis (CME) 
 
CME, often referred to as receptor-mediated endocytosis (RME), is characterized by the formation 
of rounded shallow clathrin-coated pits (CCPs) (Fig. 17) at the plasma membrane. Clathrin-coated pits 
consist of clathrin and AP-2 proteins, with Arf6 GTPase being a potential regulator of this process (Krauss, 
Kinuta et al. 2003). AP-2 comprises an indispensable component of clathrin-coated pits and is involved in 
cargo selection, in vesicle assembly (Robinson and Bonifacino 2001), as well as in the recruitment of 
clathrin and accessory proteins.  
 
 
Figure 17: Clathrin-Mediated Endocytosis (CME): Illustration of events occurring during CME of lipoprotein particles in a hen 
oocyte during yolk formation. The formation of a clathrin-coated pit results in the generation of a clathrin-coated vesicle. The 
lipoprotein particles bound to the membrane receptors appear as a dense, fuzzy layer on the extracellular surface of the plasma 
membrane—which will become the inside surface of the coated pit and vesicle (McMahon and Gallop 2005). 
 
CME initiation is defined by the formation of clathrin-coated pits. Subsequently, adaptor proteins 
bind to vesicle-coating proteins and to the cytoplasmic domains of membrane proteins, thereby linking 
specific cargoes to sites of coat assembly.  
After the assembly, clathrin-coated vesicle needs to be pinched off the membrane and released into 
the cytosol, which requires the involvement of various proteins with different functions. At first, accessor 
proteins such as epsins, endophilin and amphiphysin (Wigge and McMahon 1998; Farsad, Ringstad et al. 
2001; Ford, Mills et al. 2002) induce membrane bending, which is required for the initiation of vesicle 
formation. Dynamin 2 (Dyn2) then mediates the scission of the vesicle from a donor membrane with 
subsequent release in the cytoplasm, comprising thus an indispensable molecule for proper CME 
(Hinshaw 2000; Praefcke and McMahon 2004). 
Another component that participates in the release of coated vesicles from the plasma membrane is 
the cortical actin cytoskeleton. Actin motors for example, such as the minus-end motor Myosin VI and the 
plus-end motor Myosin 1E have been shown to participate in CME via the interaction with the adaptor 
Dab2 and PdtIns(4,5)P2 or Dyn2 and synaptojanin 1, respectively (Krendel, Osterweil et al. 2007; 
Spudich, Chibalina et al. 2007). Other actin links to the endocytic machinery include actin-binding proteins 
such as profilin, synapsin, syndapin, and cortactin, all of which, surprisingly, are known binding partners of 
dynamin as well (Molloy, Thomas et al. 1994; Johnson, Subtil et al. 1998).  
Finally, clathrin coat is removed by energy-consuming mechanism, which eventually leads to the 
fusion with the early endosomes. Endosomal sorting regulates whether the contents are recycled back to 
the membrane, or continue towards the endosomal maturation process to ultimately end up with lysosomal 
degradation.  
Vesicle formation and trafficking also involves a cooperative and dynamic interaction between lipids 
and proteins. The specific lipid composition of membranes affects membrane fluidity, receptor clustering, 
and signaling of the coating and accessory proteins. To facilitate this lipid-protein interaction, a number 
CME-associated proteins contain lipid-binding domains. In particular, PIP2, owing to its phosphoinositide-
containing membrane domains, is necessary for targeting and localizing the α- and μ2- adaptin subunits of 
AP-2 to the plasma membrane. Additionally, the interaction of Dyn2 with PIP2, is important during 
tubulation and vesicle scission processes (Mim and Unger 2012; Chappie and Dyda 2013; Meinecke, 
Boucrot et al. 2013). 
Notably, alternate endosomal fusion is a process that requires SNARE and Rab proteins (van Dam, 
ten Broeke et al. 2002), as well as protein assemblies that are similar to those involved in clathrin-coated-
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vesicle formation. For instance, the SNARE protein cellubrevin (VAMP3) is required for the fusion of 
transferrin-receptor-containing vesicles with the plasma membrane (Galli, Chilcote et al. 1994), while there 
is evidence that dominant-negative Dyn2 mutants inhibit transferrin-receptor cycling, highlighting thus the 
requirement for Dyn2 towards the formation of recycling vesicles (van Dam and Stoorvogel 2002; van 
Dam, ten Broeke et al. 2002). 
 
1.5.5.2 Clathrin-independent endocytosis (CIE) 
 
Various types of CIE have been described, while the factors involved depend on the cargo and cell 
type examined. Some of the proteins implicated in CIE include important components of the plasma 
membrane, components of the immune response (e.g. MHCI and II), transporters (e.g. calcium and 
potassium channels, glucose, and amino acid transporters), growth factor receptors (e.g. β-adrenergic 
receptor and c-Met) or cell adhesion components (e.g. ICAM1, E-Cadherin and integrins) (Sandvig, Pust 
et al. 2011; Maldonado-Baez, Williamson et al. 2013). 
Depending on the cargo protein, CIE processes are regulated by Rho GTPases such as Cdc42 and 
Rac1, RhoA (IL-2Rβ) or Arf6, and may also be either dependent or independent of dynamin-2 function 
(Howes, Mayor et al. 2010). Interestingly, CIE cargo proteins merge with CME cargoes in Rab5 and EEA1 
positive early endosomes. Moreover, recycling of CIE cargo is controlled by other members of the Rab 
GTPases such as Rab11 and Rab22a (Naslavsky, Weigert et al. 2003; Weigert and Donaldson 2004; 
Weigert, Yeung et al. 2004; Naslavsky, Rahajeng et al. 2006). CIE pathways include phagocytosis, 




Phagocytosis is a cellular process that processes solid particles of usually at least 0.5 mm in 
diameter and is generally restricted to macrophages and other phagocytes that specialize in uptake and 
digestion of large particles (Mellman 2000).  
Phagocytosis is initiated when cells use a specific receptor protein to recognize and bind particles. 
Receptor choice is defined by recognition patterns presented on phagocytic particles (defined as particles 
that trigger their engulfment by phagocytic cells, e.g. pathogens), and by availability of appropriate levels 
of opsonins - soluble multidomain proteins that bridge particle and phagocytic cell by binding to both 
particle recognition patterns and phagocyte receptors. Depending on the nature of the recognition/binding 
proteins, the engulfment of surface-bound particles is followed by the recruitment of additional cell surface 
as well as cytosolic proteins and leads to particle internalization and formation of an intracellular 





Anti-pathogen phagocytosis generally occurs in the immune cells and serves both for the removal 
of microbes and the recruitment of numerous immune cells through complex cytokine and chemokine 
secretion, to establish an effective anti-inflammatory defense. Anti-pathogen phagocytosis is mostly 
performed by phagocytes, such as immature dendritic cells (DCs) and macrophages as well as by tissue-
resident immune cells (Reddick and Alto 2014). 
 
Clearance	  phagocytosis	  or	  efferocytosis	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This type of phagocytosis is neither anti-inflammatory nor immunogenic (Rothlin, Ghosh et al. 
2007) and is also performed by macrophages and DCs. Following apoptosis, dead cells need to be taken 
up into the surrounding tissues through a process called efferocytosis (deCathelineau and Henson 2003). 
The main feature of an apoptotic cell is the cell surface presentation of a variety of intracellular molecules 
such as calreticulin, phosphatidylserine, annexin A1, oxidized LDL and altered glycans (Henson 2005). 
These molecules are recognized by macrophage cell surface receptors such as thrombospondin 1, 
Growth arrest-specific (6GAS6) and lactadherin (MFGE8), which subsequently bind to other macrophage 
receptors such as CD36 and αvβ3 integrin. Defects in apoptotic cell clearance are usually linked with 
impaired phagocytosis of macrophages and often lead to autoimmune disorders (Kruse, Janko et al. 2010; 
Roszer, Menendez-Gutierrez et al. 2011) 
 
Although the above types of phagocytosis are composed of different particles and have different 
functions, they share many molecular characteristics. Both forms of phagocytosis share the recruitment of 
F-actin structures, that is called phagocytic cup beneath the cell surface-bound particles upon the initiation 
of the process. Subsequently, cell surface shape changes locally (usually opsonins) and wraps around the 
phagocytic target. The closure of the phagocytic cup requires F-actin disassembly and leads to particle 
internalization and phagosome formation. Then, alternate series of fusion and trafficking events result in 




Central components of clathrin-independent uptake are small, flask-shaped invaginations of the 
plasma membrane named caveolae. Caveolae are involved in trans-endothelial transport, organization of 
plasma membrane domains, and may also serve as platforms for different signaling cascade networks. 
They are especially abundant in endothelial cells, where they are implicated in transcytosis and 
endocytosis of blood components. (Frank, Woodman et al. 2003; Parton and Simons 2007; Boscher and 
Nabi 2012).  
Biochemically, caveolae are characterized by their association with a family of cholesterol-binding 
proteins called caveolins. Interestingly, expression of caveolin in cells that do not normally have caveolae 
is apparently sufficient to generate these structures (Brett, Legendre-Guillemin et al. 2006).  
In addition to their role in endocytosis of specific molecules, caveolae have been found to co-
localize with several membrane receptors, signaling molecules and membrane transporters, suggesting 
that they might also act as sites of signaling activity within cells (Ceresa and Schmid 2000).  
The extent and mechanism by which caveolae mediate uptake of molecules within cells has been 
controversial. It is known that Caveolae-mediated uptake relies on the ability of caveolins to oligomerize 
and this leads to the formation of caveolin-rich microdomains, which along with increased levels of 
cholesterol lead to expansion of the caveolar invagination and to formation of endocytic vesicle (Fig. 18). 
Fission of the vesicle from the plasma membrane is then mediated by GTPase dynamin II which is 
localized at the neck of the budding vesicle. The released caveolar vesicle can fuse with early endosome 
or caveosome. The caveosome is an endosomal compartment with neutral pH which does not have early 
endosomal markers, however, contains molecules internalized by the caveolar endocytosis. This type of 
endocytosis is used for example for transcytosis of albumin in endothelial cells or for internalization of the 
insulin receptor in primary adipocytes (Parton and Simons 2007; Lajoie and Nabi 2010). 
Potocytosis, involving direct diffusion of small molecules into the cytoplasm after association with 
caveolae, has been proposed as an alternative way caveolae mediate uptake of molecules without 
membrane internalization. The finding that caveolae contain one key element of the machinery involved in 
vesicle budding, the GTPase dynamin, suggests that they also participate in membrane internalization.  
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Figure 18: Caveolae. Caveolae accumulating in a cell micro-injected with antibodies against dynamin 2 (Calzolari, Raggi et al. 
2006). 
 
Insight into the mechanism of caveolar internalization of cell-surface molecules has been obtained 
by visualizing the trafficking of cargo that internalizes through caveolae. The best characterized caveolae-
internalized cargo is SV40 virus, which was found to associate with the plasma membrane in a two-step 





Macropinocytosis refers to the formation of large, primary endocytic vesicles, generated primarily at 
ruffling membrane domains. Macropinosomes are dynamic structures, frequently moving inwards towards 
the centre of the cell, and persist for approximately 5–20 min (Gong, Weide et al. 2007). Macropinocytosis 
is a signal-dependent process that usually occurs in response to growth factor stimulation, such as 
macrophage colony-stimulating factor-1 (CSF-1), epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) (Haigler, Mckanna et al. 1979; Racoosin and Swanson 1989). The main 
characteristic of macropinocytosis is the involvement of actin-mediated membrane ruffling of the plasma 
membrane. Generally, most of the lamellipodia formed retract back to the cell. However, a subset of 
lamellipodia may fold back onto themselves and fuse with the basal membrane creating large, shaped 
vesicles named macropinosomes (Fig. 19).  
Macropinosomes are distinct from other forms of endocytic vesicles in the sense that they have no 
apparent coat structures and that they are generally larger than other endocytosis-related structures (such 
as clathrin-coated vesicles) (Hewlett, Prescott et al. 1994; Swanson and Watts 1995). Owing to their large 
size, macropinosomes, provide the cells with cells with the capability of non-selectively internalizing large 
quantities of solute and membrane.  
The primary regulator of membrane recycling between the plasma membrane and endosomal 
compartments during macropinocytosis is considered the GTPase Arf6 (Radhakrishna and Donaldson 
1997; Franco, Peters et al. 1999). Notably, studies have demonstrated that overexpression of either 
mutant Arf6 locked in its GTP-bound form, or the EFA6 GDP–GTP exchange factor for Arf6, results in both 
ruffling and the accumulation of macropinosomes. Arf6 seems to orchestrate macropinocytic processes by 
regulating the turnover and activation of different effectors. More specifically, Arf6 activates 
phosphatidylinositol 4-phosphate 5-kinase (PtdIns(4,5)P2) at the plasma membrane (Honda, Nogami et al. 
1999), suggesting that PtdIns(4,5)P2 turnover is likely to be one important means by which the dynamics 
of macropinosomes are regulated. Consistent with this, constitutive macropinocytosis in oncogene-
transformed fibroblasts requires constant PtdIns(4,5)P2 turnover. Furthermore, the spectrin–ankyrin-
based cytoskeleton provides an additional class of potential ARF6 effectors, since spectrin-like ligands 
bind spectrin SH3-domain-binding protein 1 (Hssh3bp1) to the macropinosomes, suggesting that ARF6 
activation affects both membrane trafficking and cortical actin dynamics (Xu, Ziemnicka et al. 2000). Once 
formed, macropinosomes undergo a maturation process which is briefly depicted in Fig. 19. However, this 
maturation process occurs in a different way depending on the cell type.  
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In bone marrow-derived macrophages, macropinosomes are formed in response to treatment with 
CSF-1 and within minutes they start acquiring Rab7 late endosomes marker, before their fusion with 
lysosomes and eventual degradation (Racoosin and Swanson 1989). However, Unlike bone marrow-
derived macrophages, macropinosomes in EGF-treated A431 cells have a different fate and do not fuse 
with the lysosomes. After approximately 5 min of EGF stimulation, macropinosomes in A431 cells become 
positive for transferrin receptors as well as for early endosomal antigen 1 (EEA1) (West, Bretscher et al. 
1989; Hamasaki, Araki et al. 2004). Interestingly, macropinosomes in A431 cells do not mature beyond 
the early endosomal stage as indicated by the presence of EEA1. Instead, EEA1 mediates homotypic 
fusion between macropinosomes. Finally, the macropinosome fuses with the plasma membrane, recycling 
its content to the extracellular space (Hamasaki, Araki et al. 2004; Araki, Hamasaki et al. 2006). 
Combined the above observations suggest that macropinosomes represent internalized membrane 
particles in membrane ruffles that are endocytosed upon pronounced membrane and cytoskeletal activity 
during cell activation and motility. Furthermore, macropinocytic processes differ depending on the cell 





Figure 19: Macropinocytosis pathway. Macropinocytosis involves actin cytoskeleton rearrangement at the plasma membrane 
leading to the formation of membrane ruffles. Ruffles may fold back onto themselves and fuse at the base of plasma membrane, 
trapping solute and soluble substances in macropinosomes. Early maturation of macropinosomes involves extensive tubulation 
resulting in mature macropinosomes that are more spherical. The contents of the macropinosomes are then either degraded at the 
late endosome/lysosome or recycled back to the plasma membrane. The cytoskeleton is depicted as black lines (Lim and Gleeson 
2011).  
 
Clathrin/Caveolae-independent (CCI) endocytosis 
 
This particular mode of endocytosis depends on the presence or absence of Dynamin. 
 
Dynamin-­‐dependent	  CCI	  	  
Dynamin-dependent CCI has been detected during the internalization of the β-chain of the 
interleukin-2 receptor (IL-2R-β). Interestingly, the specific endocytic pathway was not inhibited upon 
interference with clathrin-mediated endocytosis components. However, IL-2R-β uptake was strongly 
inhibited upon inhibition of dynamin-2 and RhoA, suggesting that RhoA - a key player in the regulation of 
actin dynamics - could possibly be required for the recruitment of the actin machinery to regulate 
endocytosis via this pathway (Gesbert, Sauvonnet et al. 2004).  
 
Dynamin-­‐independent	  CCI	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Dynamin-independent CCI was first detected in HeLa cells, where the expression of a mutant 
dynamin-1 blocked receptor-mediated endocytosis whereas it increased fluid-phase uptake through 
clathrin-independent endocytosis (Damke, Baba et al. 1995). A common characteristic of constitutive 
dynamin-independent CCI endocytosis appears to be the involvement of small GTPases, either Arf6, or 
CDC42. 
The role of CDC42 in dynamin-independent endocytosis was first described while studying the 
effects of a Rho GTPase inhibitor, Clostridium difficile toxin B (toxin B), or CDC42 dominant negative 
mutant on the internalization of Glycosylphosphatidylinositols-anchored proteins (GPI-APs). Interestingly, 
this dynamin-independent pathway seems to be the main route for the non-clathrin, non-caveolar uptake 
of cholera toxin B (CtxB) (Fivaz, Vilbois et al. 2002; Sabharanjak, Sharma et al. 2002).  
ARF6 has been suggested to mediate dynamin-independent CCI endocytosis of several proteins 
such as class I major histocompatibility complex molecules (MHC I), β1 integrin, carboxypeptidase E 
(CPE), E-cadherin and GPI-APs (Naslavsky, Weigert et al. 2004; Powelka, Sun et al. 2004).  
Nevertheless, although the exact factors that induce and promote the above undefined endocytic 
phenomena still remain unknown, their existence argues for the existing modes of endocytosis. 
 
1.5.6 Endocytosis link to cell transformation 
 
 The identity of the normal, polarized epithelial cell is fundamentally tied to its ability to establish an 
intact mucosal sheet with the directional flow of ions, nutrients and receptor-dependent signals. A 
polarized epithelium requires the maintenance of apical and basolateral membranes with distinct 
characteristics and segregation of functional receptors such as channels, transporters, receptors and 
adhesion molecules in defined apical and basolateral zones separated by intercellular adherens junctions 
and tight junctions (Yeaman, Grindstaff et al. 1999). Continually self-renewing epithelia must maintain 
barrier function during renewal, which is supported by dynamic intracellular vesicle trafficking pathways 
that are responsible for the turnover of polarized membrane domains. Furthermore, in order to mediate the 
exchange of nutrients and crucial proteins, internalized proteins of epithelial cells may be transcytosed to 
the opposite surface (basolateral to apical and vice versa) (Fig. 20).  
A better understanding of the above processes was enabled by the identification of epithelial cell 
channels and transporter proteins as well as apical structures such as microvilli and primary cilia 
(Nachury, Loktev et al. 2007; Muller, Hess et al. 2008; Feng, Knodler et al. 2012), which are necessary for 
maintaining all aspects of the normal epithelial physiology, including barrier functions, the presentation of 
enzymes and transporters, and the function of mucosal surfaces. Therefore, deregulated vesicle trafficking 




Figure 20: Basic model of epithelial cells. Epithelial cells arrange themselves in monolayers and are connected by junctions. Tight 
junctions (red) delineate apical vs. basolateral surfaces, while adherens junctions (blue) adhere cells to each other. Planar polarity is 
found perpendicular to the plane of apicobasal polarity. 
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Figure 21: Vesicle trafficking plays key role during epithelial transformation. Vesicle trafficking is a central contributor for the 
evolution of epithelial cancers. The early loss of cell polarity is a crucial factor in early malignant changes. These changes include 
inappropriate trafficking of junctional proteins and cell adhesion molecules (for example, integrins, E-cadherin). Similarly, progression 
to a more invasive phenotype is associated with trafficking into membrane protrusions, the relocation of integrins, and the targeted 
secretion of matrix metalloproteinases (MMPs) at the invasive front. Finally, metastatic lesions are associated with further alterations 
in vesicle trafficking that promote cell motility and lead to decreased apoptosis (Goldenring 2013). 
 
Alterations in the production or plasma membrane delivery of crucial regulators of structural polarity, 
including components of the intercellular junctions or cell adhesion molecules, influence polarized 
epithelial cell identity. Studies in Drosophila melanogaster have demonstrated that alterations in endocytic 
trafficking can lead to disruption of normal polarized cell and tissue development, and result in tumor 
formation (Morrison, Dionne et al. 2008).  
Notably, some of the mutations that can promote endocytosis-induced invasive phenotype include 
E-cadherin mutations in familial gastric cancer (Guilford, Hopkins et al. 1998), APC mutations in familial 
polyposis (Oshima, Oshima et al. 1995), and BRCA1 mutations in breast cancer (Ashworth, Bertwistle et 
al. 1999). However, even in the case of those hereditary cancer mutations, there are further genetic or 
environmental perturbations required to cause cancer dissemination such as the ones mentioned below: 
1. Aberrant trafficking (presentation or release) of a receptor ligand at the incorrect cell surface may 
lead to inappropriate signaling (Singh, Bogatcheva et al. 2013). 
2. Inappropriate trafficking may cause the redistribution of cell adhesion molecules, such as 
integrins. Since integrin signaling is linked with cell proliferation and motility responses, these 
alterations can promote a transformed phenotype (Kuwada and Li 2000; Muller, Caswell et al. 
2009; Arjonen, Alanko et al. 2012; Rainero, Caswell et al. 2012). 
3. Altered delivery of junction components could elicit changes in the trans-epithelial permeability, 
and redistribute proteins that are normally segregated to apical or basolateral domains (Yokota, 
Ishii et al. 2000; Lioni, Brafford et al. 2007; Krishnan, Lapierre et al. 2011; Hayashi, Tamura et al. 
2012). These changes can lead to aberrant signaling and promote a transformed phenotype. 
4. Losses in cell polarity can lead to inappropriate delivery of degradative enzymes such as matrix 
metalloproteinases (MMPs) to cell surfaces, thereby promoting cell invasion and transformation 
(Williams and Coppolino 2011).  
All of the above scenarios indicate that proper control of vesicle trafficking pathways is central to the 
maintenance physiological cell functions, and that alterations can contribute to epithelial transformation 
and tumor progression.  
 
1.5.7 Endocytosis promotes epithelial to mesenchymal transition (EMT) 
 
A hallmark of most solid tumors is the loss of epithelial cell markers and concomitant acquisition of 
mesenchymal cell markers, a profound phenotypic conversion referred to as epithelial to mesenchymal 
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transition (EMT). EMT phenotypes are observed in many epithelial tumors, such as non-small cell lung 
cancer (NSCLC), pancreatic, colorectal, and hepatocellular cancers particularly at the invasion front 
(Thiery and Sleeman 2006; Keshamouni and Schiemann 2009). EMT is orchestrated by the integration of 
growth factor cues, adhesion signaling pathways that control cytoskeletal morphology and gene 
expression profiles. 
A critical molecular event favoring the disassembly of cell–cell contacts during EMT is the loss of 
the cell adhesion molecule, E-cadherin, a key component of the adherens junctions (Thiery and Sleeman 
2006). EMT and metastatic progression are most often associated with a reversible downregulation of E-
cadherin (encoded by CDH1) involving either hypermethylation of the CDH1 promoter or repression by 
EMT-inducing transcription factors (Thiery and Sleeman 2006; Berx and van Roy 2009). In particular, EMT 
is accompanied by the activation of two transcription factors, Snail and Slug. Notably, however, in addition 
to transcriptional downregulation, posttranscriptional regulation of adhesive structures can also markedly 
influence the progression of EMT (D'Souza-Schorey 2005). The endocytosis and lysosomal degradation of 
E-cadherin is one such cellular mechanism that can have a profound impact on the initial stages of EMT. 
Interestingly, the cytoplasmic domain of E-cadherin contains a dileucine motif, which is a binding site for 
clathrin adaptor complexes, and mutations in the motif can inhibit E-cadherin endocytosis (Miyashita and 
Ozawa 2007).  
Growth factors such as HGF can also induce epithelial to mesenchymal transition (EMT) by 
promoting the endocytosis of E-cadherin molecules (Cox, Hengst et al. 2008; Wu and Hirsch 2009). More 
specifically, HGF can either trigger Arf6 activation, which leads to E-cadherin endocytosis (Palacios and 
D'Souza-Schorey 2003), or induce Ras-mediated activation of RIN2, an upstream activator of Rab5, which 
also results in E-cadherin endocytosis (Kimura, Sakisaka et al. 2006). 
Inerestingly, Arf6 seems to be a critical regulator of E-cadherin internalization, since sustained Arf6 
activation in 3D basement membrane cultures of epithelial cysts led to the internalization of E-cadherin as 
well as of growth factor receptors (Tushir, Clancy et al. 2010). 
 
1.5.8 Endocytosis and cell invasiveness 
 
Aberrant vesicle trafficking can result in enhanced cell migration. Generally, cell migration through a 
matrix requires the dynamic extension of cell protrusions, which are driven by the active turnover of 
cytoskeletal elements and the delivery and recycling of membranes and integral membrane proteins. 
Many components of the endocytic and recycling machinery are concentrated in the leading edges of 
invading cells (Hattula, Furuhjelm et al. 2006). Thus invasive cells are ‘’specialized’’ in their capability to 
directly deliver and recycle membrane vesicles to the invasion front. Knowledge of how these alterations 
occurs and how are maintained by vesicle trafficking pathways, is fundamental to understand the 
regulation of a cellular metastatic phenotype, which is critical for metastatic dissemination. Towards this 
end, the activity of multiple molecules that have been associated with endocytic activity (e.g. Rab proteins, 




Several studies have highlighted the role of Rab proteins in the regulation of cancer cell invasion, 
since overexpression of various Rab small GTPases and their effectors can result in invading structures 




Recent studies have reported two-pore channels to be candidate targets for the treatment of 
metastatic cancers. It has been shown that genetic or pharmacological blockage of the two-pore channel 
TPC2, a key player in the regulation of endocytic transport, reduces lung metastasis in mammary mouse 
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cancer cells. Disruption of TPC2 function blocked trafficking of β1 integrin, leading to its accumulation in 
EEA1-positive early endosomes. Therefore, invasive cancer cells were no longer capable of forming 
leading edges, which are required for efficient migration. These findings highlighted the critical function of 
NAADP- and PI(3,5)P2-sensitive Ca2+permeable cation channels in the endolysosomal system of cells, 
and further support their potential as candidate targets for the treatment of invasive cancers (Ong Nam 
Phuong Nguyen1, Carina Atzberger1 et al. 2017). 
 
Matrix degrading enzymes 
 
Directed secretion of matrix-metallo proteases (MMPs) is a prerequisite for mesenchymal cell 
invasion within a matrix. Interestingly, this process seems to be mediated by endo- and exocytosis, since it 
has been reported that Rab8 along with the SNARE protein vesicle-associated membrane protein 7 
(VAMP7) mediate the secretion of MMP14, which regulates the invasive phenotype of HeLa and 
osteosarcoma cells, indicating that the endocytosis-dependent release of degrading enzymes increases 
cell migration levels (Bravo-Cordero, Marrero-Diaz et al. 2007; Steffen, Le Dez et al. 2008; Poincloux, 
Lizarraga et al. 2009). 
Integrins 
 
A critical aspect of cell migration is the redistribution of adhesion receptors, particularly integrins. 
Migrating cells display enhanced integrin internalization and recycling from the retracting edge of the cell 
to the leading edge and at sites of cell invasion. Interestingly, these trafficking events regulate the 
formation of invasive structures such as filopodia and invadopodia (Caswell, Spence et al. 2007; 
Poincloux, Lizarraga et al. 2009). Moreover, integrins are redistributed during cell migration from focal 
adhesions that disassemble at the cell’s trailing edge towards new focal adhesions that assemble at the 
leading edges. Therefore, modifications in integrin recycling, activation and/or presentation on the cell 
surface can markedly alter the invasive behaviour of cancer cells (Muller, Caswell et al. 2009; Mai, Veltel 
et al. 2011; Rainero, Caswell et al. 2012). Indeed, several reports have described the association of 
integrin trafficking with an increase of migratory potential in several tumor cells lines (Ramsay, Keppler et 
al. 2007; Ramsay, Marshall et al. 2007). In addition, integrin turnover is also thought to facilitate the uptake 
of ECM proteins such as fibronectin and vitronectin and transport of these molecules to the lysosomes 
(Shi and Sottile 2008; Lobert, Brech et al. 2010). 
Integrins can be endocytosed either through clathrin-dependent or clathrin-independent 
mechanisms: Integrin receptor localization was detected in clathrin-coated pits (De Deyne, O'Neill et al. 
1998), and there are studies indicating that integrins can be internalized through macropinocytosis-
dependent mechanisms (Gu, Noss et al. 2011). Interestingly, regarding the latter, it has been shown that 
during growth factor-induced cell migration integrins are redistributed to dorsal circular ruffles and are 
internalized by macropinocytosis. The internalized integrins then transit to endosomal compartments to 
repopulate newly formed focal adhesions on the ventral surface (Gu, Noss et al. 2011). 
Since dynamic integrin turnover is central to cell migration, integrin association with Rab endosomal 
proteins are likely to be important for integrin signaling and of course in cell migration. Interestingly, 
genetic interference with Rab proteins impeded integrin-mediated cell adhesion and motility, indicating that 
integrin-mediated cell migration relies on proper integrin endosomal sorting (Pellinen, Arjonen et al. 2006). 
Furthermore, Rab5 and Rab21 are associated with the plasma membrane and early endosomes and 
regulate the internalization of β1 integrins via direct interaction with their α subunits (Pellinen, Arjonen et 
al. 2006). Reduction of Rab5 or Rab21 in carcinoma-associated fibroblasts decreased α5 integrin at the 
plasma membrane, which enhanced the invasion of squamous cell carcinoma. Additionally, it has been 
shown that Rab25 directly binds to the β1 subunit of α5β1 integrin and facilitates its recycling to the leading 
edge promoting invasiveness (Caswell, Spence et al. 2007). Finaly, Rab11 controls α6β4 integrin recycling 
involved in hypoxia-induced breast cancer cell invasion (Yoon, Shin et al. 2005). 
Notably, altered expression has been reported for various Rab proteins that control integrin 
trafficking, while those altered experession levels are often associated with various types of cancer. For 
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instance, Rab5 is highly expressed in lung adenocarcinoma and hepatocellular carcinoma (Fukui, Tamura 
et al. 2007), while overexpression of Rab25 is well documented in many types of cancers including 
ovarian cancer, breast cancer, testicular tumor, Wilms tumor, and bladder carcinomas (Li 2011). 
Arf6, the primary mediatiator of macropinocytosis has also been reported to control integrin 
trafficking towards cell migration. More specifically, it has been found that Arf6 and β1 integrin associate in 
Arf6-regulated recycling endosomes, and the expression of a dominant negative form of ARF6 abrogated 
Arf6-dependent recycling, leading to a significant decrease of integrin receptor recycling towards the 
leading edge (Brown, Rozelle et al. 2001; Powelka, Sun et al. 2004).  
In addition, GEP100, which is an Arf6 GEF, as well as ACAP1, which is an Arf6 GAP, also regulate 
integrin trafficking: GEP100, which is upregulated in breast cancers, has been implicated in the trafficking 
of β1 integrin receptors (Dunphy, Moravec et al. 2006; Sabe, Hashimoto et al. 2008), while ACAP1 activity 
was shown to be crucial for integrin recycling and cell migration (Li, Ballif et al. 2005). 
Thus the endocytic machinery consists of a complex network of signaling molecules and adaptors 
that is critical for many cellular functions such as internalization, recycling and redistribution of nutrients 
and receptors. However, apart from the prominent role of endocytosis in the context of import and 
recycling, the above findings indicate that it also contributes to orchestrating the framework of signaling 
pathways controlling cell invasion and metastasis. Thus, the endocytic machinery not only controls 
expression and function of surface receptors involved in migration and invasion, but also enables their 
downstream signaling, which combined can contribute to the metastatic phenotype. 
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1.6 Integrins 
 
Integrins consist a family of cell surface transmembrane receptors, responsible for cell-ECM and 
cell-cell adhesion. Due to their functions in tissue organization, integrins are considered critical molecules 
for multicellular organism development (Tamkun, Desimone et al. 1986; Hynes 1987; Hynes 1992).  
Integrins function by promoting cell adhesion, cell survival, differentiation, growth and are essential 
for connecting the intracellular with the extracellular space, leading to cytoskeleton arrangements (Cabodi, 
Di Stefano et al. 2010; Nistico, Di Modugno et al. 2014; Iwamoto and Calderwood 2015). These functions 
are fundamental during embryonal development and wound healing, as well as in various pathologies. 
Integrins are the main components of adhesion force generation, crucial mediators of mesenchymal-like 




Integrins are heterodimeric receptors composed of two non-covalently associated α (eighteen 
isoforms) and β (eight isoforms) glycoprotein subunits. Different combinations of α and β subunits (24 
different types of human integrins) provide integrin receptors with different affinities for ECM molecules. 
Both subunits span the cell membrane, with short intracellular C-terminal tails and large N-terminal 
extracellular domains (Fig. 22). The extracellular domains bind to specific amino acid sequence motifs in 
extracellular matrix proteins or, in some cases, in proteins on the surfaces of other cells (Hynes 1992). 
 
 
Figure 22: The structure of an active integrin molecule, linking the extracellular matrix to the actin cytoskeleton. The N-
terminal heads of the integrin chains attach directly to an extracellular protein such as fibronectin. The C-terminal intracellular tail of 
the integrin β subunit binds to adaptor proteins that interact with cortical actin. Talin is the best-characterized protein adaptor and 
contains a string of multiple domains for binding actin and other proteins, such as vinculin, which help reinforcing and regulating the 
linkage to cortical actin filaments. One end of talin binds to the cytoplasmic tail of the β subunit, whereas other regulatory proteins, 
such as kindlin, bind at another site on  the tail (Alberts, Johnson et al. 2015). 
 
The best-characterized recognition site for integrins is the tripeptide Arg-Gly-Asp (RGD) sequence, 
which is found in fibronectin and other extracellular matrix proteins. Additional integrin-binding sequences, 
as yet poorly defined, exist in laminins and collagens (Kanchanawong, Shtengel et al. 2010; Ross, Coon 
et al. 2013).  
The intracellular portion of an integrin dimer causes the assembly of a multiprotein complex, which 
together establish the linkage to the F-actin cytoskeleton (Fig. 22). The large adaptor protein talin is a 
component of the linkage in many cases, but numerous additional proteins are also involved. An example 
of the actin-linked cell–matrix junctions formed by integrins, are the focal adhesions that form when 
fibroblasts establish strong attachments to the rigid surface of a culture dish, as well as the myotendinous 
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junctions that attach muscle cells to their tendons. In epithelia, the most prominent cell–matrix attachment 
sites are the hemidesmosomes, where a specific type of integrin anchors the cells to laminin in the basal 
lamina (Moser, Legate et al. 2009; Hoffman, Grashoff et al. 2011; Calderwood, Campbell et al. 2013). 
 
1.6.2 Integrin activation 
 
Interaction of the integrin extracellular head domain with the ECM ligand or divalent cations leads to 
partial unfolding of the extracellular domain and separation of integrin subunits, which leads to the 
activation of the integrin heterodimer. Integrin molecules have no kinase activity. However, multiprotein 
complexes assembly, which results in the activation of intracellular signaling that regulates cellular shape 
and functions. This process is called ‘outside-in’ signaling (Campbell and Humphries 2011).  
Structural studies suggest that integrins exist in multiple conformations associated with different 
states of activity (Fig. 23) (Dong, Mi et al. 2012). In the inactive state, the external segments of the integrin 
dimer are folded together into a compact structure that cannot bind matrix proteins. In this state, the 
cytoplasmic tails of the dimer are hooked together, preventing their interaction with cytoskeletal linker 
proteins. In the active state, the two integrin subunits are unhooked at the membrane to expose the 
intracellular binding sites for cytoplasmic adaptor proteins, and the external domains unfold and extend, to 
expose a high-affinity matrix-binding site at the tips of the subunits. Thus, the switch from inactive to active 
states depends on a major conformational change that exposes the external and internal ligand-binding 
sites at the ends of the integrin molecule. External matrix binding and internal cytoskeleton linkages are 




Figure 23: Integrins exist in two   major activity states. Inactive (folded)   and active (extended) structures of an integrin molecule, 
based on data from x-ray crystallography and other methods (Takagi, Petre et al. 2002).  
 
Switching between the inactive and active states is regulated by a variety of mechanisms. Activation 
can occur by an “outside-in” mechanism whereby the binding of an external matrix protein, such as the 
RGD sequence of fibronectin, can drive some integrins to switch from the low-affinity inactive state to the 
high-affinity active state. As a result, binding sites for talin and other cytoplasmic adaptor proteins are 
exposed at the tail of the β chain. The binding of these adaptor proteins then leads to the attachment of 
actin filaments to the intracellular end of the integrin molecule. In this way, when the integrin binds its 
ligand outside the cell, the cell reacts by tying the integrin molecule to the cytoskeleton, so that force can 
be applied at the point of cell attachment (Shattil, Kim et al. 2010).  
Inversely, the cause and effect can also operate from inside to outside. This “inside-out” integrin-
activation process generally depends on intracellular regulatory signals that stimulate the ability of talin 
and other proteins to interact with the β chain of the integrin. Talin competes with the integrin α chain for 
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its binding site on the tail of the β chain. Thus, upon talin binding to the β chain, α–β linkage is blocked, 
allowing the two subunits of the integrin molecule to disintegrate (Calvete 2004). 
 
1.6.3 Integrin signaling 
 
One of the best-studied mechanisms of integrin signaling depends on a cytoplasmic protein tyrosine 
kinase called focal adhesion kinase (FAK). Focal adhesions are sites of prominent tyrosine 
phosphorylation, with FAK being one of the major tyrosine-phosphorylated proteins involved. When 
integrins cluster at cell–ECM contacts, FAK is recruited to the integrin β subunit by intracellular adaptor 
proteins such as talin or paxillin (Fig. 24). The clustered FAK molecules phosphorylate each other on the 
tyrosine residues, creating a phosphotyrosine docking site for members of the Src tyrosine kinases 
(Schlaepfer and Hunter 1997). Phosphorylated FAK can also phosphorylate phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K), phospholipase Cγ (PLCγ), and growth factor receptor bound protein 7 
(Grb7), leading to their activation (Guo and Giancotti 2004; Reardon, Neyns et al. 2011). Therefore, 
outside-in signaling from integrins via FAK and Src family kinases, is relayed into the cell in a way similar 
to the signaling pattern generated from receptor tyrosine kinases.  
The Src/Fak complex can also lead to the phosphorylation of p130CAS and paxillin, promoting the 
formation of a protein complex with Crk and Crk-dedicator of cytokinesis (Dock) (Reardon, Neyns et al. 
2011). The protein complex leads then to the activation of Rac. Rac further activates p21-activated kinase 
(PAK), Jun amino-terminal kinase (JNK), and nuclear factor κB (NF-κB), and PI3K to AKT/protein kinase 
B (PKB). Furthermore, the activated Fak/Src complex can recruit Grb2, which promotes the formation of a 
complex containing Fak and Grb2/Shc and subsequently activates the ERK/MAPK pathway (Guo and 
Giancotti 2004). 
Notably, once FAK is activated in focal adhesions, it promotes actin dynamics by recruiting Arp2/3 
in the lamellipodium (Serrels, Lund et al. 2015; Swaminathan and Waterman 2016). Subsequently, β-PIX 
and the kindlin–paxillin complex further promote Arp2/3 activity through activating the Rac1 GTPase in 




Figure 24: Integrin signaling. Integrin regulation during early stages of cell spreading. The FAK-Src complex activates several 
pathways that lead to protrusive activity via Rac and Cdc42 GTPases at sites of integrin ligation. At the same time, this complex, 
mediates suppression of actomyosin contractility by keeping the activity of RhoA low. Broken lines indicate protein-protein 
interactions (Huveneers and Danen 2009).  
 
1.6.3.1 Integrin-RTK crosstalk 
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The most compelling evidence of integrin-RTK crosstalk derives from their direct, physical 
association. Co-immunoprecipitation assays have confirmed those two receptor interactions. For instance, 
ανβ3 integrin associates with insulin-like growth factor receptor (IGFR-1), platelet-derived growth factor 
receptor (PDGFR) (Schneller, Vuori et al. 1997; Borges, Jan et al. 2000), and vascular endothelial growth 
factor receptor-2 (VEGFR2) (Soldi, Mitola et al. 1999). Additionally, α6β4 integrin has been shown to 
associate with ErbB2 (Falcioni, Antonini et al. 1997), c-Met (Trusolino, Bertotti et al. 2001), EGFR 
(Mariotti, Kedeshian et al. 2001), and macrophage-stimulating protein receptor (Santoro, Gaudino et al. 
2003). These interactions suggest that signaling crosstalk between integrins and RTKs may be the result 
of receptor co-clustering upon cell adhesion or growth factor stimulation. Growth factor stimulation of 
RTKs or ECM-integrin interactions induces an increase in the local concentration of integrins and RTKs at 
focal adhesions and at leading edges of tumor cells, such that crosstalk could occur even without direct 
physical association (Lipscomb and Mercurio 2005). The mode of signaling cooperation between integrins 
and RTKs could be reciprocal as well as uni-directional. Bi-directional cooperation between the two 
signaling systems was demonstrated for the ανβ3-IGF receptor (Maile and Clemmons 2002) and ανβ3-
PDGF- complex (Baron, Shattil et al. 2002), whereupon signaling pathways activated by both receptors 
converged downstream at common signaling effectors. Uni-directional, integrin dependent RTK activation 
was demonstrated for β1 integrin-dependent EGFR activation. β1 integrin activation leads to the c-Src 
dependent recruitment of EGFR and p130Cas, and subsequently to phosphorylation and activation of 
EGFR in an EGF-independent manner (Moro, Dolce et al. 2002).  
 
1.6.3.2 Integrin signaling and P53 
 
Notably, integrin signaling has been shown to induce p53 activity leading to the induction of 
chemotherapy resistance. It has been shown that α5β1 integrin impairs chemotherapy-induced p53 
activation (Martinkova, Maglott et al. 2010; Janouskova, Maglott et al. 2012; Janouskova, Ray et al. 2013). 
Similar findings were obtained in breast carcinoma cells revealing enhanced expression of p53 upon 
deletion of α2β1 (Morozevich, Kozlova et al. 2012). In high-grade glioma, high expression of α5 subunit 
inhibited the temozolomide-induced p53 pathway, inducing resistance to chemotherapy (Janouskova, 
Maglott et al. 2012). 
It has been reported that FAK can inhibit p53 upon direct interaction in the nucleus or cytoplasm 
(Golubovskaya and Cance 2011; Golubovskaya 2014), suggesting that integrin signaling affects p53 
function. Additionally, impairment of α5 integrin or FAK signaling in combination with activation of p53 
results in tumor cell apoptosis (Gillory, Stewart et al. 2015; Renner, Janouskova et al. 2016). Therefore, 
blocking either integrins or their downstream signaling pathways may offer new opportunities to 
synergistically enhance the p53 tumor suppressor effects. 
 
1.6.4 Integrin Functions 
 
Depending on the surrounding matrix, integrins lead to the activation of intracellular signaling 
cascades thereby controlling many aspects of cellular behavior. Hence, aberrations in integrin 
regulation/expression, or mutations in the major integrin effectors can lead to various disorders, examples 
of which are listed below (Wehrle-Haller and Imhof 2003).  
 
1.6.4.1 Embryonic development 
 
In vertebrate embryos, integrins are required for neural crest migration. In chicken, the major 
players in this process are the α4β1 and α1β1 integrins, which can bind to fibronectin and laminin-1, 
respectively (Desban and Duband 1997; Kil, Krull et al. 1998). Initiation of α4β1 expression coincides with 
the beginning of neural crest cells migration, and inhibition of the interaction between α4β1 integrin and its 
ECM ligands with blocking antibodies, ligand-mimicking peptides, or antisense oligonucleotides leads to a 
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severe reduction both in the number of migrating cells and the distance covered (Testaz and Duband 
2001) 
Integrins α5β1 and αvβ5 are involved in the renewal, survival, and differentiation of human embryonic 
stem cells. Moreover, the α5 integrin subunit, as well as fibronectin, play critical roles in the regulation of 
blood vessel development in mouse embryos, since deletion of α5 integrin leads to the development of 
considerably distended blood vessels (Francis, Goh et al. 2002). Notably, integrin α3 knockout mice are 
perinatally lethal, with marked abnormalities in lung development (Kreidberg, Donovan et al. 1996).  
 
1.6.4.2 Immune function 
 
Serious immune disorders can be caused by integrin defects: Integrin aberrant signaling can lead to 
leukocyte adhesion deficiency (LAD), which is characterized by the inability of leukocytes to adhere and 
migrate during inflammatory and host defense reactions (Etzioni 2007). As a result, patients with this 
autosomal recessive syndrome present with repeated bacterial and fungal infections. In resting leukocytes 
and platelets, the integrins are held in a bent/inactive conformation that limits their ability to interact with 
ligands (endothelial ICAMs or extracellular matrix proteins such as fibrinogen or collagen). Following 
cellular activation (by agonists including chemokines, growth factors, antigens or selectin ligands), 
integrins are activated and inside-out signaling occurs. LAD patients show complete failure to activate β1 
and β2 integrins on leukocytes, as well as β3 integrins on platelets (Kilic and Etzioni 2009). Of note, 
impaired integrin signaling derived from mutations in the kindlin gene has been confirmed as the leading 
cause of LAD. Due to those mutations, kindlin fails to be recruited to integrins, therefore integrin inside-out 
signaling is disrupted. Hence, kindlin plays a central role in the activation of hematopoietic integrins, since 
it allows leukocyte adhesion/migration in response to infection and platelet activation for normal 
thrombosis (Ussar, Moser et al. 2008; Moser, Bauer et al. 2009). 
Numerous autoimmune disorders have been characterized by an imbalance or upregulation of 
angiogenic processes. Best known are rheumatoid arthritis (Storgard, Stupack et al. 1999), psoriasis 
(Creamer, Sullivan et al. 2002), restenosis (Bishop, McPherson et al. 2001), diabetic retinopathy 
(Chavakis, Riecke et al. 2002) and tumour growth (Folkman 2002). Moreover, a variety of other allergic, 
inflammatory, traumatic, infectious, metabolic and hormonal disorders are characterised by up-regulated 
vessel growth (Carmeliet 2003). αvβ3 integrin is a receptor with a prominent role in angiogenesis, since it 
mediates the migration of endothelial cells through the basement membrane during blood vessel 
formation. Notably, αvβ3 integrin expression is found not only in endothelial cells during tumour-induced 
angiogenesis, but also during wound healing, in rheumatoid arthritis, in psoriatic plaques and during 
restenosis. 
Integrins are also implicated in age-related macular degeneration (AMD), the leading cause of 
blindness in the elderly population. AMD is characterized by neovascularization of the Retinal Pigmented 
Epithelium (RPE) (Klein and Francis 2003). Integrin ανβ5 is localized at the apical RPE and binds to 
ligands in the interphotoreceptor matrix (IPM), participating in the interactions between photoreceptors and 
the RPE (Mallavarapu and Finnemann 2010). In ανβ5 integrin-deficient mice, retinal adhesion and 
phagocytosis of photoreceptor outer segments are compromised (Nandrot, Kim et al. 2004). It has been 
revealed that ανβ1, ανβ3, and ανβ5 integrins (Friedlander, Theesfeld et al. 1996; Luna, Tobe et al. 1996) 
were expressed in neovascular ocular tissue from patients with wet AMD. Hammes and colleagues 
showed that subcutaneous injection of ανβ3 and ανβ5 antagonists remarkably prevented retinal 
neovascularization in a mouse model of hypoxia induced proliferative retinopathy (Hammes, Brownlee et 
al. 1996). These results indicate the possibility that ανβ3 and ανβ5 integrins might be a therapeutic target 
for AMD. Additionally, the effectiveness of ανβ1 and ανβ5 integrin antagonists (JNJ-26076713) against 
ocular neovascularization has been well documented (Santulli, Kinney et al. 2008). 
Interestingly, immune cell function regulation including T-cell activation and lymphocyte adhesion to 
endothelium through transforming growth factor-β (TGF-β) depends on αvβ6 and αvβ8 integrins 
(Worthington, Fenton et al. 2012). Furthermore, both integrin α4β1 and integrin αLβ2 have been associated 
with inflammatory conditions, particularly autoimmune diseases and asthma (Bao, Omana et al. 2012).  
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Integrins have been proposed to have fundamental role in activating TGFβ1 to control immune 
homeostasis. Knock-in mice expressing TGFβ1 with a point mutation in the RGD integrin binding site 
showed a remarkably similar phenotype to mice completely lacking TGFβ1 production, dying from multi-
organ inflammation early in life (Yang et al. 2007). Subsequent work has shown that integrins αvβ6 and 
αvβ8 are the key activators of TGFβ1 in the steady state immune system, as a combined lack of function of 
these integrins recapitulates the phenotype seen in TGFβ1-knockout mice (Aluwihare et al. 2009). Thus, 
integrins ανβ6 and ανβ8 play a non-redundant role in the activation of TGFβ1 in the immune system which 
is required to prevent self-harmful immune responses. 
 
1.6.4.3 Coagulation and Cardiovascular disease  
 
Integrin αIIbβ3 is the fibrinogen receptor and has a prominent role in platelet aggregation and blood 
clotting. In parallel, integrin αIIbβ3 consists the main integrin type expressed on platelets cell surface. Upon 
platelet association with collagen, integrin αIIbβ3 changes shape, leading thus to fibrin binding, clot matrix 
formation and bleeding arrest (Niu, Chen et al. 2012). Due to αIIbβ3 essential role in platelet aggregation, 
its role as an antithrombotic factor has been established and αIIbβ3 antagonists (abciximab, eptifibatide, 
and tirofiban) have been approved. Importantly, the rational targeting of αIIbβ3 and the clinical efficacy of 
αIIbβ3 antagonists established the central role of platelets in periprocedural thrombosis in the context of 
percutaneous coronary interventions (PCI) (Bledzka, Smyth et al. 2013). 
 
1.6.5 Integrins in cancer 
 
The metastases spawned by carcinomas are formed following the completion of a complex 
succession of cell-biological events, collectively termed the invasion-metastasis cascade. Briefly these 
steps are listed below: 
1. Local tissue infiltration through the degradation of the basement membrane  
2. Intravasation into the blood vessel lumen,  
3. Adhesion at the vessel well  
4. Survival of the rigors of transport through the vasculature 
5. Arrest at distant organ sites,  
6. Extravasation into the parenchyma of distant tissues 
7. Establishment of metastatic microenvironment (niche)  
8. Outgrowth (Fidler 2003) 
Since integrins are implicated in many of the stages of the invasion-metastasis cascade, it is of no 
surprise that increased expression of certain integrin subunits has been reported for Cancer Stem Cells 
(CSCs) and has been linked with poor prognosis and increased metastasis in a variety of cancers 
(Desgrosellier and Cheresh 2010; Medema 2013) (Fig. 25). Some of the integrin-attributed functions 
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Figure 25. Reprogramming of cancer cells by integrin signaling pathways: Integrin signaling is capable of reprogramming 
tumor cells to promote invasion, hematogeneous dissemination, and establishment at distant metastatic sites. Similarly, stemness 
and drug resistance are influenced by integrin-mediated cell-matrix adhesion and the underlying signaling. Understanding these 
events offers new therapeutic opportunities for cancer (Seguin, Desgrosellier et al. 2015).  
 
1.6.5.1 Anchorage-independent growth 
 
In order to grow, proliferate and survive, most cell types (e.g. epithelial, endothelial, muscle cells) 
depend on the attachment on a substratum, whereas upon loss of contact with the extracellular matrix, 
they undergo apoptosis. This form of apoptosis is called anoikis and results from the lack of the integrin-
dependent pro-survival signaling pathways (e.g. PI3K/AKT, MEK/ERK, FAK, NFκB) that manifests when 
cell adhesion decreases (Vachon 2006; Griffiths, Grundl et al. 2011). Mutations that disrupt or override this 
form of anchorage-dependent growth inhibition and make cells resistance to anoikis often occur in cancer 
cells, promote tumor progression and favor the emergence of metastasis (Paoli, Giannoni et al. 2013; 
Buchheit, Weigel et al. 2014). When tumor cells escape from the primary tumor and intravasate into the 
blood or lymphatic vessels, they need to survive in the absence of adhesion to ECM. Mounting evidence 
supports a pivotal role for aberrant integrin signaling in controlling growth and survival when no anchorage 
is available, a property critical for hematogeneous metastasis. For instance, integrin β1 mediates 
anchorage-independent growth in prostate (Schooley, Andrews et al. 2012) and breast cancer cells by 
activating a FAK/PAK/MAPK signaling pathways (Cagnet, Faraldo et al. 2014), whereas integrin β3 
interacts with c-Src to suppress anoikis and promote lymph node metastasis in breast cancer as well as 
pancreatic tumor models (Desgrosellier, Lesperance et al. 2014).  
In melanoma cells, TIMP1, an MMP inhibitor, interacted with CD63 and integrin β1 conferring 
resistance to anoikis (Toricelli, Melo et al. 2013). Additionally, zinc finger transcription factor ZNF304 was 
recently identidied as a novel transcriptional regulator of β1 integrin that promotes cancer cell survival, and 
protects against anoikis in ovarian cancer (Aslan, Monroig et al. 2015), while cilengitide, an αvβ3/β5 integrin 
inhibitor, induced atypical anoikis involving necrosis and autophagy in glioma cells (Silginer, Weller et al. 
2014). Furthermore, suppressed anoikis was recently attributed to enhanced integrin endosomal signaling 
(Alanko, Mai et al. 2015).  
The above examples portray the different ways through which a cancer cell can acquire resistance 




Integrins have been implicated in all steps of tumor progression, including detachment and invasion 
of tumor cells, intravasation into lymphatic and blood vessels, survival and transport through the 
circulation, arrest in distant organs, extravasation into distant organs, and growth of secondary lesions. 
The initial steps of tumor dissemination from a primary site involve a variety of functions mediated and 
regulated by different integrin combinations (Weis and Cheresh 2013; Desgrosellier, Lesperance et al. 
2014).  
The capacity to dynamically interact with and respond to the surrounding tissue is an essential 
prerequisite of a cancer cell to migrate. The result of this interaction can be the phenotypic conversion 
known as the epithelial-to-mesenchymal transition (EMT). This process is critical during development but 
is also frequently triggered during cancer metastasis. EMT is characterized by the transition to a 
mesenchymal phenotype, involving the disassembly of cell-cell contacts, cytoskeletal reorganization, and 
acquisition of mesenchymal markers and migratory properties (Lamouille, Xu et al. 2014). It is of no 
surprise that the mechanisms critical for EMT, stemness and drug resistance demonstrate significant 
overlap (Singh and Settleman 2010), and it is likely that integrins play a critical role in allowing tumor cells 
to become more aggressive and therapy-resistant. 
Matrix degradation is another cellular process that increases tumor cell invasion. Notably, integrins 
are known regulators of MMPs, facilitating ECM degradation and remodeling (Borrirukwanit, Pavasant et 
al. 2014; Missan, Mitchell et al. 2015). Additionally, integrins have also been shown to regulate 
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angiogenesis, thus contribute also to later stages of tumor development (Schaffner, Ray et al. 2013).  
The crosstalk between integrins and GFs also accelerates tumor cell motility and invasion. Clinical 
and functional analyses showed that CD151 (member of the tetraspanin family) and α3β1 integrin were 
elevated in glioblastoma. Both synergized with EGF/EGFR complex to accelerate tumor cell motility and 
invasion (Zhou, Erfani et al. 2015). Additionally, it has been demonstrated that fibronectin matrix mediates 
PDGFR-β association with α5β1 integrin in focal adhesions, leading to enhanced cell migration (Veevers-
Lowe, Ball et al. 2011). Moreover, HGF-mediated c-Met activation induces collective cancer cell invasion 
through β1 integrin trafficking (Mai, Muharram et al. 2014). Hence the above findings suggest that β1 
integrin and GFs either synergistically act in parallel signaling pathways or share the same signaling 
pathways to modulate cancer cell migration. 
 
1.6.5.3 Colonization of the metastatic niche 
 
Metastatic colonization of distant organs requires the survival as well as the expansion of cancer 
cells at the secondary site. Since seeding a ‘’metastatic niche’’ requires specific recognition mechanisms 
between the cancer cells and their surrounding ECM, only a minority of cancer cells will eventually 
manage to reach the distant organ and accomplish the process. Since the integrin expression pattern 
determines the capability of a cancer cell to ‘’seed the niche’’ and initiate metastatic colonization, integrins 
may therefore be considered critical for the ‘’homing’’ of tumor cells into tissue environments that enhance 
metastasis.  
Interestingly, the propensity for metastasis has been associated with the accumulation of certain 
ECM proteins within a particular metastatic niche. For instance, tenascin C, a ligand for β1 and β3 
integrins that is produced within the lung metastatic niche, correlates with poor outcome in breast cancer 
patients (Oskarsson, Acharyya et al. 2011). Furthermore, the αvβ3 ligand L1-CAM is expressed in breast 
cancer cells and is required for breast cancer metastasis to the lungs, enabling tumor extravasation 
towards the lung endothelium (Zhang, Wong et al. 2012). Similarly, integrins αvβ3, α2β1, and α4β1 play 
critical roles in bone metastasis, as their ligands represent ECM proteins normally expressed in bone-
associated cells (Esposito and Kang 2014). Furthermore, knock-out mice for α11β1 integrin, a cell-specific 
receptor for fibrillar collagen overexpressed in carcinoma associated fibroblasts (CAF), abolished the 
metastatic potential of lung adenocarcinoma cells to bone, kidney, or brain (Navab, Strumpf et al. 2016). 
Cumulatively, the above findings portray the complexity of integrin-ligand binding events that govern the 
mechanisms during the formation of new micrometastatic colonies arising from tumor circulating cells.  
Once entrenched within an appropriate metastatic niche, tumor cells must adapt again to survive 
and proliferate. Integrin β1-mediated filopodium-like protrusions that support the initial interactions 
between the extravasated cancer cells and ECM components of the host tissue induce the formation of 
filopodia-like protrusions that ultimately lead to the initiation of adhesion-dependent signaling events such 
as FAK phosphorylation and subsequent activation of ERKs, that result in rapid proliferation and 
spreading (Shibue and Weinberg 2009; Shibue, Brooks et al. 2012). Upon the occurrence of the 
aforementioned adhesion-dependent events, it is also likely that the expression of the integrins providing 
anchorage-independent growth has less influence over the adhesion-dependent growth while prevailing 
growth advantages for circulating cells. Since an integrin receptor can bind to multiple ligands, and a 
single ligand can recognize multiple integrin heterodimers, spatiotemporal regulation patterns of integrin 
vs. ligand expression ultimately determine how a cell senses and responds to its environment. 
 
1.6.5.4 Integrin endosomal signaling and cell migration 
 
Integrin function is not only achieved through ligand engagement and binding of intracellular 
proteins but also through integrin endocytic trafficking. Integrin trafficking offers an important 
complementary mechanism for regulating integrin–ECM adhesion turnover and controls many aspects of 
cellular behavior, including cytokinesis, cell motility, and invasion. Internalization pathways for integrins 
include clathrin-dependent as well as clathrin-independent mechanisms. These include macropinocytosis 
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from circular dorsal ruffles (CDRs) triggered by growth factor receptor signaling (Gu, Noss et al. 2011) as 
well as caveolae-mediated endocytosis (Bridgewater, Norman et al. 2012). There is clear evidence that 
integrin endocytosis comprises an important regulation mechanism for cell migration both in 2D and 3D 
(Caswell and Norman 2008; Valdembri and Serini 2012).  
 
Focal adhesion turnover and cell migration control 
Integrin trafficking has been linked to cell migration mainly through the turnover of focal 
adhesions/focal complexes (Webb, Parsons et al. 2002). Focal adhesions are essential components 
towards the regulation of cellular adhesion and migration. Integrins have to be trafficked from the rear to 
the front of the cell to assemble new focal adhesions. These newly formed adhesions are subsequently 
disassembled for cell detachment. These continuous cycles of focal adhesion assembly/disassembly are 
crucial for cell migration as they provide the cell with a constant pool of free integrins to engage the ECM 
and generate new adhesions (Scita and Di Fiore 2010; Morgan, Hamidi et al. 2013). Hence integrins need 
to be dynamically turned over, which is achieved by endocytic trafficking (Ridley, Schwartz et al. 2003; 
Maritzen, Schachtner et al. 2015). 
 
Integrin association with cytoskeletal structures 
Actin-binding proteins or nucleation/assembly factors have been reported to play crucial roles in the 
pro-invasive activity of integrins: FMNL2 (Formin-like 2-actin nucleation and assembly factor), which is 
upregulated in several aggressive cancers, interacts with RhoC to drive α2β1 and α5β1 integrin 
internalization/trafficking and invasive motility of cancer cells (Wang, Arjonen et al. 2015). Furthermore, 
microtubules mediate the delivery of the mitogen-activated protein kinase kinase kinase kinase 4 
(MAP4K4) to focal adhesions, which leads to enhanced focal adhesion dissolution through an Arf6-
dependent mechanism (Yue, Xie et al. 2014). Additionally, microtubule-associated cytoplasmic linker 
associated proteins 1 and 2 (CLASP1 and CLASP2) have been shown to trigger FA disassembly and 
turnover through the exocytosis of MMPs (Stehbens, Paszek et al. 2014). 
Another mechanism involving integrin trafficking in cell migration is the formation of invasive 
structures such as invadopodia and filopodia: Invadopodia are sites of active ECM degradation mainly by 
the type 1 matrix metalloproteinase (MT1-MMP, also known as MMP14) and consist a typical 
characteristic of invasive cells (Linder, Wiesner et al. 2011). On the contrary, filopodia are integrin-
dependent structures implicated in cancer cell invasion (Arjonen, Kaukonen et al. 2014). Although 
invadopodia and filopodia share similarities, invadopodia-mediated cell invasion depends on active MT1-
MMP recycling (Monteiro, Rosse et al. 2013), whereas filopodia-driven cell invasion depends on integrin 
recycling.  
 
RTKs link to integrin trafficking  
RTK signaling has also been demonstrated to positively regulate integrin trafficking. More 
specifically, stimulation with PDGF resulted in the formation of circular dorsal ruffles, which were enriched 
in β1 and β3 integrins that had been taken up by macropinocytosis. Obviously, this increased integrin 
uptake creates an internal pool of integrins that can be subsequently recycled and promote the formation 
of new adhesions at the leading edge (Gu, Noss et al. 2011). 
Tensin-4, an oncoprotein, and a known β1-integrin-binding partner provides an additional link 
between c-MET and β1 integrin traffic. More specifically, tensin-4 interacts with active c-MET, interferes 
with its endocytosis and leads to constitutive c-Met signaling. Therefore, the tensin-4–c-Met complex 
promotes cell survival, proliferation, tumor growth and cell migration, suggesting that the trafficking 
pathways of c-MET and β1 integrin are closely linked (Muharram, Sahgal et al. 2014). 
It appears that αvβ3 integrin is implicated in VEGFR2 signaling. Pharmacological blockage of αvβ3 
with small molecule inhibitors such as Cilengitide in endothelial cells, increased Rab4-dependent VEGFR2 
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recycling, protecting from its degradation in the presence of VEGF and increasing its levels on the cell 
membrane. Hence, this resulted in VEGF-driven endothelial cell migration, sprouting and tumor 
angiogenesis in vivo, which ultimately led to enhanced tumorigenesis (Reynolds, Hart et al. 2009). 
It has been shown that Rab-coupling protein (RCP) associates with α5β1 integrin and drives RCP-
dependent recycling of α5β1 to the plasma membrane and its mobilization to dynamic ruffling protrusions 
at the cell front. These RCP-driven changes in α5β1 trafficking lead to the increase of cell migration both in 
2D and 3D matrices. RCP-dependent α5β1 recycling has also been shown to promote EGFR and c-Met 
recycling, further promoting cell scattering as well as tumor cell migration in 3D (Caswell, Chan et al. 2008, 
Muller, Trinidad et al. 2013). Therefore, RCP has been suggested to function as scaffold that promotes the 
association of α5β1 integrin with EGFR and c-Met RTKs and that this drives migration of tumor cells in 3D. 
Notably, this pro-invasive function of RCP has been attributed to p53 gain of oncogenic function 
mutations, providing thus an indirect link among integrin recycling, RTK internalization and mutated p53 
during oncogenesis. From a clinical perspective, this consists an interesting novel finding, since EGFR 
and c-Met have been reported to be activated in various cancers, and combination strategies in 
vivo and in vitro to inhibit both receptors have been found to be more effective than inhibition of only one 
(Stommel, Kimmelman et al. 2007; Kawaguchi, Murakami et al. 2009; Brevet, Shimizu et al. 2011; Xu, 
Stabile et al. 2011). Furthermore, the elucidation of the integrin molecules and RTKs that are activated by 
mutant p53 may highlight combinations of anti-integrin agents and RTK inhibitors that would be 
particularly effective in the treatment of mutant p53-expressing cancers (Muller, Caswell et al. 2009; 
Muller, Trinidad et al. 2013; Muller, Trinidad et al. 2014).  
 
Rab proteins control pro-migratory integrin trafficking 
Upon endocytosis, integrins are carried to early endosomes, where sorting into recycling and 
degradative pathways take place. Alterations during this process or mutation in specific Rab proteins 
or/and their effectors can affect the composition of focal adhesions, thereby influencing cell migration 
(Maritzen, Schachtner et al. 2015). 
In invasive cancer cells migrating in 3D, Rab25 mediates the sorting of ligand-occupied, active-
conformation α5β1 integrin to late endosomes/lysosomes. Subsequently, integrins are transported and 
recycled to the plasma membrane through Chloride Intracellular Channel Protein 3 (CLIC3), increasing 
thus the invasive/metastatic behavior of cancer cells (Dozynkiewicz, Jamieson et al. 2012). Furthermore, 
Rab5 and Rab21 regulate integrin endocytosis from the plasma membrane to the early endosome. Direct 
interactions of integrins with Rab21 through its conserved membrane-proximal WKLGFFKR sequence 
have been found in the majority of the integrin α subunits and mediate β1 integrin endocytosis to EEA1-
containing early endosomes (Hynes 2002). Notably, Ras GTPase-Activating Protein 1 (RASA1) 
displacement from Rab21 drives β1 integrin recycling from EEA1-containing endosomes back to the 
plasma membrane and is crucial for directional cell motility. In the same direction, Rab21 promotes cell 
adhesion and migration on collagen, implying thus a pro-migratory role for the endocytic trafficking of the 
collagen-binding integrins (α1β1, α2β1, α10β1 and α11β1) (Humphries, Byron et al. 2006; Pellinen, Arjonen et 
al. 2006).  
Integrins and MMPs can be recycled using the same pathways. It has been shown that the 
increased expression of Rab5a, one of the three functionally redundant Rab5 genes, is predictive of 
increased local and distant relapse in estrogen receptor–positive (ER+) and lymph node–negative (N0) 
breast cancer patients. Interestingly, Frittoli and colleagues revealed that Rab5a mediates its biological 
activities through Rab4. In particular, they found that Rab5a promotes Rab4-dependent recycling of β3 
integrin and membrane-type 1 matrix metalloprotease (MT1-MMP), thus promoting 








The main focus of the present doctoral study is the function of the Ser/Thr Mitogen-Activated Protein 
Kinase Kinase Kinase Kinase (MAP4K4) in the dissemination of Medulloblastoma tumors (see the following 
chapter ‘’Objective & Aims’’). Therefore, to analytically describe the properties, functions of MAP4K4 as well 
as the signaling cascades it is implicated, a detailed review article is listed in the current chapter. The review 
article entitled ‘’The Ser/Thr kinase MAP4K4 controls pro-metastatic cell functions’’ analyzes the biology of 
MAP4K4 (orthologues, structure, identified substrates, signaling pathways involved), and outlines the 
expression of MAP4K4 in cancer tissues and its correlation with tumor progression and prognosis. 
Additionally, we portray the implication of MAP4K4 control in pro-invasive functions of cancer progression, 
and we eventually report the current therapeutic agents that target MAP4K4 functions and their potential as 
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Abstract
The search for novel targeted therapies for major human conditions such as diabetes, cardiovascular diseases
and cancer is a slow and costly process. Progress is often hampered by poor drug efficaciousness in the patients,
low selectivity/specificity of the compounds and cellular evasion mechanism that are rather common in anti-cancer
therapies. This is particularly true also for compounds inhibiting kinases, which in theory are optimal targets thanks
to their druggable enzymatic activity. Novel targeting strategies are needed to reduce side effects and treatment
failure caused by non-specific drug function and target resistance, respectively. An ideal compound will repress the
relevant kinase effector function, while leaving kinase functions that are not disease-relevant unaltered. To achieve
function-specific inhibition, the molecular mechanism of the drug target that governs the pathological process, must
be identified.
The Ser/Thr kinase MAP4K4 is implicated in inflammatory and metabolic disorders and cancer progression. In
this review, we describe the molecular effector functions of MAP4K4 that exert those activities and how they have
been identified and characterized both in invertebrate organisms and mammals. We discuss how the modulation of
the cellular cytoskeleton by MAP4K4 may be connected to pathological conditions such as aberrant angiogenesis
and cancer metastasis, and we describe the molecular mechanisms that are so far known to be mechanistically
involved in these processes.
Keywords: MAP4K4; Cytoskeleton; Cancer metastasis; Cancer
progression
Introduction
MAP4K4 (Mitogen activated protein kinase kinase kinase kinase 4,
also known as Hepatocyte progenitor kinase-like/germinal center
kinase-like kinase (HGK) and Nck-interacting kinase (NIK)) is a
serine/threonine protein kinase and member of the human STE20
family kinases; it was first identified as a kinase interactor of the
adaptor protein Nck in mice [1] and short time later the human
orthologue was cloned as well [2]. The MAP4K4 gene is located on
chromosome 2 at position q11.2 and encodes from 33 exons a protein
containing 1288 amino acids. Structurally, MAP4K4 contains an N-
terminal kinase domain, a coiled-coil domain, a C-terminal
hydrophobic leucine-rich citron homology domain (CNH) and two
putative caspase cleavage sites [3,4]. An interdomain connecting the
kinase and the CNH domain is involved in protein-protein interactions
but is structurally and functionally only poorly understood. Alternative
splicing results in five isoforms that display differences in interdomain
composition, while kinase and CNH domain are 100% homologous.
MAP4K4 is well conserved and orthologues are found across species.
Genetic interference and gene expression analyses have implicated
MAP4K4 activity in a plethora of cellular functions relevant for
physiological and pathophysiological processes, including organ
development, systemic inflammation, metabolic disorders and cancer.
The astounding bandwidth of these functions, which are further
detailed below, indicates the interaction of MAP4K4 with a range of
structurally and functionally different effectors. Surprisingly however,
only a few interactors have so far been described, highlighting the still
incomplete understanding we currently have of how MAP4K4 exerts
its functions. Most of the so far identified MAP4K4 interactors are
functionally associated with the modulation of the actin and
microtubule cytoskeletons. It is thus tempting to speculate that
MAP4K4 modulates cell behavior via targeting the underlying
cytoskeleton dynamics. In this review, we will particularly focus on the
role of MAP4K4 in cancer and cancer progression and discuss how
MAP4K4-controlled cytoskeleton dynamics could initiate and sustain
the complex morphodynamic processes associated with cancer
initiation and progression.
Signaling Through MAP4K4
Since its discovery in the late nineties, only relatively few details on
the regulation of MAP4K4 activity and its substrates could be revealed.
This is all the more surprising, considering the wealth of its
implications in development, metabolic disorders and cancer.
Convincing evidence in different mammalian and fly cell systems
revealed MAP4K4 functions closely associated with the tumor necrosis
factor alpha (TNFα)-induced c-jun N-terminal kinase (JNK) signaling
pathway [1,2,5,6]. TNFα-induced JNK activation by MAP4K4 involves
signal transmission through the kinases TAK1, MKK4 and MKK7 [2].
Interestingly, MAP4K4 not only mediates TNF-α signaling but also
promotes TNFα expression [2], while TNFα can also cause the specific
increase in MAP4K4 expression via the transcription factors c-Jun and
ATF2 [7,8]. On the one hand, this positive feed-back regulation of
TNFα signaling through MAP4K4 is likely involved in physiological
cell functions during development and for tissue homeostasis. On the
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other hand, aberrant TNFα signaling through MAP4K4 was also
linked to pathophysiological processes using genetic ablation and
pharmacological inhibition approaches.
These processes include insulin sensitivity [8], systemic
inflammation [9], pathogen-dependent oncogenic progression [10,11]
and vascular inflammation and atherosclerosis [12]. In addition to the
TNFα-receptor, growth factors (GF) such as PDGF or EGF activate
MAP4K4 through receptor tyrosine kinases (RTKs) [2] and trigger the
phosphorylation and activation of the MAP4K4 substrates sodium-
proton exchanger [1] (NHE1) [13], ezrin, radixin, moesin (ERM)
family proteins [14] and actin-related protein [2] (Arp2) [15]. Genetic
studies in C. elegans identified an interaction between the worm
ortholog of MAP4K4–MIG-15–and integrin/PAT3 [16].
Whether integrin receptor engagement could activate MAP4K4
signaling analogous to the TNFα receptor or the RTKs described above
is currently not known. However, compelling evidence indicates that
MAP4K4 decreases surface availability of active integrins [17], for
example by inactivating integrins via moesin phosphorylation, which
concomitantly competes with talin for integrin binding [18], or by
accelerating their endosomal trafficking [19].
Still in the context of integrin signaling, MAP4K4 was found to be
phosphorylated by the focal adhesion kinase Pyk2 [20], which is
regulated by intracellular calcium levels and activated by G-protein-
coupled receptors [21].
Although not directly activated by transforming growth factor ß/
bone morphogenic protein (TGFß/BMP), MAP4K4 as well as the
closely-related TNIK and MINK promote inhibitory phosphorylation
of Thr312 in the TGFß/BMP effector R-Smads1/2/3/5/8 [22].
Somewhat counterintuitively, MAP4K4 along with its relatives
MAP4K1-6, were recently also found to phosphorylate and activate the
kinase Large Tumor Suppressor 1/2 (LATS1/2) under conditions of
serum starvation [23], which inactivates Yes-associated protein 1
(YAP1) in the evolutionary conserved Hippo pathway. Hippo pathway
activation and phosphorylation-dependent cytosolic retention of the
YAP transcriptional regulator is tumor suppressive, as it prevents pro-
proliferative and anti-apoptotic YAP signaling [24].
Together, a still incomplete picture begun to emerge, where
MAP4K4 activation in membrane proximal, upstream compartments
occurs in response to TNFα receptor, RTKs, and–possibly–also G-
protein-coupled receptor ligation, to trigger JNK and Hippo pathway
activation, sodium-proton exchange, actin polymerization and plasma
membrane remodeling (Figure 1).
Figure 1: Overview of the major MAP4K4 signaling pathways.
From Insulin Resistance to Cell Motility: The Panoply
of MAP4K4 Control of Physiological Processes
Glucose up-take and insulin function
The pathological failure of cells to respond to insulin with glucose
up-take and metabolization is referred to as insulin resistance. It causes
blood glucose levels to raise above the normal range, is associated with
obesity, hypertension and cardiovascular diseases and eventually
results in type 2 diabetes [25,26]. Causative mechanisms for insulin
resistance include impaired insulin receptor (IR) signaling and the
concomitantly deficient ability to restrict hepatic glucose output, as
well as reduced uptake of glucose into muscle and adipose tissue
through the glucose transporter GLUT4. An siRNA screen identified
MAP4K4 as a negative regulator of GLUT4 control of glucose
metabolism in adipocytes that impairs GLUT4 expression and
function 8. Inflammation-associated TNFα regulates insulin action
negatively by repressing signaling downstream of the insulin receptor
and by preventing GLUT4 translocation. Depletion of MAP4K4
ameliorates systemic inflammation in a murine model by reducing
TNFα expression in macrophages [9]. This led to the hypothesis that
MAP4K4 could also mediate the detrimental effects in glucose
metabolizing cells exposed to systemic TNFα. Indeed, silencing
MAP4K4 reverted TNFα-dependent IRS2 depletion and insulin
repression in beta cells [27], and it restored peroxisome proliferator-
activated receptor gamma (PPARgamma) expression by de-repression
of mTORC for a normalized glucose and lipid metabolism in
adipocytes [28]. Consistently, microRNA 30d repression of MAP4K4
expression in pancreatic cells protected beta-cells against TNFα-
induced suppression of both insulin transcription and secretion,
further confirming MAP4K4 targeting as a beneficial strategy for
diabetes prevention [29].
MAP4K4 has also been suggested as a potential biomarker in non-
obese type 2 diabetes, since decreased MAP4K4 expression rates-
attributed to increased methylation of the MAP4K4 promoter-were
observed in non-obese type 2 diabetes patients compared to healthy
subjects [30]. Further in vivo studies demonstrated that MAP4K4
deletion led to decreased fasting blood glucose concentrations and
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enhanced insulin signaling in adipose tissue and liver [31], and that
MAP4K4 mediates hyperinsulinemia in chronic obesity by promoting
islet hypertrophy and insulin secretion from pancreatic cells [32].
MAP4K4 is also implicated in vascular inflammation and the
formation of atherosclerotic plaques, where it enhances TNFα-induced
vascular endothelial permeability, macrophage recruitment and
adhesion [12].
These clear indications of the functional significance of MAP4K4 in
inflammation-associated pathologies call for the use of therapeutics
specifically targeting MAP4K4. However, the discovery of conditional
MAP4K4 deficiency in T cells causing systemic inflammation and
insulin resistance in mice sound a note of caution [33]. In T cells,
MAP4K4 directly phosphorylates TNF receptor-associated factor 2
(TRAF2), leading to its degradation, repression of IL-6 production and
the concomitant suppression of Th17 cell differentiation, which
triggers an insulin resistant phenotype. Another study revealed that
MAP4K4 expression in CD4+ T-cells restricts lung inflammation in
response to the environmental pollutant ozone-oxidized black carbon
(oBC), which is characterized by increased numbers of macrophages,
lymphocytes, neutrophils, cytokine secretion and bronchoalveolar
lavage fluid accumulation (BALF) [34]. Finally, mice lacking
endothelial MAP4K4 displayed lymphatic defects such as dilated
lymphatic capillaries, insufficient lymphatic valves, and impaired
lymphatic flow [35], suggesting that beneficial effects of MAP4K4
targeting in the atherosclerotic blood vasculature may have negative
impact on lymphatic drainage. Thus, careful future studies will be
required to assess the cell-type specific functions of MAP4K4 and their
role in metabolic and inflammatory diseases.
Development and Differentiation
The Drosophila ortholog of MAP4K4 – misshapen (MSN) – was
initially identified as shape control gene in the Drosophila eye [36].
Subsequent studies implicated it upstream of Drosophila JNK to
control dorsal closure during late embryogenesis [5]. In mammals,
MAP4K4 plays a critical role in stimulating migration of presomitic
mesodermal cells away from the Primitive Streak (PS) and in
promoting the differentiation of presomitic mesoderm into somites
[37]. Its absence causes embryonic lethality between days 9.5 and 10.5.
MAP4K4 is also involved in the control of epithelial to mesenchymal
transition (EMT) during gastrulation, where it along with the p38-
interacting protein (p38IP) activates p38 to downregulated E-cadherin
expression [38]. E-cadherin down-regulation contributes to the
mesenchymal phenotype, which is prerequisite for cells to move away
from the primitive streak. Interestingly, the above signaling cascade
functions independently from the well characterized EMT-associated
pathway that involves FGF and the Snail transcription factor, and
suggests an alternative route requiring MAP4K4 activation of p38 [38].
TGFß/BMP signaling, which is involved in early development, axis
formation and patterning [39], is negatively regulated by MAP4K4 and
prevented from exerting its correct function during Drosophila
imaginal disk formation [22]. Although speculative, MAP4K4 could
thus be involved in spatio-temporal fine tuning of TGFß/BMP
signaling during development. It is also conceivable, that alterations in
this regulation in the context of aberrant MAP4K4 activation could
result in developmental defects in the embryo and cancer initiation/
progression in the adult organism. In addition to its role in the
developing organ, MAP4K4 also contributes to reshaping the adult
organism, where it restricts differentiation of myoblasts into myotubes
[40] or in enteroblasts, where it controls differentiation by
phosphorylation of the Hippo pathway core component LATS1/2 and
concomitant degradation of the transcriptional regulators YAP/TAZ
[41].
Axon Navigation and Neurite Outgrowth
Axonal migration during development is a complex process that
controls the correct orientation and connection of axons. MAP4K4 is
involved in axonal navigation and neuronal pathfinding with the first
evidence being identified in Drosophila with the identification of Msn/
MAP4K4 control of photoreceptor pathfinding [42]. Shortly after, the
genetic interaction of MIG-15/MAP4K4 and the integrin Ina-1 was
found to be required for proper axon navigation in C. elegans [16].
While MIG-15 appears to be dispensable for lamellipodia and
filopodia dynamics during growth cone outgrowth and cell migration,
it is required for proper directional control of neuronal outgrowth [43].
Comparative time lapse imaging of growth cone dynamics revealed
that MIG-15 mechanistically interacts with the ezrin/radixin/moesin
ortholog ERM-1 at the rear end of the growth cone, to restrict lateral
protrusions and to maintain directional migration [44]. In mammalian
cells, MAP4K4 was identified in a high-throughput screen for
regulators of neurite outgrowth. In contrast to its neuro-promoting
functions during development, MAP4K4 depletion in cerebellar
granule neurons significantly increased the length of regenerating
neurites, suggesting that MAP4K4 in mammals restricts neuronal
outgrowth [45]. This finding was confirmed by an unrelated study
using a militarinone-inspired 4-hydroxy-2-pyridone inhibitor targeting
MAP4K4, which resulted in neuritogenesis [46]. MAP4K4 inhibition is
also a reported target of kenpaullone, an inhibitor of Amyotrophic
Lateral Sclerosis (ALS) [47]. Consistent with a potentially destructive
function of MAP4K4 for neuronal integrity, kenpaullone improved the
survival of human motor neurons derived either from mouse
embryonic stem cells or from ALS-patient-induced pluripotent stem
cells. Interestingly, kenpaullone efficiency was partially attributed to its
inhibition of the MAP4K4-TAK1-MKK4-JNK-c-Jun cell death
signaling cascade.
Together, these somewhat conflicting results from developing
organisms and mature neurons corroborate the relevance of proper
MAP4K4 function for neuronal development and integrity. However,
future research will be necessary to reconcile the stabilizing functions
of MAP4K4 during neuronal development with its destructive
signaling in mature neurons. It will also be of particular interest to
explore whether kenpaullone could be used to treat brain cancers with
increased MAP4K4 expression such as glioblastoma [3,48] and
medulloblastoma [49].
MAP4K4 is Overexpressed in Solid Tumors
A comparative analysis of healthy tissues with lines of the National
Cancer Institute tumor panel reveled striking up-regulation of
MAP4K4 in latter, with glioblastoma cancer cell lines displaying the
highest upregulation in MAP4K4 expression levels [3]. Since then, a
number of studies listed below have noted increased expression and/or
altered function of MAP4K4 in tumors.
Brain tumors
Transcription analyses in glioblastoma multiforme cell lines and
primary samples revealed that EGFRvIII, a constitutively activated
EGFR mutant, leads to specific upregulation of a group of genes
including MAP4K4 [48]. Also in a glioblastoma model, MAP4K4 was
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found to interact with the focal adhesion-related kinase Pyk2 and to
cooperate with it for glioblastoma cell migration [20]. MAP4K4
expression is also markedly higher in pediatric Medulloblastoma,
particularly in the SHH and Group 4 subgroups, compared to healthy
cerebellum tissue, and promotes tumor cell migration and invasion
downstream of the hepatocyte growth factor receptor c-Met [49].
Pancreatic ductal adenocarcinoma
MAP4K4 is overexpressed in 46% of stage II Pancreatic Ductal
Adenocarcinoma (PDA) primary samples, with particular
overexpression detected in the neoplastic epithelium compared to the
PDA stroma [50]. Furthermore, multivariate statistical analyses in
PDA samples revealed the association of MAP4K4 expression with
poor overall and recurrence-free survival, recommending it as a
prognostic marker for patients with stage II PDA [51].
Colorectal cancer
MAP4K4 and four additional genes (LYN, SDCBP, DKK1, and
MID1) consist a five-gene signature in colorectal cancer highly
correlated with poor overall survival of the patients. In addition,
increased MAP4K4 mRNA expression per se closely correlates with
metastasis, tumor invasion and decreased overall patient survival [52].
Lung adenocarcinoma
Adenocarcinoma is the most common histological subtype of lung
cancer and accounts for almost half of all lung cancers. Elevated
MAP4K4 expression is closely associated with lung adenocarcinoma
progression and is an independent prognostic factor predicting poor
overall survival [53].
Hepatocellular carcinoma (HCC)
MAP4K4 expression is increased in Hepatocellular carcinoma
(HCC) specimens compared to adjacent non-tumor liver tissues, and
its upregulation correlates positively with tumor size, tumor grade and
intrahepatic metastasis. Consistently, high MAP4K4 expression is an
independent predictor of poor prognosis in HCC patients [54].
Gastric cancer
Gastric cancer is the second most common cause of cancer-
associated mortality worldwide. In more than 2/3 of gastric cancer
patient samples increased MAP4K4 expression levels were detected
compared to adjacent non-tumorous regions [55].
Ovarian cancer
In contrast to all other solid tumors investigated, MAP4K4
expression levels correlate negatively with tumor load in a murine
model of ovarian cancer. In this study, non-transformed ovarian
epithelial cells were compared to their spontaneously transformed
counterparts using genome-wide transcriptome analysis. Alterations in
the gene expression profile were then correlated with the profiles of
four different human ovarian cancer types [56].
microRNA regulation of MAP4K4 expression in cancer
microRNAs (miRNAs) are endogenous, small noncoding RNAs,
with a length of approximately [19–24] nucleotides that negatively
regulate gene expression by base pairing complementary sites on the
3’-untranslated region (3’-UTR) of target messenger RNAs [57].
Several MAP4K4-targeting miRNAs were found repressed in tumors,
leading thus to increased levels of MAP4K4 expression. These include
Let7a in Kaposi sarcoma, miR-194 in CRC [58] and HCC [59] and
miR-622 in CRC [60].
MAP4K4 Controls Pro-Metastatic Functions in Cancer
Progression
Increased expression levels of MAP4K4 at mRNA or protein levels
have been correlated with tumor aggressiveness and reduced patient
survival. But what are the molecular events controlled by MAP4K4
that trigger or maintain the transformed cellular phenotype and
promote metastatic disease? Despite research efforts ongoing for close
to 20 years, this question still remains incompletely answered.
Improved gene interference strategies and the development of small
compound inhibitors of MAP4K4 have simplified the identification of
effector pathways and putative molecular interactors. Nevertheless, the
effector molecules of MAP4K4 and how their interaction with altered
MAP4K4 expression or function is coupled to the biological outcome,
remains enigmatic in most instances. Key biological functions
controlled by MAP4K4 are reviewed in the following section.
Tumor cell growth
Ras-transformation of NIH3T3 fibroblasts enables these cells to
grow independent of adhesion to a rigid matrix (anchorage
independent growth). Ablation of MAP4K4 function in such NIH3T3
fibroblasts by the overexpression of a kinase-inactive MAP4K4 mutant
completely abrogated anchorage independence, suggesting that
MAP4K4 contributes an essential function to anchorage-independent
survival and growth [3]. Knock-down of MAP4K4 caused cell cycle
arrest and apoptosis in HCCs [54] and in gastric cancer cells (GCCs)
[55]. Cell cycle arrest and apoptosis after MAP4K4 knock-down was
accompanied by the repression of JNK, NF kappa B, and toll-like
receptor (TLR) signaling in HCC cells [54], and increased the Bax/
Bcl-2 ratio and decreased Notch signaling in GCCs [55]. Whether
impaired HCC and GCC growth after MAP4K4 ablation is indeed the
consequence of repressed JNK, NF-kappa B and TLR signaling, or
rather mediated by an alternative route in these cancer cell lines is not
clear. However, since MAP4K4 ablation does not cause growth arrest
and apoptosis in all cancer cell lines, the susceptibility factor in the
sensitive ones remains to be determined.
Cell migration and invasion
Early studies in Drosophila and C. elegans pointed towards cell
shape and migration control as hallmark functions of MAP4K4
signaling [5,36,61]. Since disturbed morphodynamics and cell
migration control are intimately associated with the cancerous
phenotype, studies in cancer cell lines soon confirmed the pro-
migratory function of MAP4K4 [3,62]. MAP4K4 implications in
migration control in the context of cell transformation was also shown
in macrophages infected with the protozoan parasite Theileria
annulata, where parasite-induced TNFα secretion by the host cell
activates MAP4K4 in an autocrine manner, to drive migration and
invasion of the host cell [11]. In an inflammatory context as well,
MAP4K4 promotes Kaposi Herpes virus-infected cell migration by
controlling the expression of genes responsible for motility and
invasiveness such as COX-2, MMP-7 and MMP-13. In HCC, MAP4K4
depletion markedly reduced cancer cell migration both in vitro and in
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vivo, reduced cell adhesion to extracellular matrix (ECM) proteins and
impaired the expression of NF-κB and the Matrix Metalloproteases 2
and 9 [54,63]. In the malignant pediatric brain tumor
medulloblastoma, MAP4K4 is overexpressed and mediates migration
and invasion downstream of HGF and EGF [49], whereas in adult
glioblastoma cells, MAP4K4 was found to interact with Pyk2, a
member of the focal adhesion kinase family, and to be required for
migration and invasion [20]. Molecular mechanisms linking MAP4K4
activity to pro-metastatic functions Figure 2.
Figure 2: Upregulation of F-actin cytoskeleton turnover and
membrane dynamics at the leading edge of cancer cells facilitate
migration and tissue invasion. Small compound inhibitors targeting
MAP4K4 block these pro-migratory functions and cells revert to a
more stationary and less migratory phenotype.
Mechanistically, the identification of C. elegans integrin as an
interaction partner of MAP4K4 during commissural axon navigation
[16] hinted towards functional implication of MAP4K4 in cell
adhesion and migration control. The ezrin, radixin, moesin ERM
family were then identified as MAP4K4 substrates and interactors,
which mediate lamellipodium extension in response to growth factor
(GF) stimulation in breast adenocarcinoma cells [14] and in highly
motile macrophages transformed by intracellular pathogen Theileria
annulata [11]. Interestingly, in C. elegans, MIG-15 and the moesin
orthologue ERM-1 function in the same pathway to direct
commissural axon migration [44]. Mechanistically, MIG-15 and
ERM-1 enable the stabilization of the rear end of the growth cone and
the retraction of non-productive protrusions. Whether this structural
stabilization of the growth cone by MIG-15 and ERM-1 in C. elegans is
mechanistically related to lamellipodium stabilization in mammalian
cells is not clear. Consistent with the notion that MAP4K4 controls cell
adhesion are two recent studies describing accelerated turnover of
integrin-based adhesions: On the one hand Yue et al. identified
MAP4K4 as a focal adhesion (FA) disassembly factor acting in
conjunction with microtubule ending binding protein 2 (EB2) and IQ
motif and SEC7 domain-containing protein 1 (IQSEC1) in
keratinocytes [64]. On the other hand, Vitorino et al. found that
endothelial cell MAP4K4 phosphorylates moesin to displace the F-
actin binding protein talin from the intracellular tail of ß1 integrin
[18]. Common to both studies is that MAP4K4 activity triggers the
turnover of adhesion complexes. Indeed, depletion of MAP4K4 or its
inactivation causes the cells to spread and adhere more tightly
[3,11,14]. Acceleration of focal adhesion turnover may thus be one
function of MAP4K4 to facilitate cell displacement, in particularly also
inside 3D matrix, where focal adhesions, the adhesion associated
signaling complexes and their coordinated turnover controls
mesenchymal cancer cell migration [65].
Cytoskeleton dynamics at the cell front during migratoion are
controlled among many other factors by local pH gradients. The
sodium/proton (Na+/H+) exchanger 1 (NHE1) causes spatially-
restricted H+ efflux at the leading edge of cells [66]. In addition to its
exchanger activity, NHE1 also acts as a membrane anchor for the
cytoskeleton and an assembly point for signaling molecules [67-69].
MAP4K4 binds to and phosphorylates the C-terminus of NHE1 and
causes its activation, which increases the intracellular pH in proximity
of the plasma membrane [13]. NHE1 is involved in cell migration
control [70-72] and associated with metastatic functions in cancer cells
[73-75]. GF control of this central regulator of cortical cell functions
through MAP4K4 may contribute to local remodeling of the
cytoskeleton [76,77] and enable the formation of invasive membrane
protrusions. Not surprisingly, targeting NHE1 has emerged as a
potential strategy in tumor treatment [78].
Another possible function of MAP4K4 in cell migration and
invasion control is its activity towards the actin-related protein 2
(Arp2) subunit of the Arp2/3 complex. Arp2 phosphorylation by
MAP4K4 increased the actin nucleation activity of the Arp2/3 complex
in vitro and in EGF-stimulated cells, demonstrating that MAP4K4 can
couple growth factor (GF) signaling to F-actin polymerization [15].
MAP4K4 accumulates at the leading edge of cells migrating on/in
either 2D or 3D matrix [3,11,14,49,79]. Thus, MAP4K4-driven F-actin
polymerization at the leading edge combined with its activity towards
focal adhesions make it a prime candidate for GF control of the
membrane protrusions at the leading edge of cells that drive invasive
cancer cell motility. Indeed, depletion of MAP4K4 in medulloblastoma
cells infiltrating collagen I matrix caused a defect in protrusion
formation and completely abrogated GF-induced cancer cell invasion
[49].
Therapeutics Targeting MAP4K4 Functions
The broad implication of MAP4K4 in human disease conditions
including metabolic and inflammatory disorders as well as cancer have
incited efforts in the pharmaceutical industry to develop a specific
small compound inhibitor. Genentech applied two separate fragment-
based lead discovery approaches, which identified pyridopyrimidine
scaffold-based compound 29 (C29) [80] and C35 [40]. Starting from a
micromolar pyrrolotriazine fragment hit, Genentech developed a series
of MAP4K4 inhibitors with single digit nanomolar IC50s by utilizing
crystal structures and molecular modeling. Calculated properties were
used to guide the optimization of solubility and in vitro stability,
yielding compounds with excellent biochemical potencies, ligand
efficiencies and favorable in vivo bioavailability in mice. However, as
with many small compound kinase inhibitors, moderate kinase
selectivity was observed and the closely related kinase Misshapen-like
kinase 1 (MINK1) and TRAF2- and Nck-interacting kinase (TNIK)
were also effectively inhibited by both compounds. C35 was found to
be even less specific as it also blocked activities of Cdk1, Flt3, KDR,
KHS1, and Mink1 by more than 75% [40]. Nevertheless, C29 was
found to be a valuable tool in in vivo studies but its applicability
suffered from the shortcoming that it was poorly tolerated when dosed
repeatedly [80]. Its capability to permeate into the CSN was suspected
to cause the poor tolerability. Medical chemistry efforts were therefore
undertaken to reduce penetration of C29 into the CNS. The resulting
GNE-495 reduced brain exposure while maintaining potent activity
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and good kinase selectivity, and recapitulated the phenotypes of
MAP4K4 inducible knockout mice [81]. In a search for
pharmacologically active compounds targeting pathological
angiogenesis, the GNE-220–yet another MAP4K4 inhibitor from
Genentech–was identified. This compound prevented MAP4K4-
dependent talin replacement by C-terminally phosphorylated moesin
from the intracellular domain of integrin β1, and reversed membrane
retraction defects in endothelial cells associated with pathological
angiogenesis [18].
A virtual screening approach using the crystal structure of the
MAP4K4 kinase domain was employed by Pfizer, and the compound
PF-6260933 with excellent selectivity was developed [82]. However,
similar to the Genentech compounds, PF-6260933 also inactivated
TNIK and MINK. PF-6260933 was used in a study investigating
MAP4K4 function in vascular inflammation and atherosclerosis. It
phenocopied the MAP4K4 knock–down and ameliorated plaque
development in a murine model for atherosclerosis [12].
MAP4K4 is highly expressed in the brain tissue and its implications
in neurodegenerative disorders have been addressed in the context of a
search for natural products with neurotrophic and/or neuroprotective
activities [46]. One such bioactive compound - militarinone-A - was
identified as metabolite of a Cordycept fungus. Militarinone-A analogs
were generated and as their protein targets were not known, they were
analyzed for kinase selectivity. To evaluate the neurotrophic activity of
those Militarinone-A analogs, they were subjected to phenotypic
screening in the human neuroblastoma cell line SH-SY5Y. Compound
11e enhanced neurite outgrowth and inhibited MAP4K4 kinase
activity in vitro, making it a suitable starting compound for future
studies related to neurological disorders and – possibly - also
MAP4K4-dependent brain tumors [46].
Concluding Remarks
The amazing diversity of MAP4K4 pathological function in different
human conditions calls for a more general reflection on the biological
processes it is involved with, and how they are associated with a
specific disease condition. In this context, the regulation of the actin
cytoskeleton is a good example, as it not only enables cellular
morphodynamics but also spatially controlled signaling, surface
receptor trafficking and turnover and endocytic up-take, to name only
a few. MAP4K4 modulates the remodeling of the F-actin cytoskeleton
in response to growth factors (GF) such as HGF, EGF and PDGF or the
pro-inflammatory cytokine TNFα, both by directly controlling
polymerization dynamics as well as signaling mediators associated
with cytoskeleton control. The tripartite mechanism control of F-actin
remodeling by MAP4K4 through pH regulation [13], actin
polymerization and branching [15] and F-actin anchoring [14],
strongly argues for MAP4K4 effectively translating growth factor (GF)
signaling into cytoskeleton alterations affecting not only the overall
morphology of the cell, but also how signals are transmitted inside the
cell and how surface receptors are made available. Such alterations also
support the disease conditions MAP4K4 was found associated with, in
particular in pathological angiogenesis and cancer metastasis. On the
one hand, it will thus be of importance to further dissect the
downstream effector mechanisms of MAP4K4 specific to the
condition, in order to more specifically target its function in this
process. On the other hand, the signaling functions of MAP4K4 should
not be observed isolated, but rather in the context of its broader impact
on the cytoskeleton. Consequently, inflammatory signaling triggered
by TNFα and mediated by MAP4K4, should thus also be investigated
under the angle of the effects MAP4K4 may have on cytoskeleton
modulation. An example for such context-dependent, global
modulation of cell function was observed in a host-pathogen model,
where parasite-dependent, TNFα-induced MAP4K4 signaling in the
host cells bifurcates into JNK expression and activation on the one
hand and ERM protein-associated control of lamellipodium dynamics
and invasive motility on the other hand [11]. Through its activity at
different levels of cell function, specific targeting of its context-
dependent actions may thus emerge as a therapy specifically tailored to
the disease-causing activity, and hence reduce non-desired side-effects
of treatment.
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2.	  Rational	  &	  Hypothesis	  
	  






Cellular and molecular mechanisms controlling migration, invasion and dissemination of 
Medulloblastoma (MB) are only poorly understood. The main focus of the host lab is to identify and better 
understand mechanisms that control the metastatic dissemination of MB. Aberrantly activated kinase 
signaling pathways have been linked to cancer cell migration and metastasis. One kinase with oncogenic 
functions is the Ser/Thr protein kinase MAP4K4, which has been linked to cytoskeletal rearrangements, cell 
shape and migration control, cell transformation and metastasis in human cancer (reviewed in the previous 
chapter). Using a host-pathogen cell transformation model, the host lab linked MAP4K4 functions to the pro-
invasive phenotype of macrophages infected with the protozoan parasite Theileria annulata. In this study, Ma 
et al. had shown that parasite-induced, autocrine secretion of TNFα by the host cell activates MAP4K4, 
which promotes migration and invasion of the host cells. This study and studies from several other labs have 
thus clearly linked MAP4K4 functions to the establishment or the maintenance of a pro-metastatic 
phenotype, in particular through its control of cytoskeleton dynamics. However, despite the fact that MAP4K4 
is overexpressed at mRNA levels in glioma, MB and MB cell lines, little was known about MAP4K4 function 
in metastatic brain tumors. An un-published mass spectrometry analysis of the host lab of putative MAP4K4-
interacting proteins identified a number of proteins related to the regulation of the cytoskeleton and/or the 
endocytic machinery. Cumulatively, these observations provided a strong rational to explore MAP4K4 as pro-
metastatic oncogene in MB and to determine the implication of the actin cytoskeleton and the endocytic up-















3.	  Objective	  &	  Aims	  
	  






The objective of this study was to determine whether and how MAP4K4 functions control migration 





1. To develop appropriate tools for the analysis of MAP4K4 function in MB  
2. To determine whether MAP4K4 controls actin dynamics and endocytic up-take in MB cells  
3. To determine whether the MAP4K4-controlled processes identified in aim 2 mediate pro-invasive 



















Aim 1: To develop appropriate tools for the analysis of MAP4K4 function in MB  
 
In this aim I explored different methods of interference with MAP4K4 expression and activity in MB cell 
lines. These included the downregulation of MAP4K4 expression (small interference RNA - siRNA, inducible 
expression of short hairpin RNA - shRNA, Clustered Regularly Interspaced Short Palindromic 
Repeats/CRISPR-associated protein-9 nuclease - CRISPR/CAS9 - technology) and the overexpression of 




The cells were transfected using either Silencer Select siRNA specific for MAP4K4 or Silencer select 
negative control (Fig. 26A).  
 
shRNA 
Inducible shRNA DAOY cell lines were generated by lentiviral transduction pLV-H1TetO-RFP-Bsd 
vectors encoding either MAP4K4 shRNA or scramble shRNA. Doxycycline-containing medium was added for 
48 h for shRNA induction and protein downregulation was verified by IB (Fig. 26D). 
 
CRISPR/Cas9 
MAP4K4 genomic locus was screened for the exons of interest to be targeted by sgRNAs. The exons 
of interest were determined based on their presence in all MAP4K4 isoforms. Subsequently, CRISPR guide 
RNA binding sites were screened with the ‘’Optimized CRISPR design’’ online tool (http://crispr.mit.edu/) and 
the candidate CRISPR sgRNAs with the minimum off-target effects (with a score of >80%) were selected. 
sgRNAs were designed as 20 bps sequences. The synthesized sgRNAs were cloned in BFP containing 
lentiviral vectors and lentiviral transduction was subsequently used to generate MAP4K4-Lenti-CRISPR MB 
cell lines (McComb, Aguade-Gorgorio et al. 2016). 
 
MAP4K4 overexpression 
MAP4K4-ectopically expressing MB cell lines were generated using lentiviral transduction of vectors 






Figure 26: Methods of interfering with MAP4K4 expression in DAOY cells (Immunoblots). A, B and D: Downregulation of 
MAP4K4 expression using siRNA, Lenti-CRISPR constructs and shRNA respectively. C: Ectopic expression of MAP4K4 wild type (wt) 
and K54R kinase dead mutant.  
 






Aim 2: To determine whether MAP4K4 controls actin dynamics and endocytic up-
take in MB cells 
 
4.1 Foreword Manuscript 1 
 
Following the establishment of the necessary tools to study MAP4K4 function, the second aim of my 
project focused on the function of MAP4K4 in the regulation of MB cell motility. In particular, our studies 
focused on the implication of MAP4K4 in the HGF-induced cell dissemination. HGF and its receptor c-Met 
have been associated with poor outcome in MB patients. Furthermore, c-Met expression is increased in MB 
tumor samples and cell lines (Li, Lal et al. 2005), while increased expression of HGF promotes formation and 
growth of MB tumors in mice (Binning, Niazi et al. 2008). In parallel, increased c-Met activity has been 
associated with proliferation, anti-apoptosis, and migration in MB, whereas activating mutations for MB-
expressed c-Met have not yet been reported (Li et al. 2005; Provencal et al. 2009; Guessous et al. 2012; 
Guessous et al. 2010; Kongkham et al. 2010; Onvani et al. 2012).  
The molecular mechanisms and downstream effectors that mediate HGF-induced MB cell 
dissemination are poorly understood. Therefore, in the manuscript listed below entitled: ‘’The Ser/Thr kinase 
MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma’’, we 
aimed to investigate the functional significance of the HGF-c-Met signaling pathway in MB cell 
dissemination. We used cell-based in vitro 2D and 3D motility assays combined with live-cell imaging and 
biochemical assays to examine and identify druggable mediators of HGF-c-Met-induced MB cell 
dissemination. 
 Remarkably, in the manuscript listed below, we identified MAP4K4 as a novel mediator of c-Met-
induced invasive cell dissemination. We found that MAP4K4 controls of F-actin dynamics in invasive 
protrusions, enhancing thus MB cell invasive motility, suggesting that MAP4K4 could present a putative 
target for treating growth factor-induced dissemination of MB tumors. Notably, the main findings that signify 
MAP4K4 involvement in the HGF-c-Met signaling pathway are depicted in Figures 4B, 5 and 6 and represent 
my contribution to the study. 
 
























The Ser/Thr kinase MAP4K4 drives c-Met-induced
motility and invasiveness in a cell-based model of
SHH medulloblastoma
Karthiga Santhana Kumar1†, Dimitra Tripolitsioti1†, Min Ma1†, Jasmin Grählert1,2, Katja B Egli1, Giulio Fiaschetti1,
Tarek Shalaby1, Michael A Grotzer1 and Martin Baumgartner1,3*
Abstract
Medulloblastoma (MB) comprises four molecularly and genetically distinct subgroups of embryonal brain tumors
that develop in the cerebellum. MB mostly affects infants and children and is difficult to treat because of frequent
dissemination of tumor cells within the leptomeningeal space. A potential promoter of cell dissemination is the
c-Met proto-oncogene receptor tyrosine kinase, which is aberrantly expressed in many human tumors including
MB. Database analysis showed that c-Met is highly expressed in the sonic hedgehog (SHH) subgroup and in a
small subset of Group 3 and Group 4 MB tumors. Using a cell-based three-dimensional cell motility assay combined
with live-cell imaging, we investigated whether the c-Met ligand HGF could drive dissemination of MB cells expressing
high levels of c-Met, and determined downstream effector mechanisms of this process. We detected variable c-Met
expression in different established human MB cell lines, and we found that in lines expressing high c-Met levels,
HGF promoted cell dissemination and invasiveness. Specifically, HGF-induced c-Met activation enhanced the capability
of the individual cells to migrate in a JNK-dependent manner. Additionally, we identified the Ser/Thr kinase MAP4K4 as
a novel driver of c-Met-induced invasive cell dissemination. This increased invasive motility was due to MAP4K4 control
of F-actin dynamics in structures required for migration and invasion. Thus, MAP4K4 couples growth factor signaling to
actin cytoskeleton regulation in tumor cells, suggesting that MAP4K4 could present a promising novel target to
be evaluated for treating growth factor-induced dissemination of MB tumors of different subgroups and of other
human cancers.
Keywords: Medulloblastoma; Cancer cell dissemination; Cell motility; c-Met; MAP4K4; Actin dynamics
Background
Medulloblastoma (MB) is the most common malignant
brain tumor in children and accounts for approximately
10% of all pediatric cancer deaths. MB is thought to arise
from neuronal progenitor cells harboring defects in the
regulation of gene expression that normally controls
growth and development of the cerebellum (Roussel and
Hatten 2011). MB cells can disseminate from the primary
tumor in the cerebellum throughout the central nervous
system and cause metastatic disease in as many as 30%
of patients at diagnosis. MB comprises a diverse set of
tumors (Northcott et al. 2012a) and four molecular
subgroups with differential metastatic potential, named
WNT (wingless), SHH (sonic hedgehog), Group 3, and
Group 4 (Taylor et al. 2012), have been classified, which
remain stable from primary to recurrent MB (Ramaswamy
et al. 2013). Treatments that specifically target metastatic
dissemination are needed to improve patient survival and
reduce treatment-related morbidity.
The receptor tyrosine kinase mesenchymal epithelial
transition factor (c-Met) is activated by hepatocyte growth
factor/scatter factor (HGF), its only known ligand to date,
which triggers phosphorylation of Tyr1230, Tyr1234, and
Tyr1235 in the intracellular domain of c-Met. c-Met phos-
phorylation promotes the induction of various intracellular
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signaling pathways (Trusolino et al. 2010) to control cell
proliferation, survival, and mobilization through the regu-
lation of integrin function and cytoskeleton dynamics
(Trusolino et al. 2010). Aberrant c-Met activation occurs
in various human cancers in different organs, including
the brain, and is associated with disease progression and
metastatic dissemination (Sierra and Tsao 2011; Li et al.
2005; Joo et al. 2012).
c-Met is expressed in surgical MB specimens and MB
cell lines and its expression and the expression of its lig-
and HGF is associated with significantly worse outcome
in patients (Li et al. 2005). Along with SHH, increased ex-
pression of HGF promotes formation and growth of MB
tumors in mice (Binning et al. 2008). An increased level
of HGF was found sufficient to drive invasiveness of
orthotopically xenografted DAOY MB cells (Li et al. 2005).
No activating mutation has been reported for MB-expressed
c-Met to date, whereas increased c-Met activity has been
linked to proliferation, anti-apoptosis, and migration in MB
(Li et al. 2005; Provencal et al. 2009; Guessous et al. 2012;
Guessous et al. 2010; Kongkham et al. 2010; Onvani et al.
2012). c-Met was found to increase the expression of the
transcription factor v-myc avian myelocytomatosis viral
oncogene homolog (MYC) (Li et al. 2008), which is the
hallmark of the most aggressive form of MB (Taylor et al.
2012). Pro-metastatic functions of c-Met are supported by
the hyaluronan (HA) receptor CD44 and in particular
by its transcript variant CD44v6, which supports c-Met-
dependent signaling (Orian-Rousseau et al. 2002). Al-
though CD44 expression has been associated with WNT
and SHH signaling in MB, it’s expression has not yet been
analyzed in MB (Katoh and Katoh 2009; Asuthkar et al.
2012).
The molecular mechanisms and downstream effectors
that mediate HGF-induced MB cell dissemination are in-
completely understood. Herein we used cell-based in vitro
two- and three-dimensional (2D/3D) motility assays com-
bined with live-cell imaging and biochemical approaches
to investigate and characterize potentially druggable medi-
ators of HGF-c-Met-induced MB cell dissemination.
Results
c-Met and its co-receptor CD44 are highly expressed in a
subset of MB tumors and patient derived cell lines
To determine the potential clinical relevance of c-Met in
larger cohorts of MB, we compared the mRNA expres-
sion levels of c-Met in the Gilbertson, the Kool and the
Delattre datasets available through the R2 platform for
visualization and analysis of the microarray data. As con-
trol, we used nine cerebellum samples of patients aged
between 23 and 50 years. We found that the median
mRNA level of c-Met and its ligand HGF in MB tumors
from these three different primary sample cohorts were
clearly below that of normal human cerebellum (Figure 1A).
However, a sub-population of MB tumors averaging 17.5%
(Figure 1A, c-Met high) showed significantly increased
c-Met expression. Moreover, the same datasets revealed
high mRNA expression of the c-Met co-receptor CD44
(Orian-Rousseau et al. 2002) in all MB tumor samples.
By analyzing 103 primary MB tumors of the Northcott
103 dataset (Northcott et al. 2011), Onvani et al. described
the association of c-Met with the SHH subgroup (Onvani
et al. 2012). We confirmed this finding using the 285
tumors of the MAGIC dataset (Northcott et al. 2012b)
(Additional file 1: Figure S1A). An analogous but less
marked association was also observed for HGF (Additional
file 1: Figure S1B), but not for CD44 (Additional file 1:
Figure S1C). Using quantitative real-time PCR (Figure 1B)
and immunoblotting (IB) approaches (Figure 1C), we de-
tected high c-Met, CD44, and CD44v6 expression both at
the mRNA and protein levels in DAOY and UW228 cell
lines, and much less (c-Met) or no (CD44/CD44v6) ex-
pression in D341 and D425 cell lines. Interestingly, three
bands were detected in the anti-CD44v6 blot (Figure 1C,
arrowheads), suggesting the presence of different CD44
isoforms with incorporated v6 variable region. DAOY cells
are sensitive to sonic hedgehog (Gotschel et al. 2013) and
considered a SHH-like MB cell line, whereas D341 is
considered a group 3 cell line (Snuderl et al. 2013). We
confirmed surface expression of c-Met, CD44, and CD44v6
on DAOY (Figure 1D) and UW228 cell lines (not shown)
by flow cytometry. This analysis revealed that >90% of
DAOY cells expressed c-Met, 100% expressed CD44, while
only approximately 40% expressed the CD44v6 isoform.
We therefore continued our studies by focusing specifically
on c-Met and by studying what effects c-Met activation by
its ligand HGF may have on cell migration and invasion
and which effector pathways are needed to mediate the
c-Met responses.
HGF stimulation activates JNK and MAPK/ERK pathways
and promotes motility
To determine dynamics of c-Met-induced ERK and JNK
activation in DAOY and UW228 cells, we stimulated the
cells with HGF in a time course experiment. We found
that HGF stimulation of DAOY or UW228 cells promotes
rapid phosphorylation of c-Met (IB p-c-Met) within five to
ten min (Figure 2A) and the concomitant activation of the
downstream effector extracellular-signal-regulated kinase
(ERK, IB p-ERK) (Figure 2B). c-Met and ERK phos-
phorylations were blocked when the cells were pretreated
for 2 h with the ATP-competitive c-Met inhibitor PHA-
665752 (Christensen et al. 2003) but not with the non
ATP-competitive inhibitor ARQ197 (Munshi et al. 2010)
(Figure 2B). However, we found that 24 h ARQ197 pre-
treatment was necessary to block acute, HGF-induced
c-Met signaling (Figure 2C). c-Met can activate the c-Jun
N-terminal kinase (JNK) (Rodrigues et al. 1997), which
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controls growth and invasion of MB cells (Zavarella et al.
2009). Consistently, we detected PHA-665752-sensitive
phosphorylation of mainly the p46 isoform of JNK within
five to ten minutes of HGF stimulation (Figure 2D). Inter-
estingly, 24 h treatment with ARQ197 (Figure 2C) also
caused increased JNK phosphorylation by an unknown
mechanism, which was not further increase by HGF stimu-
lation, because c-Met activity was blocked. To determine
whether HGF stimulation and/or c-Met inhibition affected
cell viability and/or proliferation, we performed a
Figure 1 Expression of c-Met in medulloblastoma clinical samples and cell lines. (A) Expression analysis of c-Met, HGF and CD44 in three
different MB tumor collections (ntotal = 195) and in normal adult cerebellum (n = 9). (B) Comparative quantitative real-time PCR expression analysis
of c-Met, CD44 and CD44v6 in established MB cell lines and adult cerebellum sample. (C) Expression and activation analysis of the c-Met pathway,
CD44, and CD44v6 by immunoblotting (IB) in four different MB cell lines using the antibodies indicated to the right of the blots. (D) Flow cytometry
analysis of DAOY cells quantifying surface expression of c-Met, CD44, and CD44v6. Dot plots compare expressions of c-Met and CD44 or c-Met and
CD44v6. Histograms show relative fluorescence intensities of isotype control and specific antibody samples.
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Figure 2 c-Met is activated by HGF in medulloblastoma cells and promotes wound closure. (A) IB of DAOY and UW228 lysates of cells after
HGF stimulation. Antibodies used as indicated to the right of the panels. B) IB analysis of PHA-665752 and ARQ 197 (1 μM, 2 h pretreatment) effects on
HGF-induced (50 ng/mL, 10 min) c-Met and ERK pathway activation (anti-p-c-Met and anti-pERK, respectively). (C) IB analysis as in B of the effect of
prolonged (24 h) pretreatment with ARQ197 inhibitor on HGF-induced c-Met and ERK activation in UW228 cells. (D) IB analysis of HGF-induced activation
of JNK and ERK in DAOY cells (20 ng/mL HGF −/+ 250 nM PHA-665752). (E) Schematic showing how the area covered by the cells in the Oris migration
assay was determined. Light grey: cell monolayer at T0h. White: gap after removal of the plug. Dark grey: area covered by cells at T10h. (F) Quantification
(means + S.D.) of Oris migration assays using DAOY or UW228 cells in HGF-treated (20 ng/mL) medium containing 0% FCS and pharmacological
inhibitors (PHA-665752 and ARQ 197, both at 125 nM). (G) As F) but progression of gap closure shown for 0–10 h only.
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tetrazolium salt WST assay on DAOY and UW228 cells
treated with various combinations of HGF and PHA-
665752 or ARQ197. Corresponding to c-Met expression
levels (high in DAOY and UW228, low in D425), prolifera-
tion/viability was effectively reduced by the c-Met inhibi-
tors in DAOY and UW228 cells and only moderately
affected in D425 cells (Additional file 2: Figure S2). To
monitor HGF-induced cell migration, we used the Oris
migration assay (Gough et al. 2011) (Figure 2E) and mea-
sured the effect of HGF-c-Met signaling on the cells’
capability to close a circular gap created by the inser-
tion of a rubber stopper into the well that prevented
cell attachment and growth (Figure 2F). Using time
lapsed video microcopy imaging, we found that HGF
treatment significantly accelerated gap closure within 24 h -
both under serum-free (Figure 2F) and 10% serum
(Additional file 3: Figure S3A) conditions. Importantly,
time-lapse imaging showed that HGF treatment strikingly
increased migration already within 5 h of incubation
(Figure 2G). In DAOY cells, PHA-665752 treatment in
the absence of ectopically added HGF reduced gap
closure by nearly 50%, suggesting that an endogenous
or a serum-derived factor activates the c-Met signaling
axis and promotes pro-migratory signals (Additional file 3:
Figure S3B). Overall, we showed that c-Met signaling
was active in MB cells, that it was further activated by the
exogenous addition of HGF and that it contributed to cell
migration on 2D surfaces.
HGF promotes single cell motility and invasiveness
In assays that measure the area covered by cells such as
wound healing assays or end-point Oris migration assay,
it is not possible to discriminate between individual cell
migration and proliferation. To determine whether HGF-
induced c-Met activation indeed caused increased cell mo-
tility, we determined the speed of single cells. Towards
that end, we measured the pathlength of single cells that
migrated over a given time (speed) by time-lapse video
microscopy. We found that HGF promoted a twofold
increase in cell speed both in DAOY and UW228 cells
(Figure 3A), which was blunted when c-Met was pharma-
cologically inhibited by either PHA-665752 or ARQ197.
HGF also significantly increased single cell motility in
the matrigel invasion in a c-Met-dependent manner
(Figure 3B). However, the matrigel invasion assays does
not permit monitoring the behavior of single cells inside a
3D matrix and measuring their speed of migration. To
solve that problem, we developed a versatile micro bead
invasion assay for MB cells and assessed cell dissemination
from the beads into the surrounding collagen. Import-
antly, cells migrating inside the matrix are fully accessible
for fixed- and live-cell microscopy (Figure 3C, upper). We
found that HGF or epidermal growth factor (EGF) treat-
ment promoted massive cell dissemination (Figure 3C
and D). As expected, PHA-665752 prevented HGF- but
not EGF-induced dissemination, confirming the specifi-
city of this compound for the c-Met receptor tyrosine
kinase. We observed that cells migrating in the collagen
matrix displayed marked, F-actin rich invasive protru-
sions at the leading edges (Figure 3E), suggesting that
local F-actin polymerization in the lamellipodia of cells
is instrumental for motility. Taken together, these data
demonstrate that HGF triggers dissemination of MB cells in
2D and 3D environments by accelerating motility at the sin-
gle cell level. We furthermore detected enhanced local F-
actin polymerization, suggesting F-actin turnover acting at
the leading edge in HGF-stimulated cells as driving force.
JNK and MAP4K4 are downstream effectors of HGF-induced
motility
JNK is highly expressed in the brain and controls neur-
onal cell migration during development (Zdrojewska and
Coffey 2014) and in MB cells, HGF stimulation promoted
JNK activation (Figure 2D). To test whether JNK activity
was necessary for HGF-induced motility, we treated MB
cells with the JNK inhibitor SP600125 (Han et al. 2001).
We found that HGF-stimulated single cell motility (speed)
was markedly reduced when JNK activity was blocked
(Figure 4A). Interestingly, the ablation of JNK activity
in the absence of HGF significantly reduced speed of sin-
gle UW228 but not DAOY cells, indicating that serum-
dependent motility bypasses JNK in DAOY but not in
UW228 cells (Figure 4A) and suggesting different JNK
pathway regulation in these closely related cell lines. We
confirmed the sensitivity of HGF-induced single cell
motility to JNK inhibition with the two additional JNK
inhibitors JIP-1 (153–163) and AEG 3482 (Additional
file 4: Figure S4). One upstream kinase of the JNK sig-
naling pathway is the Ser/Thr kinase mitogen-activated
protein kinase kinase kinase kinase 4 (MAP4K4) (Su et al.
1997). MAP4K4 mediates HGF effects on anchorage-
independent growth and invasiveness (Wright et al. 2003),
promotes F-actin dynamics in lamellipodia and cell motil-
ity (Baumgartner et al. 2006; Ma and Baumgartner 2014)
and contributes to the progression of solid tumors in
humans (Collins et al. 2006; Hao et al. 2010; Liang et al.
2008; Liu et al. 2011; Qiu et al. 2012). In human MB sam-
ples of all four subgroups, MAP4K4 is highly expressed,
most significantly in the SHH and Group 4 subgroups
(Additional file 1: Figure S1D). Depletion of MAP4K4
using a small interfering RNA (siRNA) approach abro-
gated the pro-migratory effect of HGF and also signifi-
cantly reduced steady-state motility (Figure 4B). Thus,
HGF-Met signaling increases speed of single migrating
cells through mechanisms requiring JNK activity and
MAP4K4 function, suggesting that these two kinases
are essential regulators of MB cell dissemination.
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Figure 3 (See legend on next page.)
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HGF promotes cortical actin polymerization and
membrane protrusion
Increased F-actin dynamics and cell motility indicated
that c-Met could be active in lamellipodia to control
F-actin dynamics in these structures. We used immuno-
fluorescence (IF) microscopy to localize c-Met and p-
c-Met in MB cells. Indeed, in lamellipodia of DAOY
(Figure 5A, arrowheads) and UW228 (Additional file 5:
Figure S5A) cells, we detected accumulations of c-Met
and p-c-Met (Figure 5A, arrows). To test whether c-Met
activation promoted cortical actin dynamics (Rottner and
Stradal 2011), we stimulated MB cells with HGF and mon-
itored immediate and late changes in cortical F-actin by
immunofluorescence analysis (Figure 5B) and live cell im-
aging (movies Additional file 6: SM1, Additional file 7:
SM2, Additional file 8:SM3), respectively. Interestingly,
within 15 min we observed de novo synthesis of lamelli-
podial branched F-actin in the extension zone in HGF-
stimulated cells (Figure 5B, magnifications), which was
prevented when cells were pretreated with PHA-665752.
We also observed accelerated and more prominent
cortical F-actin turnover in HGF-stimulated UW228
cells (movies Additional file 6: SM1, Additional file 7:
SM2, Additional file 8: SM3). To test whether MAP4K4
could promote cortical F-actin dynamics in MB cells,
we expressed either enhanced green fluorescent pro-
tein (EGFP)-tagged wild-type (EGFP-MAP4K4-wt) or a
kinase-defective (EGFP-MAP4K4-k/d) mutant of MAP4K4
in DAOY cells together with Lifeact fused to mCherry
(LA-mCherry). We monitored F-actin dynamics by con-
focal live cell microscopy and quantified morphodynamic
alterations of cell protrusions by kymography (Figure 5C
and Additional file 5: Figure S5B). We found that F-actin
polymerization dynamics in lamellipodia were significantly
higher in cells expressing MAP4K4-wt and blunted in cells
expressing MAP4K4-k/d. Interestingly, cells depleted of
MAP4K4 by inducible short hairpin RNA expression
(shRNA, see below) were also no longer able to respond
to HGF stimulation with scattering (Figure 5D) and
morphological alterations (contraction, measured as area
covered per cell, 5E). Specifically, we observed that
HGF-induced cell scattering evident in a culture of semi-
confluent cells 24 h after HGF stimulation and resulting in
dissociated cells with few cell-cell contacts, was abrogated
by MAP4K4 depletion using shRNA. Reduced scattering
may in part be due to reduced motility of single cells
(Figure 5F). However, in shRNA MAP4K4-expressing cells,
we also observed more cells with intact cell-cell contacts,
suggesting that MAP4K4 effects on cell dissemination
impact different levels of cell migration control. Taken
together, our data show that MAP4K4 orchestrates HGF-
induced morphodynamic processes and MB cell motility
by controlling F-actin cytoskeleton dynamics and its
depletion reduces the capability of MB cells to scatter
in response to HGF.
MAP4K4 promotes HGF-induced single cell scattering and
collagen invasion
To test whether MAP4K4 was driving HGF-induced in-
vasive motility in collagen, we used MB cells expressing
doxycycline (doxy)-inducible scrambled control shRNAs
(shScr) or shRNAs targeting MAP4K4 (shMAP4K4)
(Additional file 5: Figure S5C) in the micro bead inva-
sion assay. Confocal microscopy imaging showed that
HGF-promoted dissemination was markedly reduced
in MAP4K4-depleted cells (Figure 6A). To quantify in-
vasiveness of larger numbers of cells, we visualized cell
nuclei (Figure 6B) and measured the distance between
the bead and the individual nuclei (Figure 6C). We found
that HGF-induced single cell dissemination in 3D was sig-
nificantly reduced when MAP4K4 was depleted, both in
0% and 10% FCS medium. Importantly, HGF-stimulated
shScr cells displayed considerably higher F-actin content
at the leading edge than did MAP4K4-depleted cells
(Figure 6D), indicating that MAP4K4-induced F-actin
polymerization activity (Figure 5C–E) was also needed
for forming invasive protrusions during cell migration
in collagen. In conclusion, HGF promoted MB cell dis-
semination in collagen is driven by MAP4K4, probably
by triggering the invasive, F-actin-rich membrane protru-
sions required for cells to invade and migrate (Figure 6E).
Discussion
In this study, we have investigated the functional signifi-
cance of the HGF-c-Met signaling pathway for MB cell
dissemination. We found that c-Met expression is upreg-
ulated in the SHH subgroup and in a subset of Group 3
and Group 4 MB tumors, as well as in some established
(See figure on previous page.)
Figure 3 HGF promotes invasive motility of single medulloblastoma cells. (A) Single cell motility of DAOY and UW228 cells was measured using
live cell imaging (HGF: 20 ng/mL, ARQ197 and PHA-665752 250 nM). Box plots of three independent experiments are shown. (B) Boyden chamber
invasion assay under conditions as described in (A). Mean total numbers of cells transmigrated and S.D. of representative triplicate experiment
are shown. Statistical analysis: T-test, * = 0.0454, ** = 0.0038. (C) Upper: schematic of microbead invasion assay setup. Lower: microbeads coated with
DAOY cells were embedded in collagen and cells were allowed to disseminate for 24 h. Confocal microscopy analysis of LA-EGFP fluorescence 24 h
after embedding is shown (left: maximum intensity projection of Z-stacks, right: single cross-section through middle of beads). D) Quantification of
mean and range of cell dissemination from microbeads shown in C (triplicate measurements, ten beads quantified per measurement, dot plot with
SD). E) High-resolution confocal images of an HGF-induced (20 ng/mL) LA-EGFP expressing DAOY cell migrating in collagen. F-actin distribution is
shown as inverted grey scale. Arrow: direction of migration. Note high F-actin content in invasive protrusions at leading edge of the cell.
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SHH MB laboratory cell lines. We demonstrated that c-
Met activation by its ligand HGF promotes single cell mo-
tility of MB cells and their invasion into Matrigel and 3D
collagen gels. We further showed that HGF-induced mo-
tile and invasive cell behavior requires the Ser/Thr kinase
MAP4K4, which controls F-actin cytoskeleton dynamics in
cellular protrusions necessary for motility and invasiveness.
Thus, our studies reveal a novel, growth factor-dependent
signaling circuit that promotes MB cell dissemination
through MAP4K4-dependent cytoskeleton regulation, and
underscore the necessity of patient stratification based on
growth factor sensitivity of the tumor for rational targeting
of cancer promoting signaling pathways.
Others and we have revealed a striking association of
c-Met expression with SHH MB ((Onvani et al. 2012) and
Additional file 1: Figure S1A) and we found that c-Met
is overexpressed in approximately 18% of MB tumors
compared to cerebellum controls. It is possible that c-Met
could contribute to tumor progression by causing dissem-
ination of the subset of recurrent SHH tumors reported
recently (Ramaswamy et al. 2013). Importantly, c-Met
function could also contribute to MB tumor cell dissemin-
ation in other subgroups by driving cell motility. However,
other cellular parameters such as the capability to survive
in the CSF or to colonize the new niche will be as import-
ant as well, and which could explain the discrepancy in
the relative clinical outcomes between c-Met-high SHH
and for example c-Met-low Group 3 tumors. Future
studies examining large cohorts of patients in a subgroup-
specific manner will now be required to fully appreciate
the role of c-Met signaling in this context. Although the
expression of the c-Met co-receptor CD44 was high in all
MB tumor samples analyzed, its role in MB is unclear and
further studies will also be needed here to reveal c-Met-
related and un-related effects of CD44 in MB pathogen-
esis. Unlike CD44 expression in tumor samples, CD44
expression in MB cell lines was restricted to those ex-
pressing c-Met. Of these, only 40% co-expressed also
the HGF-c-Met-interacting variant isoform CD44v6. In
glioblastoma, CD44 expression conferred growth ad-
vantages and therapeutic resistance (Xu et al. 2010) and
it remains to be resolved whether analogous mecha-
nisms are also active in MB, in particular in the context
of c-Met interaction with CD44v6.
Several earlier studies have implicated a role of HGF-
c-Met in MB growth and dissemination and scratch
wound healing assays revealed the involvement of c-Met
in wound closure (Kongkham et al. 2010). However, it
remained unclear whether c-Met inhibition reduced MB
cell dissemination because it impaired proliferation or
because it impaired cell motility. We clarified this point
by providing direct evidence that HGF-c-Met function
promotes the capability of MB cells to migrate, which
ultimately accelerates their dissemination both in 2D and
3D environments. It can be assumed that the dual func-
tion of c-Met, stimulation of proliferation and of single
cell motility is effective in other cell types or tumor cells
expressing high c-Met and explains in part the effective
tumorigenic activity of this receptor.
How c-Met-induced JNK promotes MB cell motility is
not known; it is possible that JNK is relevant in MB cells
for proper function of the microtubule skeleton during
Figure 4 HGF-induced single cell motility is mediated by the
Ser/Thr kinases JNK and MAP4K4. (A) Motility of single cells
migrating on flat 2D surfaces in the absence or presence of HGF
(20 ng/mL) and the JNK inhibitor SP665757 (10 ng/mL). Box plots of
three independent experiments are shown. (B) Same experimental
approach as in (A) but instead of using a pharmacological inhibitor,
MAP4K4 was depleted from cells using validated MAP4K4-specific
(+) siRNA. (−) is a negative control siRNA .
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Figure 5 (See legend on next page.)
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Figure 6 MAP4K4 drives HGF-induced cell dissemination in fibrillar collagen. (A) Z-stack maximum intensity projection of collagen embedded,
disseminating DAOY-doxy-MAP4K4 cells. Short hairpin RNA expression was induced by doxy stimulation for 48 h before the start of the experiment
(lower panel). Cells were stimulated with HGF (20 ng/mL) for 24 h. Green: F-actin, blue: DNA. (B) Representative montaged images of inverted
grey-scale fluorescence of nuclear DNA to visualize cell dissemination. shRNA control or shMAP4K4_1/_3 expression with doxycycline and FCS
and HGF treatments as indicated. C) Quantification of average velocities of disseminating cells with treatments as indicated. The averages of
three independent experiments and S.D. are shown. D) High resolution confocal Z-stack of invading shScr and shMAP4K4 LA-EGFP cells. Note
reduced F-actin in invasive protrusions of shMAP4K4 cells E) Schematic representation of signaling pathways investigated. Highlight blue is
the central MAP4K4 controlled machinery that we propose to drive the dynamic remodeling of the actin cytoskeleton required for cell dissemination
downstream of growth factor signaling.
(See figure on previous page.)
Figure 5 HGF promotes cortical actin dynamics in medulloblastoma cells. (A) Immunofluorescence analysis (IFA) of c-Met and phosphorylated
c-Met (p-c-Met) localization in lamellipodia of DAOY cells. Color overlay and inverted grey-scale images of p-c-Met (red), actin (green) and c-Met (blue)
are shown. Magnifications are 4× of boxed area in overlay. Arrows indicate c-Met-rich lamellipodia. (B) IFA of Alexa-488-phalloidin-stained F-actin
cytoskeletons in un-stimulated and HGF-stimulated (20 ng/mL, t = 10 min) DAOY cells, −/+ PHA-665752 (500 nM). Inverted grey-scale images
of Alexa-488-phalloidin fluorescence are shown. Magnifications are 4× of boxed areas. Lower left magnification is 4× of sheet-like protrusion
in b). Arrows: filopodia, arrowheads: leading edge of F-actin sheet (extension zone, see schematic). (C) F-actin dynamics in DAOY cells transfected with
LA-mCherry and either enhanced green fluorescent protein-tagged, wild-type (wt) or kinase-defective (k/d) MAP4K4 were recorded by confocal live cell
microscopy imaging. See Additional file 5: Figure S5 for still images of representative cells. Dot blots show protrusion lengths in control cells or cells
expressing either EGFP-MAP4K4-wt or EGFP-MAP4K4-k/d. (D) Still images of time-lapse movies of DAOY-LA-EGFP-shScr or DAOY-LA-EGFP-shMAP4K4_1
cells stimulated with HGF (20 ng/mL). T0 is 0 h and T18 is 18 h after HGF stimulation. Inverted grey-scale of LA-EGFP fluorescence (F-actin cytoskeleton)
is shown. (E) Cells were treated as described in (D). Box plots of areas in pixels covered by individual cells quantified at T0 and T18. (F) Box plot of
speeds of single sh control or shMAP4K4 cells in the presence of HGF. Statistical analysis: T-test (*: P = 0.0208).
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motile processes through its activity toward the micro-
tubule regulatory proteins superior cervical ganglion 10
(SCG10), doublecortin (DCX) (Zdrojewska and Coffey
2014) or microtubule-associated protein 1b (MAP1b)
(Yamasaki et al. 2011). In addition to JNK, we identified
MAP4K4 as a novel kinase essential for efficient dis-
semination of MB cells. MAP4K4 and its murine (Nck-
interacting kinase), fly (misshapen) and worm (MIG15)
orthologs are evolutionary conserved and control migra-
tion of both neurons (Chapman et al. 2008; Poinat et al.
2002; Shakir et al. 2006; Teuliere et al. 2011) and cancer
cells (Collins et al. 2006; Wright et al. 2003; Hao et al.
2010; Liang et al. 2008; Liu et al. 2011; Qiu et al. 2012).
Although its function downstream of HGF has been
suggested (Wright et al. 2003), our findings are the first
to demonstrate the involvement of MAP4K4 downstream
of c-Met in tumor cells. Depletion of MAP4K4 reduced
dissemination and the accumulation of F-actin in focal
invasion structures. This finding is consistent with estab-
lished functions of MAP4K4 as a regulator of cortical actin
dynamics (Baumgartner et al. 2006; Poinat et al. 2002;
Teuliere et al. 2011; Ma and Baumgartner 2014; Wright
et al. 2003; Yan et al. 2001) and it is thus conceivable that
MAP4K4 triggers and coordinates spatio-temporal actin
polymerization and turnover, both of which are essential
for efficient cell movement. Thus, MAP4K4 function is
likely needed at the single cell level to trigger invasive
cell protrusions, which in turn are necessary for motility
and invasiveness of MB tumors. Although MAP4K4 is an
established upstream activator of JNK (Machida et al.
2004), we could not provide convincing evidence that
MAP4K4 is active in this function in MB cells as well
(not shown). Hence, we concluded that while both kinases
are essential for MB motility, they do probably act in par-
allel pathways rather than in a serial one. Considering that
MAP4K4 is activated by various growth factors including
HGF, PDGF (Yan et al. 2001), TNFα (Yao et al. 1999)
or integrin activation (Poinat et al. 2002), we assume
that several different receptor-mediated pathways trig-
ger MAP4K4-dependent MB cell dissemination. Conse-
quently, MAP4K4 could act as a hub to divert extracellular
derived cues toward morphodynamic processes promoting
motility and invasiveness (Figure 6E). Thus, we now need
to further refine our understanding of upstream activators
and downstream effectors of MAP4K4 in MB, because of
its potential significance as a druggable anti-metastatic
target for a recently synthetized novel MAP4K4 inhibi-
tor (Crawford et al. 2014).
In summary, we have shown that the HGF-c-Met sig-
naling pathway promotes MB cell dissemination by enab-
ling cell dissociation, rapid movement and efficient matrix
invasion of single cells. We revealed the implication of
the Ser/Thr kinase MAP4K4 and its cytoskeleton mod-
ulatory functions and suggest it as a potential novel
anti-metastatic target worth to investigate further. Fi-
nally, the pro-migratory functions of MAP4K4 through
cytoskeleton regulation revealed herein might contribute
to the metastatic progression of SHH subgroup and other
MB tumors where MAP4K4 is overexpressed.
Conclusions
We have established a novel, cell-based assay to monitor
cancer cell dissemination in three-dimensional matrices.
We show for the first time that HGF-induced c-Met ac-
tivation enhanced the speed of migration of the individual
Medulloblastoma cells and show that the Ser/Thr kinase
MAP4K4 is an essential mediator in this process. We
conclude that MAP4K4 couples growth factor signaling
to actin cytoskeleton regulation in tumor cells, suggest-
ing that MAP4K4 could be a promising novel target to
be evaluated for treating growth factor-induced dissemin-
ation of Medulloblastoma tumors of different subgroups
and of other human cancers.
Methods
Ethics statement
This work was conducted according to the ethical guide-
lines of the University of Zürich. No donor material was
used.
Expression analysis using R2 database
All data used are accessible through the open access plat-
form R2 for visualization and analysis of the microarray data
(http://r2.amc.nl). The following datasets were used: Delattre
54 MAS 5.0 – u133p2 (54 MB samples), Gilbertson 76
MAS 5.0 – u133p2 (76 pediatric MB samples, PubMed link:
22722829), Kool 62 MAS 5.0 – u133p2 (62 human MB
samples, PubMed link 18769486), Northcott 103 rma_
sketch – huex10t (103 primary MB samples, PubMed link
20823417) and MAGIC 285 rma-sketch – hugene11t (285
primary MB samples, PubMed link 22832581) Analysis was
performed as described in (Fiaschetti et al. 2014). The nine
normal cerebellum samples are from human subject aged as
follows: Donor 1–25 year old male; donor 2–38 year old
male; donor 3–39 year old female; donor 4–30 year old
male; donor 5–35 year old male; donor 6–52 year old male;
donor 7–50 year old female; donor 8–48 year old female;
donor 9–53 year old female; donor 10–23 year old female.
Reagents
HGF: 0.25 μM= 20 ng/mL (Preprotech), JIP-1 (153–163)
(1565, Tocris), ARQ 197 (A-1109, Active Biochemicals),
PHA-665752 10 μM, AEG 3482 5 μM (Axon), (Selleck
Chemicals, 10 μM). SP600125 20 μM (S5567), Doxycycline
(44577) Blasticidin (15205) (Sigma-Aldrich), AEG 3482
(1291, Axon Medchem).
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Cell culture
DAOY, UW228-2, D341, and D425 cells were grown as
described in (Fiaschetti et al. 2014). DAOY-LA-EGFP were
generated by lentiviral transduction of DAOY with cells
pLenti-LA-EGFP.
Transfection
5 × 105 cells/well were seeded in 6-well plates and 24 h
later transiently transfected using Jet-Pei (101–10 Polyplus),
with 2.5 μg of plasmids expressing LA-mCherry (pLenti-
LA-mCherry) and either MAP4K4-wt (pEGFP-C2
NIKwt) or MAP4K4-kinase dead (pEGFP-C2 NIKD152N)
(Baumgartner et al. 2006).
Immunoblotting
RIPA buffer lysates were probed with the following primary
and secondary antibodies: phospho-c-Met (44888, Life
Technologies), c-Met (3148), phospho-STAT3 (9131),
STAT3 (9132), phospho-JNK (4668), JNK (9258), phospho-
ERK1/2 (9101), ERK1/2 (9102), CD44 (3578) (Cell Signaling),
anti-MAP4K4 (80418, Abcam), α-tubulin (T9026, Sigma-
Aldrich), and CD44v6 (MAB4073, clone VFF-18, Millipore),
anti-mouse horseradish peroxidase (HRP)-linked (7076)
and anti-rabbit HRP-linked (7074) (Cell Signaling).
Primary antibodies were diluted 1:1000 except for
α-tubulin (1:40000). Secondary antibodies were diluted
1:2000.
Immunofluorescence analysis
Cells were fixed and treated as described in (Ma and
Baumgartner 2014). Primary antibodies were diluted 1:200
and incubated overnight at 4°C: α-phospho-c-Met (#44888,
Life Technologies), c-Met (3148), CD44 (3578) (Cell
Signaling), α-tubulin (T9026, Sigma-Aldrich), Alexa488-
(A12379, Life Technologies), Cy3- (711-165-152), and Cy5-
coupled (415-175-166) secondary antibodies were used
(Jackson Immuno Research). Secondary antibodies and
tetramethylrhodamine isothiocyanate-coupled phalloidin
(Sigma-Aldrich) were diluted 1:500. Images were acquired
on an Axioskop 2 mot plus fluorescence microscope
(Zeiss).
Confocal live cell imaging
DAOY and UW228 cells stably expressing LA-EGFP were
seeded in serum-free HEPES-buffered (25 mM) medium
overnight on ibidi 8-well slides (5000 cells/well). PHA-
665752 (500 nM) was added 1 h prior to and HGF (20 ng/
mL) was added at the start of image acquisition in SP8
Leica confocal microscope. A 63× water immersion ob-
jective was used to acquire 60 Z-stacks of six images of
EGFP fluorescence/timepoint (15 s intervals, 15 min).
Average intensity projections of the stacks were assembled
into QuickTime movies (10 fps, 150x speed).
Oris migration assay
The Oris™ 96-well cell migration assay kit (CMA1.101,
Platypus Technologies) was used (3.5 × 104 cells seeded/
well). After plug removal, cells were treated without or
with HGF (20 ng/ml) and PHA-665752 or ARQ197. Cell
migration was monitored for 25 h using an automated
ImageXpress Micro 2 (Molecular Devices) equipped with
environmental control. Images were acquired at 5 h inter-
vals with a 10× 0.2 NA Plan Apo objective (Nikon) and
Roper CoolSNAP HQ camera (Roper Scientific). Wound
closure was quantified using the threshold method in the
MetaXpress software (Version MX 3.1.0.93).
Matrigel invasion assay
A total of 25’000 cells were suspended in complete medium
and seeded on the upper side of the Matrigel-coated mem-
brane (BD 354480). Complete medium with or without
20 ng/ml HGF as used in the lower chamber. After 24 h,
transmigrated cells were fixed with 4% PFA and stained
with 0.05% crystal violet.
Single cell motility assay
Cells were seeded on 96-well glass bottom plates (In Vitro
Scientific)) at 40% confluency in assay medium with or
without HGF (20 ng/mL) and cell motility was acquired
using the ImageXpress Micro 2 microscope. Cell speed
(total path length/time) was determined by manually
tracking the cells at 5 min intervals for 6–18 h using
ImageJ software (National Institutes of Health, USA).
Flow cytometry
Cells were detached with Accutase (A6964, Sigma-Aldrich),
fixed in 0.5% PFA for 10 min and washed in 0.5% Tween
20 (P9416, Sigma-Aldrich) and collected in flow cytometry
(FC) buffer (5% FBS, 0.5% BSA, 0.1% Na-azide in PBS).
0.25 × 106 cells per sample were stained with the following
primary antibodies: CD44-Alexa488 (103016, 1:50), Isotype
control-Alexa488 (400625, 1:50) (BioLegend), c-Met-biotin
(13–8858, 1:100), c-Met (5631, 1:100) (Cell Signaling),
Isotype control-biotin (13–4301, 1:100) and CD44v6
(BMS125, 1:100) (eBioscience), and Isotype control mouse
IgG1 (02–6502, Life Technologies, 1:10 – 1:50). Sec-
ondary antibodies: anti-mouse-Alexa647 (A31571, Life
Technologies, 1:10000) and Streptavidin-PE (12–4317,
eBioscience, 1:10000). Sequential incubations (double
staining) were interrupted by three washes. Sample ac-
quisition (10000 events) in BDFACSCanto II flow cyt-
ometer (BD Bioscience).
RNA expression analysis by qRT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Basel, Switzerland) following the manufacturer’s
instructions 1 μg of total RNA was used as template for
reverse transcription, which was triggered by random
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hexamer primers and performed by using the High-
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). qRT-PCR was performed under conditions
optimized for the ABI7900HT instrument, using Gene Ex-
pression Master Mix (Applied Biosystems). Probe-primer
specific for the following genes (purchased from Applied
Biosystems) were used: c-Met (Hs HS01565584_m1),
HGF (Hs00300159_m1), CD44 (HS01075854_m1), CD44v6
(Hs01075854_m1). The relative gene expression was calcu-
lated for each gene of interest by using the ∆∆CT method,
where cycle threshold (CT) values were normalized to
the housekeeping gene 18S (Hs03003631_g1) (Applied
Biosystems).
Microbead invasion assay
Approximately 500 Cytodex Microcarrier beads (Sigma
Aldrich C3275) per 1.25 × 104 LA-EGFP-DAOY cells/ml
were mixed in FACS tubes (BD Falcon T7597-5 J) and
incubated at 37°C for 6 h, followed by incubation under
rotation for 18 h. Non-adherent cells were removed. Cell-
coated microbeads were resuspended in 2.5% bovine colla-
gen I (5005-B, Advanced BioMatrix) in 96-well plate, after
polymerization of collagen overlaid with fresh medium
and treated with appropriate concentrations of c-Met in-
hibitors or HGF. After 24 h, cells were fixed with 4% PFA
and stained with Hoechst. Images were acquired using
the ImageXpress microscope. The distance between the
microbead and the nuclei of the invaded cells was mea-
sured using ImageJ software. Velocity was calculated as
the distance of displacement/time.
Generation of inducible cell lines
Inducible shRNA DAOY cell lines were generated by
lentiviral transduction. Virus was produced in HEK293T
using 4.5 μg of inducible pLV-H1TetO-RFP-Bsd vectors
encoding either MAP4K4 shRNA (Biosettia, sh_NM_
001242559 1–4) or scramble shRNA (Biosettia) along
with lentivirus packaging plasmids pRev (1 μg), pMDL
(3 μg), and pVSV (1.5 μg). Lentivirus-containing su-
pernatants were added to recipient cells in the pres-
ence of 10 μg/ml of Polybrene (AL-118, Sigma,-Aldrich).
At 48 h post-transduction, the culture medium was
removed and stable cells were selected with 5 μg/ml blas-
ticidin (15205, Sigma-Aldrich). Doxycycline-containing
(Sigma, 44577) medium was added for 48 h for shRNA
induction and protein downregulation was verified by
IB and qRT-PCR.
RNA interference
The cells were transfected using either Silencer Select
siRNA specific for MAP4K4 (ID: 18096) or Silencer
select negative control #1 (ID: 4390843) (Ambion).
Each siRNA was used at the final concentration of 5
nM in combination with Dharmafect 4 transfection
reagent (Dharmacon), according to the manufacturer’s
instructions. MAP4K4 (ID: 18096) or Silencer select nega-
tive control #1 (ID: 4390843) (Ambion) were used. After
24, 48, and 72 h cells were harvested for both mRNA and
protein extraction, to assess gene expression by qRT-PCR
and protein content by immunoblotting.
Statistical analysis
Data are represented as the mean ± SD. Statistical ana-
lyses were performed using one-way analysis of variance
(ANOVA) followed by Bonferroni’s Multiple Comparisons
test (for details please see Additional file 9: Table ST1) if
not otherwise stated. P-values <0.05 were considered
significant. [* < 0.05, ** < 0.01, *** < 0.001].
Additional files
Additional file 1: Figure S1. c-Met and HGF is specifically increased in
the SHH subgroup of medulloblastoma. Comparison of subgroup-specific
expression of (A) c-Met, (B) HGF, (C) CD44, and (D) mitogen-activated
protein kinase kinase kinase kinase 4 (MAP4K4) in the MAGIC (n = 285)
and Northcott (n = 103) datasets. Box plots show median, mean (+), and
whiskers: 5–95 percentile.
Additional file 2: Figure S2. PHA-665752 and ARQ197 block proliferation/
viability of medulloblastoma cells at low molar concentrations. DAOY
and UW228 cells in medium containing 0% or 10% FCS were treated
with PHA-665752 or ARQ197 as indicated. Proliferation and viability of
the cells were measured using the WST assay at 0 h and after 24, 48,
and 72 h.
Additional file 3: Figure S3. c-Met inhibitors block basal and HGF-induced
gap closure in medium containing 10% fetal calf serum (FCS). (A) Oris
migration assays using DAOY or UW228 cells in 10% FCS-containing
medium treated with HGF (20 ng/mL) and c-Met inhibitors PHA-665752
and ARQ 197 (125 nM). Progression of gap closure over time expressed
as area in pixels covered by cells is shown. (B) As A) but progression of
gap closure shown for 0–10 h only.
Additional file 4: Figure S4. Pharmacological JNK inhibition blocks
HGF-induced motility. Speed of single cells in the absence or presence
of HGF (20 ng/mL) and the JNK inhibitors AEG 3482 (5 μM) and JIP-1
(10 μM) was acquired using live cell microscopy imaging. Path lengths
of individual cells after 18 h are shown (bars = means).
Additional file 5: Figure S5. (A) IFA of c-Met and p-c-Met localization
in lamellipodia of UW228 cells. Color overlay and inverted grey-scale images
of p-c-Met (red), F-actin (green), and c-Met (blue) are shown. Magnifications
are 4× of boxed area. Arrows indicate c-Met-rich lamellipodia. (B) Still
images of representative cells from movies. Panels to the right of
each image show kymographic analysis of protrusion along lines
perpendicular to the cortical F-actin. C) Immunoblotting analysis of
stable, doxycycline-inducible DAOY shControl (scrambled) and shMAP4K4_3
and shMAP4K4_3 cell lines after 48 h doxycycline treatment using
concentrations as indicated.
Additional file 6: SM1F-actin dynamics in UW228 cells expressing
Lifeact (LA)-enhanced green fluorescent protein (EGFP. 15 min
recording time, 10 frames per second (fps), acceleration 150x.).
Additional file 7: SM2F-actin dynamics in HGF-stimulated (20 ng/ml,
3 h) UW228 cells expressing LA-EGFP. 15 min recording time, 10 frames
per second (fps), acceleration 150x.
Additional file 8: SM3F-actin dynamics in HGF-stimulated
(20 ng/ml, 3 h) UW228 cells expressing LA-EGFP treated with
PHA (250 nM). 15 min recording time, 10 frames per second (fps),
acceleration 150x.
Additional file 9: ST1List of statistical analyses performed.
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Abbreviations
2D/3D: Two- and three-dimensional; c-Met: Mesenchymal epithelial transition
factor; ERK: Extracellular-signal-regulated kinase; JNK: c-Jun N-terminal kinase;
HA: Hyaluronan; HGF: Hepatocyte growth factor/scatter factor;
MAP4K4: Mitogen-activated protein kinase kinase kinase kinase 4; Myc: v-myc
avian myelocytomatosis viral oncogene homolog; MYCN: Avian
myelocytomatosis viral oncogene neuroblastoma derived homolog;
SHH: Sonic hedgehog; WNT: Wingless.
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4.2 Foreword Manuscript 2 
 
Following the completion of aim 2, we asked how MAP4K4 mediates pro-invasive functions during 
Medulloblastoma dissemination. Therefore we investigated the underlying molecular mechanisms. 
Interestingly, we had observed that cells overexpressing MAP4K4-wt form presented enhanced vesicle 
trafficking, with both the number and the rate of the internalized vesicles being increased compared to the 
cells expressing MAP4K4-KD mutant (Fig. 27). Subsequently, we performed dextran particle internalization 
assays in MB cells and we revealed decreased dextran uptake upon MAP4K4 inhibition (Fig. 28), further 
confirming the above findings. Therefore, we suspected that MAP4K4 controls vesicle trafficking events. In 
parallel, we were aware of the crucial regulatory function of endocytic turnover in cell migration (Hattula, 
Furuhjelm et al. 2006; Beaumont, Hamilton et al. 2011; Rainero, Caswell et al. 2012; Nguyen, Grimm et al. 
2017). Thus, we hypothesized that MAP4K4 controls cell migration through the positive regulation of 
endocytic processes. The strategy we followed to test our hypothesis included functional endocytosis 




Figure 27: MAP4K4 promotes endocytic uptake. Still images of time lapse movies of DAOY cells transfected with vectors expressing 
MAP4K4 wild-type or mM4K4D152N (K/D) kinase dead mutant (Su, Han et al. 1997). LA-mCherry in red, EGFP-mM4K4 in green. 








Figure 28: MAP4K4 promotes endocytic uptake. Representative images of 70 kDa DS red dextran uptake in DAOY cells treated with 
either DMSO, or C29. Green: F-actin, blue: DNA, Red: Dextran.  
 
Aim 3: To determine whether the MAP4K4-controlled processes identified in aim 2 
mediate pro-invasive functions in MB. 
 
 Migration and invasion of MB tumor cells can be driven and regulated by growth factors, adhesion to 
extracellular matrix and non-specifically induced by photon irradiation. Latter is particularly intriguing as 
radiation therapy represents a standard-of-care for cancer patients. In aim 3, I used dextran up-take assays, 
confocal microscopy and biochemical approaches in combination with pharmacological and genetic 
interference strategies to determine the significance of endocytic up-take and cell migration control in MB. 
The results of the above experiments are listed in the second publication below, which is entitled ‘’Kinase 
control of receptor turnover promotes tumor cell invasion in Medulloblastoma’’.  
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Medulloblastoma (MB) cell dissemination causes metastatic disease associated with poor prognosis and 
high morbidity. Little is still known about intrinsic regulators of MB cell migration and invasion, the cell 
functions that enable metastatic dissemination in the patients. We therefore sought to identify regulators of 
cell migration and invasion in MB and to determine the underlying molecular mechanisms that promote the 
cell dissemination process. 
Methods: 
We used human MB tumor tissue micro array and patient-derived xenograft samples to determine protein 
expression levels of MAP4K4, a potentially pro-metastatic Ser/Thr kinase. We used genetically engineered 
MB cell lines, biochemical and confocal microscopy analysis and organotypic cerebellum slice culture to 
explore the consequence of altered MAP4K4 expression or activity on MB cell motility control.  
Results: 
We found that MAP4K4 is overexpressed in primary MB tumor samples and identified it as a driver of 
migration and invasion downstream of growth factor signaling and photon irradiation in MB cell lines. We 
found that MAP4K4 mediates pro-metastatic cell functions by enhancing reception and transmission of 
microenvironmental cues. We demonstrate that MAP4K4 enhances endocytic activity and accelerates 
activation and turnover of integrin and growth factor receptors. The consequence of these novel functions of 
MAP4K4 is aberrant actin based-motility and invasiveness. 
Conclusions: 
Our study identified a novel function of MAP4K4 as a facilitator of endocytic trafficking and receptor turnover 
in response to micro-environmental cues. This function enables oncogenic signaling and morphological 
alterations facilitating migration and invasion, which both are of high relevance for metastatic progression. 
These pro-metastatic activities render MAP4K4 a potential novel therapeutic target for the treatment of 
metastatic MB.  
 
Key words: 
Medulloblastoma, MAP4K4, cell migration and invasion, receptor trafficking 
  





Medulloblastoma (MB) is the most common malignant brain tumor in childhood and is a leading cause 
of cancer-related deaths in children. MB arises in the cerebellum, locally infiltrates and has the propensity for 
leptomeningeal spread through the cerebrospinal fluid (CSF). MB has been molecularly classified in several 
subgroups, which currently include WNT (Wingless), SHH (Sonic hedgehog) p53-wild-type and SHH TP53-
mutant, as well as the two non-WNT/non-SHH groups 3 and 4 (Louis, Perry et al. 2016). Surgical resection, 
chemotherapy as well as local and craniospinal irradiation are the current treatment modalities for MB, and 
survival rates of approximately 70% can be reached (Sanders, Onar et al. 2008). However, these therapeutic 
strategies are associated with substantial side effects in the developing central nervous system of the 
patients and cause high morbidity. Moreover, metastatic and recurrent MB remain clinically very challenging 
diseases with high mortality rates. Therefore, therapies that target tumor cell infiltration and metastatic 
dissemination specifically are urgently needed to halt the progression towards recurrent or metastatic 
disease.  
Cancer cell infiltration is a complex morphodynamic process relying on aberrant signaling, enhanced 
cytoskeleton dynamics as well as elevated vesicle trafficking for membrane receptor turnover and 
extracellular matrix (ECM) remodeling (Sanz-Moreno and Marshall 2010; Wolf and Friedl 2011; Maritzen, 
Schachtner et al. 2015). A key role is ascribed to the integrin adhesion receptors, which are critically involved 
in cell migration both under physiological and pathophysiological conditions (Huttenlocher and Horwitz 2011). 
Their redistribution through internalization and endocytic recycling leads to the establishment of new focal 
adhesions at the leading edge of the migrating cell and the formation of invasive structures such as 
invadopodia and filopodia (De Franceschi, Hamidi et al. 2015; Jacquemet, Hamidi et al. 2015), which both 
are necessary for cell migration in complex tissue environments. Thus, the aberrant recycling, activation 
and/or cell surface presentation of integrins can markedly enhance the invasive behaviour of cancer cells 
(Ramsay, Keppler et al. 2007; Ramsay, Marshall et al. 2007; Muller, Caswell et al. 2009; Mai, Veltel et al. 
2011; Rainero, Caswell et al. 2012). Consequently, trafficking of ß1 integrin has been identified as novel 
therapeutic target for anti-metastatic therapy (Nguyen, Grimm et al. 2017). Analogously, endocytic turnover 
of receptor tyrosine kinases (RTKs) such as c-Met (Barrow-McGee and Kermorgant 2014), FGFR (Auciello, 
Cunningham et al. 2013) or EGFR (Amessou, Ebrahim et al. 2016) determines strength, specificity and 
duration of signaling. 
One kinase involved both in integrin activation (Yue, Xie et al. 2014; Vitorino, Yeung et al. 2015) and 
RTK signal transmission towards migration and invasion (Baumgartner, Sillman et al. 2006; Santhana 
Kumar, Tripolitsioti et al. 2015) is the serine/threonine protein kinase MAP4K4 (Mitogen activated protein 
kinase kinase kinase kinase 4, also known as Hepatocyte progenitor kinase-like/germinal center kinase-like 
kinase (HGK) and Nck-interacting kinase (NIK)). MAP4K4 is a member of the human STE20 family kinases 
(Su, Han et al. 1997; Yao, Zhou et al. 1999) and contains an N-terminal kinase domain, a coiled-coil domain, 
a C-terminal hydrophobic leucine-rich citron homology domain (CNH) and two putative caspase cleavage 
sites (Wright, Wang et al. 2003; Delpire 2009). MAP4K4 is well conserved and orthologues are found across 
species (Su, Treisman et al. 1998; Poinat, De Arcangelis et al. 2002). Genetic interference and gene 
expression analyses have implicated MAP4K4 activity in a plethora of cellular functions relevant for 
physiological and pathophysiological processes, including organ development, systemic inflammation, 
metabolic disorders and in particular also cancer (Gao, Gao et al. 2016; Tripolitsioti, Grotzer et al. 2017).  
An important step towards the development of improved, personalized therapy approaches against 
metastatic cancers is the identification of druggable mediators of cancer cell migration and invasion such as 
protein kinases, for which a number of targeting approaches have been developed (Zhang, Yang et al. 2009; 
Fabbro, Cowan-Jacob et al. 2012; Gross, Rahal et al. 2015). However, since pharmaceutic kinase 
inactivation is not always advisable, or possible, and may cause rapid emergence of resistant phenotypes, 
this study focused on the biology underlying the pro-metastatic kinase function. We investigated the 
relationship between the increased expression of MAP4K4 and the biology of migration and invasion in the 
pediatric brain cancer medulloblastoma. It addresses the question how MAP4K4 actin-targeting functions are 
coupled to migration control and specifically focuses on the regulation of receptor turnover in response to 
growth factor stimulation and matrix adhesion. 
  




Materials and Methods 
Reagents: 
HGF: 20 ng/mL (Preprotech), Dyngo 4a (10 uM, SML0340, Sigma Aldrich), C29 (2.5 uM, 140630, 
Genentech) EIPA (25 uM, A3085, Sigma Aldrich), Dextran, Tetramethylrhodamine (1 mg/ml, D1818, 
ThermoFischer), Integrin blocking antibody (ab24693, Abcam), Normal mouse IgG (sc-2025, SantaCruz). 
 
Cell culture  
DAOY human MB cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, 
USA). UW228 (Keles, Berger et al. 1995) was generously provided by John Silber (Seattle, USA). DAOY and 
UW228 cells were cultured as described in (Fiaschetti, Schroeder et al. 2014). DAOY LA-EGFP and UW228 
LA-EGFP cells were produced by lentiviral transduction of DAOY and UW228 cells with pLenti-LA-EGFP. 
Cell line authentication and cross contamination testing was performed by Multiplexion by SNP profiling.  
 
Immunohistochemistry (IHC):  
IHC of FFPE samples, of the MB Tissue Microarray (TMA) and normal brain sections was performed by 
Sophistolab (Muttenz, Switzerland) on a Lecia BondMax instruments using Refine HRP-Kits (Leica DS9800). 
All buffer-solutions were purchased from Lecia Microsystems Newcastle, Ltd and used according to the 
manufacturer’s guidelines. Paraffin-slides were de-waxed, pre-treated and incubated as follows: ER-solution 
2 for 10 minutes at 95°C, ER-solution 2 for 20 minutes at 100°C and ER-solution 2 for 30 minutes at 100°C. 
The TMA slides were captured digitally using Axio Observer 2 mot plus fluorescence microscope (Zeiss, 
Munich, Germany). Anti MAP4K4 (HPA008476, Atlas) was used at a dilution of 1:50) and expression was 
assessed independently at 5x to 20x magnifications. The samples in the TMA slides were classified by H 
scores by the assessor who was blind to the clinicopathological data of the patients as high, moderate, low 
and negative expression.  
 
Immunofluorescence  
Cells (50,000 per condition) were fixed with 4% paraformaldehyde (PFA), permeabilized with 0.5% Triton X-
100/PBS and blocked with 10% FBS/PBS. Primary antibodies were incubated overnight and were diluted as 
following: mouse mc anti-MAP4K4 (MO-7, clone 4A5, Abnova 1:100), c-Met (11C4) Mouse mc (Flow 
Specific, 5631 Cell Signaling 1:200), phospho-c-Met (Tyr1230/Tyr1234/Tyr1235) rabbit pc (07-810, Merck, 
1:150), Integrin beta 1 mouse mc (12G10) (ab30394, Abcam, 1:200), Rab7 rabbit mAb (9367, Cell signaling, 
1:200). Secondary antibodies were icubated for 2h at room temperature and diluted as following: Cy3-
conjugated Donkey Anti-Rabbit IgG (H+L) (711-165-152, Jackson Immunoresearch, 1:300), Cy5-conjugated 
Rat Anti-Mouse IgG (H+L) (415-175-166, Jackson Immunoresearch 1:300). Cells were subsequently stained 
with Hoechst 1:5000 (B2883, Sigma-Alrich) or phalloidin-488 (Molecular Probes, 1∶500) and mounted with 
glycergel (Dako, C0563). Images were acquired on an Axioskop 2 mot plus fluorescence microscope (Zeiss) 
or in an SP8 Leica confocal microscope. 
 
Transfection 
5 × 105 DAOY-LA-EGFP cells/well were seeded in 6-well plates and 24 h later transiently transfected using 
Jet-Pei (101-10 Polyplus), with 2.5 μg of plasmids expressing LA-mCherry (pLenti-LA-mCherry) and either 
MAP4K4-wt (pEGFP-C2 NIKwt) or MAP4K4-kinase dead (pEGFP-C2 NIKD152N) (Baumgartner, Sillman et 
al. 2006). 
 
Live cell imaging 
DAOY cells were transfected with LA-mCherry and either pEGFP-C2 NIKwt or pEGFP-C2 NIKD152N. 24 h 
after transfection, cells were seeded in fresh cell culture medium in ibidi 8-well slides (5000 cells/well). 
mCherry and EGFP emission spectra were acquired 48 h after transfection under temperature and CO2-
controlled conditions in a SP8 Leica confocal microscope equipped with a 63× multi-immersion objective. 60 
Z-stacks of six images each were acquired (0.34 µm Z-distance, 15 s intervals, 15 min). Average intensity 
projections of the stacks were assembled into QuickTime movies (10 fps, 150x speed). Alternatively, F-actin 
dynamics in DAOY cells stable expressing LA-EGFP were recorded in ibid slides as described above with a 




temperature- and CO2 controlled Zeiss Axio Observer epifluorescence microscope using a glycerol 63x 
objective (30 s intervals, 60 min).  
 
Single cell motility assay  
Cells were seeded in 96-well glass bottom plates (In Vitro Scientific) at approximately 40% confluency in cell 
culture medium without FCS for 18 h. Starvation medium was replaced with fresh pre-warmed starvation 
medium without or with HGF (20ng/mL). Cell motility was acquired using a temperature- and CO2-controlled 
ImageXpress Micro 2 microscope for 18h. Cell speed (total path length/time) was determined by manually 
tracking the cells at 5 min intervals for 6 - 18 h using ImageJ software (National Institutes of Health, USA).  
 
RNA interference: 
The cells were transfected using either Silencer Select siRNA specific for MAP4K1 (ID: 22080), MAP4K2 
(ID:S1688), MAP4K3 (ID:S552), MAP4K4 (ID: 18095), MAP4K5 (ID:22078), MAP3K1 (ID: S8668), MAP3K6 
(ID: S17289) or Silencer select negative control #1 (ID: 4390843) (Ambion). Each siRNA was used at the 
final concentration of 5 nM in combination with Dharmafect 4 transfection reagent (Dharmacon), according to 
the manufacturer’s instructions. 30 h after transfection, the cells were re-seeded for single cell migration. 
 
Statistical Analysis 
Mean ± SD are shown. Unpaired student’s t-test was used to test significance of differences between two 
samples acquired in three independent experiments. For all other analyses one-way ANOVA repeated 
measures test using Bonferroni's Multiple Comparison using Prism software was performed. P-Values < 0.05 
were considered significant (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). Where indicated, asterisks show statistical 
significances between control and test sample.  
 
MAP4K4 depletion by LentiCRISPR: 
BFP tagged LentiCRISPR plasmids were generously provided by Dr. Scott McComb (Ottawa, Canada). 
Cloning of sgRNA into the LentiCRISPR plasmids was performed with a single-tube restriction and ligation 
method as described in (McComb, Aguade-Gorgorio et al. 2016). Production of lentiviral vectors was 
performed according to the standard protocol. In brief, 293T cells were transfected with using HEPES-
buffered saline solution (HeBS) and 0.5 M calcium phosphate with LentiCRISPR, pVSV, pMDL, and pRev 
(Kindly provided by Dr. Oliver Pertz, Bern, Switzerland) in a ratio of 4.5:1.5:3:1. The media was changed 
after 12 h and the virus was collected at 72 h after transfection of plasmids. Viral transductions were 
performed using hexadimethrine bromide (H9268, Sigma-Aldrich). sgRNA sequences were screened for 
MAP4K4 expression in DAOY and UW228 cells by IB. The most effective sequence (Exon 3) was chosen for 
further experiments. The specific sg target sequences used are listed below:  
 
Gene Exon Sg target sequence  
MAP4K4 Exon1 TGTGATTCACCGGGATATCAAGG 
MAP4K4 Exon2 GGGCGGAGAAATACGTTCATAGG 
MAP4K4 Exon3 CAGGACATGATGACCAACTCTGG 
 
Immunoblotting (IB): 
RIPA buffer lysates were resolved by SDS-PAGE and transferred to a nitrocellulose membrane using a 
transfer apparatus according to the manufacturer’s instructions (Bio-Rad). Membranes were probed with 
primary antibodies against MAP4K4 (80418, Abcam), ERK1/2 (9102, Cell Signaling), phospho-ERK1/2 
(9101, Cell Signaling), FAK (610088, BD Biosciences), pFAK (44-624G, ThermoFischer), c-Met (8198s, Cell 
Signaling), phospho-c-Met (2270325, Merck Millipore) and tubulin (T9026, Sigma-Aldrich). Primary 
antibodies were diluted 1:1000 -except for tubulin (1:40000)- in 5% milk. Secondary antibodies [anti-mouse 
horseradish peroxidase (HRP)-linked (7076, Cell signaling) and anti-rabbit HRP-linked (7074) (Cell 
Signaling)] were used to detect the primary antibodies and were diluted 1:5000 in 5% milk. 
Chemiluminescence detection was performed using ChemiDoc Touch Gel and Western Blot imaging system 
(BioRad) and FujiFilm LAS 3000 (Bucher biotech) Integrated density of Immuno-reactive bands was 




quantified using Adobe Photoshop CS3.  
 
RNA expression analysis by qRT-PCR: 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Basel, Switzerland) following the manufacturer’s 
instructions. 100 ng of total RNA was used as a template for reverse transcription, which was initiated by 
random hexamer primers. The cDNA synthesis was carried out using High capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). qRT-PCR was performed under conditions optimized for the 
ABI7900HT instrument, using TaqMan® Gene Expression Master Mix (4369016, Applied Biosystems). 
Primer probes specific for the following genes (4331182, Applied Biosystems) were used: MAP4K1 
(Hs00179345_m1), MAP4K2 (Hs00387564_m1), MAP4K3 (Hs00269284_m1), MAP4K4 (Hs00377415_m1), 
MAP4K5 (Hs00179088_m1), MAP3K1 (Hs00394890_m1), MAP3K6 (Hs01085775_m1). Cycle threshold 
(CT) values were normalized to housekeeping gene GAPDH (Hs02786624_g1). ΔΔCT method was used to 
calculate the relative gene expression of each gene of interest. 
 
Spheroid invasion assay (SIA): 
2,500 cells/100 μl per well were seeded in 96 well Corning® Spheroid microplate (CLS4520, Sigma-Aldrich) 
(DAOY cells) and in cell-repellent 96 well microplate (650790, Greiner Bio-one) (UW228 cells). The cells 
were incubated at 37°C overnight to form spheroids. 60 µl of the medium were removed from each well, and 
remaining medium with spheroid overlaid with 2.5% bovine collagen 1. Following the polymerization of 
collagen, fresh medium was added to the cells and treated with growth factors / cytokines and/or with 
inhibitors. The cells were allowed to invade the collagen matrix for 24 h, after which they were fixed with 4% 
PFA and stained with Hoechst. Images were acquired on an Axio Observer 2 mot plus fluorescence 
microscope (Zeiss, Munich, Germany) using a 5X objective. Cell invasion is determined as the average of 
the distance invaded by the cells from the centre of the spheroid as determined by our cell dissemination 
counter software aCDc (Kumar, Pillong et al. 2015). For the beta 1 integrin blockage, cells were treated with 
10 ug/ml beta 1 integrin antibody or control mouse IgG for 2 h at 37
o
C before collagen embedment. 
 
Replating assay 
Integrin activation by ligand engagement was tested as described in (Alanko, Mai et al. 2015): Cells were 
serum starved for 24h, detached with HyQTase, and kept in suspension in serum-free medium for 1 h stop 
adhesion signaling. Dyngo4a (10 μM) or equal volumes of DMSO were added to cells 15 min before 
replating on collagen type I (5 μg/ml) coverslips for 15 min at +37°C. Cells were subsequently fixed with 4% 
PFA and proceeded for Immunofluorescence. Cell imaging took place in Leica SP8 confocal microscope. 
 
Quantification of intracellular (endosomal), activated b1 integrin  
Intracellular activated beta 1 integrin on the endosomal structures was quantified using FIJI. Briefly, TIFF 
format images were split into subchannels. Rab7-channel (Red) images were thresholded in order to 
measure the area of the endosomes. Subsequently, in the beta 1 integrin channel (Blue), the integrated 
density that corresponded to the respective area of the endosomes was measured. Next, the division of beta 
1 integrated density divided by the endosomal area was defined as the intracellular endosoml beta 1 
activated integrin. 
 
Dextran uptake assays 
DAOY cells were seeded in a 24-well plate (25,000 cells/well) on top of Immunofluorescence round cover 
slips in a final volume of 1 ml/well. Cells were starved overnight and the following day compound treatment 
followed (C29: 2.5 uM, 5 hours, EIPA: 25 uM 30 min) in serum starvation medium. Subsequently medium 
was removed and replaced with TMR Dextran-containing medium, with or without HGF. After incubation at 
37
o
C for 30 min, cells were washed with ice-cold PBS for 5 times. Next, cells were ficed with 4 % PFA and 
subsequently proceeded for Immunofluorescence. Cell imaging took place in Axio Observer 2 mot plus 
fluorescence microscope (Zeiss, Munich, Germany) 
 
Quantification of Dextran uptake 




Dextran uptake quantification was performed using FIJI. Briefly, TIFF file images were split into subchannels. 
LA-EGFP-channel (Green) images were thresholded in order to measure the area of the cells. Subsequently, 
in the Dextran channel (Red), the integrated density that corresponded to the respective cell area was 
measured. Next, the division of dextran integrated density divided by the cell area was defined as the 
dextran uptake index. 
 
c-Met internalization assay 
c-Met internalization assay was performed as described in (Crupi, Richardson et al. 2015). Briefly, DAOY 
cells (10
6
) were seeded in 10 cm dishes and when reached 70% confluency were starved overnight. The 
following day cell medium was removed while cells were on ice and was replaced with biotin-containing 
medium [2.5 mg of Biotin (EZ-Link Sulfo-NHS-Biotin, 21331, ThermoFischer) / 5 ml Biotinylation Buffer 1X 
(1.54M NaCl, 100 mM Hepes, pH 7.6, 30 mM KCl, 10 mM MgCl 2, 1.0 mM CaCl 2, 100 mM glucose, 10X] 
per condition, for 45 min at 4
o
C in order to coat the cells with biotin. Next, cells were washed with ice-cold 
PBS and were subsequently incubated with HGF for the necessary timepoints. Following HGF incubation, 
cells were washed with PBS and biotinylated membrane receptors were stripped using MeSNa (Sodium-2-
mercaptoethanesulfonate, 63705, Sigma-Aldrich) in 1X MeSNa Buffer (1.0 M NaCl, 500 mM Tris–HCl, pH 
8.6, 10 mM MgCl 2, 1 mM CaCl 2, 10X), 20 min at 4
o
C, 2 times. Then, cells were placed on ice, washed with 
ice cold PBS, lysed with RIPA buffer (500 ul/dish) and centrifuged for 15 min full speed on ice. Next, the 
supernatant was subjected to BCA quantification (23227, ThermoScientific). Next, 100 ug of Whole cell 
lysate (WCL) samples were kept as control, and then 500-800 ug of protein was added to 22 ul magnetic 
Streptavidin beads (88816, Thermofischer) and was incubated overnight at 4
o
C under rotation. The following 
day, beads were washed with RIPA bufer for three times, using a magnetic rack. Next, beads were treated 
with Loading Buffer (1X) (RotiLoad, K929.1, KarlRoth), boiled for 5 min at 95
o
C and lysate was subjected to 
Immunoblot. During this procedure, the necessary control samples [Total protein, TP, as well as the MeSNa 
stripping control, M/0] were kept and lysed along with the experimental samples. 
 
c-Met antibody feeding assay  
DAOY LA-EGFP cells (30,000) were seeded in 24-well plate Poly-L-Lysine (PLL, P9155 Sigma Aldrich) – 
coated coverslips in serum starvation medium. The following day cells were incubated with c-Met antibody 
(11C4, 56315 Cell Signaling) for 1 h at 4
o
C. Subsequently, cells were washed three times with ice cold PBS 
and were then incubated with or without HGF for 30 min at 37
o
C. Next, cell medium was removed, cells were 
fixed with 4% PFA and were subsequently subjected to immunofluorescence. 
 
c-Met activation assay 
DAOY cells (400,000) were seeded on Poly-L-Lysine (PLL, P9155 Sigma Aldrich)-coated 6-well plates and 
were overnight incubated at 37
o
C. The following day cells were treated with compounds and/or HGF and 
incubated for 30 min at 37
o
C. Subsequently cells were lysed using RIPA buffer and were immediately 
subjected to Immunooblot. 
  






The Ser/Thr kinase MAP4K4 is overexpressed in Medulloblastoma 
 
Several studies detected increased expression of MAP4K4 in various solid human cancers and 
suggested its contribution to tumor growth and progression (Wright, Wang et al. 2003; Badea, Herlea et al. 
2008; Liang, Wang et al. 2008; Hao, Chen et al. 2010; Qiu, Qian et al. 2012). To determine whether 
increased MAP4K4 expression could also be associated with MB, we analyzed the genomic information 
available for a number of MB clinical samples in the R2 genomic analysis and visualization platform. This 
analysis revealed increased expression of MAP4K4 in MB compared to normal cerebellum (cb) or normal 
brain (Fig. 1 A). We confirmed increased MAP4K4 expression at mRNA levels by quantitative real time PCR 
(qrt-PCR) using a small cohort of MB confirmed clinical samples (Fig. 1B). Immunohistochemistry (IHC) 
detected strongly increased MAP4K4 protein expression in human non-WNT/SHH MB, a moderate increase 
in group 3 and SHH patient-derived xenograft (PDX) and again very high expression levels in a Ptch/P53 null 
genetic mouse model (Fig. 1C). Consistent with the relatively low mRNA expression levels in normal 
cerebellum, we only detected a weak MAP4K4 signal in healthy cb tissue adjacent to the tumor (Fig. 1C,a). 
To explore the potential clinical significance of MAP4K4 in MB patients, we probed an MB tissue micro array 
(TMA) containing 68 human tumor samples and 7 cb controls. MAP4K4 expression levels were scored by H 
score by a pathologist into negative, low, moderate and high. This analysis revealed a clearly increased 
expression of MAP4K4 in tumor tissue compared to adjacent cb, with some tumors showing very high levels 
of MAP4K4. These data demonstrate that the expression of MAP4K4 in MB is increased, both at the mRNA 
and the protein level.  
 
MAP4K4 expression in SHH MB cell model is required for migration and invasion.  
 
A number of MB laboratory and patient-derived xenograft (PDX) lines derived from SHH or G3 MB 
are available. We compared MAP4K4 expression in some of those lines by qrt-PCR (Fig. 2A) or immuno blot 
(IB, Fig. 2B). The highest mRNA expression levels were detected in the atypical MB PDX line MedPDX311, 
which also displayed high MAP4K4 protein. Nevertheless, no marked differences in MAP4K4 protein levels 
were noticeable between the MB cell lines. However, the presence of multiple bands of variable intensities 
indicate variant expression in the different lines. We detected MAP4K4 in and around the nucleus in the two 
SHH lines DAOY and UW228, and - similar to previous observations (Baumgartner, Sillman et al. 2006; Ma 
and Baumgartner 2014) – in lamellipodia (Fig. 2C). Five human MAP4Ks are listed in NCBI (MAP4K1-5). We 
previously showed that MAP4K4 is required for efficient migration in response to hepatocyte growth factor 
(HGF) stimulation (Santhana Kumar, Tripolitsioti et al. 2015). To determine whether the other MAP4Ks could 
be also involved in migration control, we depleted each variant with individual siRNAs. We found that 
depletion of MAP4K1-3 had no effect on HGF-induced single cell migration in 2D, whereas depletion of 
MAP4K4 and MAP4K5 completely abrogated migration (Fig. 2D). Since the siRNA targeting MAP4K5 also 
caused marked reduction of the MAP4K4 transcript (Fig. S1A), we consider MAP4K4 the predominant kinase 
in particular also as it showed the highest mRNA expression (Fig S1B). To quantify cell migration and 
invasion, we used the spheroid invasion assay (Kumar, Pillong et al. 2015), which measures how far cells 
disseminate from a tumor cell spheroid into a collagen gel (Fig. 2E, schema). Distance of dissemination is 
quantified from the center of the spheroid using aCDc software (Kumar, Pillong et al. 2015). We depleted 
MAP4K4 either using lentivirus encoding tetracyclin-inducible short hairpin RNA targeting MAP4K4 mRNA or 
a CRISPR/CAS9 cassette guided towards MAP4K4. shRNA depletion of MAP4K4 in DAOY (Fig. 2E) or 
UW288 (not shown) cells significantly impaired HGF- and EGF-induced migration and invasion (Fig. 2E). For 
each we used three different constructs and identified for both approaches two constructs that led to at least 
70% downregulation. Depletion of MAP4K4 by shRNA impaired HGF-, EGF- and IGF-induced migration and 
invasion but did only moderately affect dissemination induced by bFGF, where a significant proportion of 
cells are refractory to the effect of MAP4K4 depletion (Fig. 2E, S2A). CRISPR/CAS9 mediated depletion of 
MAP4K4 confirmed the significance of MAP4K4 function for c-Met signaling-induced migration and invasion. 
Moreover, the pyridopyrimidine scaffold-based compound 29 (C29) MAP4K4 inhibitor (Crawford, Ndubaku et 
al. 2014) prevented HGF-induced collagen invasion, indicating that MAP4K4 kinase activity is required for 




the pro-migratory function of MAP4K4 (Fig. 2 G). To determine whether the increased levels of MAP4K4 
detected in MB tumors per se and independent of an additional stimulus could be sufficient to trigger 
migration and invasion, we generated DAOY cells stably expressing either wt or the kinase dead mutant of 
MAP4K4 (K54R (Wright, Wang et al. 2003)). The over expression of the wt but not of K54R MAP4K4 
triggered collagen invasion in the absence of HGF similar to control cells in the presence of HGF (Fig. 2H), 
with considerably more cells migrating longer distances. Overexpression of K54R MAP4K4 in the presence 
of HGF did only partially reduce migration and invasion, suggesting that it only incompletely acts as a 
dominant negative (data not shown). Taken together, these data demonstrate that MAP4K4 plays an 
essential role in growth factor induced migration control in MB cells and that overexpression of MAP4K4 
alone is sufficient to trigger its pro-migratory functions in the absence of additional exogenous stimulation.  
 
MAP4K4 mediates radiation induced migration and invasion 
 
 Radiotherapy is a standard therapy in medulloblastoma and required for preventing metastasizing 
disease (Halberg, Wara et al. 1991; Deutsch, Thomas et al. 1996). The role of photon radiation on the motile 
and invasive behavior of the tumor cells remains controversial and may be cell and context dependent 
(Fujita, Yamada et al. 2015). However, sub lethal doses of radiation can induce pro-metastatic phenotypes 
and increase the migratory and invasive potential of tumor cells. This effect can either be mediated by 
changes in the tumor stroma (Ohuchida, Mizumoto et al. 2004; Asparuhova, Secondini et al. 2015), or by 
intrinsic alterations in the tumor cells (Wild-Bode, Weller et al. 2001; Qian, Mizumoto et al. 2002; Nalla, 
Asuthkar et al. 2010; De Bacco, Luraghi et al. 2011). To explore the potential impact of photon irradiation on 
the migratory behavior of MB cells, we irradiated collagen-embedded sgControl DAOY and sgControl 
UW228 spheroids with different radiation doses and measured collagen invasion. We found that irradiation 
doses of 1 and 2 Gray (Gy) increased the migratory capability of DAOY and UW228 cells, respectively (Fig. 
3A). Radiation-induced migration is similar to that induced by HGF but generally more modest (fewer cells 
migrating shorter distances). To determine, whether radiation and HGF synergize, we combined irradiation 
and HGF treatment. We observed no marked additive or even synergistic effect, indicating that irradiation 
either induces c-Met pathway functions or the presence of a convergence effector required downstream of 
both cues. To test whether MAP4K4 could be such an effector, we compared coll I invasion after irradiation 
of sgControl and sgMAP4K4 cells. Interestingly, both in the absence or presence of HGF, the depletion of 
MAP4K4 abrogated coll I invasion. To establish a better understanding of the biologically relevant differences 
of migration, we determined the frequency distributions of the different dot plots and measured the are under 
the curve above and below a cut-off point of 250. MAP4K4 depletion completely abrogated migration induced 
by IR beyond cut-off 250 in the absence of HGF. Coll I invasion was partially rescued in the presence of HGF 
in sgMAP4K4 cells, but only to a level similar to sgControl without HGF. These data indicate that MAP4K4 
controls a mechanism required for both migration induced by HGF and by irradiation. 
 
MAP4K4-dependent migration is associated with increased actin dynamics and endocytic activity 
 
To determine in which subcellular compartment MAP4K4 functions might be relevant for migration control, 
we overexpressed either wt or a kinase-dead mutant (mMAP4K4-D152N) of mMAP4K4 fused to EGFP in 
MB cells and monitored EGFP and F-actin dynamics during migration. We observed that MAP4K4 co-
localized with the dynamic F-actin at the leading edge (Fig. 4A, movie 1) and also accumulated in perinuclear 
regions. The pronounced ruffling activity at the leading edge was accompanied by rapid trafficking of F-actin 
decorated vesicles towards the perinuclear regions. In cells expressing MAP4K4 k/d, ruffling was markedly 
slowed and speed of vesicle trafficking reduced. Interestingly, EGFP-MAP4K4-k/d associated with the F-
actin-decorated vesicles, suggesting that delayed vesicle trafficking could be related to the lack of MAP4K4 
kinase function. To test whether its kinase activity is required for vesicle emergence and trafficking from 
dynamic lamellipodia, we compared F-actin dynamics in DMSO control treated cells and cells treated with 
the MAP4K4 inhibitor C29 (Crawford, Ndubaku et al. 2014). C29 completely abrogated F-actin ruffling and 
the emergence of F-actin coated vesicles (Fig. 4B a). Exposure of the cells to 70 kDa ds dextran caused 
rapid up-take of the fluorescent dextran (Fig. 4Bb). This up-take is enhanced by GFs in MB cells as dextran 
internalization increased in response to HGF (Fig. 4C) or EGF (Data not shown) stimulation. Pre-treatment 




with C29 abrogated GF-induced dextran up-take, suggesting that MAP4K4 could mediate GF-induced 
endocytic activity (Fig. 4D). Consistently, depletion of MAP4K4 impaired HGF-induced dextran endocytosis 
(Fig. 4E), whereas the overexpression of wt-MAP4K4 alone was sufficient to increase endocytic activity to a 
level similar to GF-stimulated cells (Fig. 4F). Together, these data indicate the function of MAP4K4 in vesicle 
trafficking and endocytosis to control the up-take of macromolecules into the tumor cells.  
 
MAP4K4 promotes integrin activation on endosomes 
 
Cell migration requires proper binding to extracellular matrix proteins through the family of integrin adhesion 
receptors and their coordinated turnover through the endocytic machinery (Ridley, Schwartz et al. 2003; 
Maritzen, Schachtner et al. 2015). The adhesion to extracellular matrix (ECM) proteins causes the 
internalization of activated ß1 integrins, which accumulate in an activated state on endosomes to promote 
adhesion and pro-migratory signaling through focal adhesion kinase (FAK) (Alanko, Mai et al. 2015). 
Therefore, we tested whether MAP4K4 control of global macromolecular uptake through endocytic 
processes (Fig. 4D-F) is coupled to integrin activation. We quantified the levels of intracellular activated ß1 in 
cells seeded onto coll I using confocal IFA. Since passage of activated integrins through Rab7-positive late 
endosomes is one mechanism of integrin recycling (Dozynkiewicz, Jamieson et al. 2012), we monitored 
abundance of active ß1 integrins at the level of late endosomes. We detected significant decreases in ß1 
integrin activation in cells treated with Dyngo 4a, a dynamin inhibitor preventing activity-dependent bulk 
endocytosis in neurons (McCluskey, Daniel et al. 2013). Interestingly, we found that MAP4K4 is also involved 
in bulk up-take of activated ß1 integrins, as impairing MAP4K4 functions either by C29 treatment or by 
siRNA-mediated depletion of MAP4K4 caused a significant drop of activated ß1 integrin in MB cells (Fig. 5A). 
Since our studies focus particularly on cancer cell migration in 3D environment, where leading edge invasive 
protrusions play a major role during matrix invasion, we monitored the effect of MAP4K4 depletion on HGF-
driven ß1 activation in lamellipodia. HGF stimulation causes a significant increase in active ß1 integrin in 
lamellipodia of cells migrating inside collagen gels (Fig. 4B). This increase is completely abrogated in 
MAP4K4-depleted cells (Fig. 4B). To confirm that ß1 integrin is necessary for collagen invasion and 
migration, we prevented ß1 integrin function using either blocking anti-Iß1 antibody (Fig. 5C) or by siRNA-
mediated depletion (Fig. 5D). ß1 integrin blockade using anti-Iß1 caused a significant reduction in 3D cell 
migration. Frequency distribution analysis revealed that while the majority of cells migrated less efficiently, a 
considerable number still infiltrated longer distances. (Fig. 5C, right). This is probably due to incomplete 
antibody blockade of Iß1, as si-Iß1 reverted collagen invasion induced by HGF. One relevant downstream 
function of Iß1 is the activation of FAK on endosomes, where among many other proteins MAP4K4 was 
found as well (Alanko, Mai et al. 2015). We therefore tested whether reduced Iß1 activation in cells with 
impaired MAP4K4 function also causes reduced FAK activation. We tested the levels of activated FAK of MB 
sgC and sgM4K4 cells embedded in collagen gels by IB using anti phospho-Y397-FAK antibody. We found 
pFAK levels in cells with impaired MAP4K4 function significantly reduced (Fig. 5 E) and this level of reduced 
pFAK was not increased in the presence of HGF. 
Taken together, these data show that MAP4K4 is required for integrin activation on endosomes in response 
to collagen adhesion and that this MAP4K4-dependent Iß1 activation is required for migration and invasion 
and for the activation of FAK. 
 
MAP4K4 controls c-Met function 
 
The receptor tyrosine kinase and proto-oncogene c-Met can promote migration and invasion in MB 
and other solid tumors (Li, Lal et al. 2005; Provencal, Labbe et al. 2009; Trusolino, Bertotti et al. 2010; Sierra 
and Tsao 2011; Guessous, Yang et al. 2012; Santhana Kumar, Tripolitsioti et al. 2015). c-Met functions are 
also regulated at the level of receptor endocytosis and c-Met signaling from endocytic vesicles promotes 
growth, survival and cell migration (Barrow-McGee and Kermorgant 2014). Consistently, pharmacological 
inactivation of dynamin-dependent endocytosis using Dyngo 4a impaired c-Met activation, caused reduced 
activation of ERK and repressed FAK activation in MB cells (Fig. 6A). We therefore tested whether MAP4K4 
control of endocytic activity (Fig. 4) could also affect HGF-induced c-Met and ERK activation. We found that 
MAP4K4 depletion caused a marked reduction of HGF-induced activation of c-Met and of downstream ERK 




signaling (Fig. 6B), whereas steady state c-Met phosphorylation was not affected or rather increased. 
Consistent with decreased levels of activated FAK observed in MAP4K4-depleted cells embedded in 
collagen, we also found FAK activation in response to HGF impaired in the absence of MAP4K4 (Fig. 6B). 
The inhibition of dynamin-dependent endocytosis causes a significant reduction in intracellular activated c-
Met, which in control cells accumulated on vesicular structures in the cytoplasm. (Fig. 6C). We therefore 
tested whether the reduced global c-Met activation in MAP4K4-depleted cells could be associated with 
reduced trafficking of activated c-Met or maintenance in vesicles. Cortical F-actin was increased in HGF- 
stimulated sgControl cells and the appearance of pc-Met-decorated vesicles in the cytosol was apparent. In 
contrast, sgM4K4 cells displayed reduction of cortical F-actin and a striking decrease in pc-Met-positive 
vesicles (Fig. 6D). We quantified the number of pc-Met-positive vesicles under all conditions and measured 
their size using Imaris (Fig. 6C and D, lower). This quantification showed that intracellular vesicle-associated 
pc-Met was significantly reduced when endocytic activity was impaired or MAP4K4 functions repressed. This 
experiment furthermore revealed trafficking of activated c-Met through intracellular compartments and that 
either activation or internalization of c-Met is impaired when MAP4K4 is absent. To determine whether 
altered internalization of c-Met could explain reduced levels of activated c-Met inside the cells, we quantified 
HGF-induced c-Met internalization after surface biotinylation. Comparison of control and HGF stimulation 
revealed that raising the temperature from 0°C to 37 alone was sufficient to cause marked c-Met 
internalization within 30 min. HGF stimulation further enhanced this effect (Fig. 6E). In the absence of 
MAP4K4, both temperature shift-induced and HGF-dependent c-Met uptake was completely blocked (Fig. 
6E). Taken together these data strongly suggest the implication of MAP4K4 in the control of HGF signaling 























Fig. 1  
MAP4K4 is overexpressed in in MB tumors. A) MAP4K4 mRNA U133P Affymetrix gene chip micro array 
expression levels in normal tissue samples (cerebellum and brain regions) versus MB tumors. Statistical 
significance of difference is indicated in table below horizontal bar-dot plot. B) qRT-PCR quantification of 
MAP4K4 mRNA expression levels in 12 MB patient samples from the University Children’s Hospital Zurich. 
Red line indicates 2-fold increase of MAP4K4 expression levels compared to normal cerebellum control. C) 
Anti-MAP4K4 IHC analysis in a non-WNT/non-SHH MB primary tumor, a G3 MB PDX and a Ptch/P53 null 
SHH model of MB a’ – f’ are 4x magnification of boxed areas. a’ is healthy cerebellar tissue, and b’ is tumor 
tissue. c’ and d’ are different zones in same tumor. e’ and f’ show MAP4K4-positive neoplastic cells 
infiltrating the granular layer. D) MAP4K4 expression in MB tumor tissue microarray of MB tumor (T) and 
cerebellum tissue (Cb) samples and H score quantification.  
 
Fig. 2 
MAP4K4 promotes migration and invasion. Analysis of MAP4K4 mRNA (A) and protein (B) expression in 
different MB cell lines and PDX models by qRT-PCR and immunoblot, respectively. C) IFA of MAP4K4 
subcellular localization in migrating DAOY and UW228 cells. Signals of polyclonal (pc) and monoclonal (mc) 
anti-MAP4K4 were compared. Arrowheads indicate MAP4K4 localized in the lamellipodia. Magnificiations 
are 4x of red boxed areas. D) XY plot shows comparison of the speeds of single cells (n=30) transfected with 
siRNAs against the indicated MAP4 kinases without or with 20 ng/mL HGF. E) left: Schematic representation 
of cell dissemination in collagen I (spheroid invasion assay, SIA) without or with growth factor (GF). Purple 
concentric circles indicate variable ranges of dissemination from the spheroid center. Right: SIA of DAOY 
cells expressing control or one of two different MAP4K4-targeting shRNAs in the absence or presence of 
different GFs (HGF: 20 ng/mL, EGF: 30 ng/mL, IGF: 20 ng/mL, bFGF: 100 ng/mL). F) SIA of cells with 
CRISPR/CAS9-mediated knock-down of MAP4K4 without or with HGF. Bar graphs show frequency 
distribution for each condition (dissemination ranges: basal: 100 – 200, low: 200 – 300, intermediate: 300 – 
400, high: 400 – 500, very high: 500+). G) SIA of DAOY cells treated without or with C29 and HGF. Images 
to the right are representative images of quantification. H) SIA with DAOY control, or DAOY ectopically 
expressing either MAP4K4 wild-type (wt), or MAP4K4 kinase-dead mutant (K54R). IB shows relative 
MAP4K4 expression in control and overexpressing cells. Bar graphs shows frequency distribution for each 
condition (dissemination ranges: basal: 100 – 200, low: 200 – 300, intermediate: 300 – 400, high: 400 – 500, 
very high: 500+). . *p < 0.05, **p < 0.01, ***p < 0.001 (1way Anova). 
 
Fig. 3 
A) Left: Representative dot plots of SIA of DAOY and UW228 cells (shControl and sgMAP4K4_2) exposed to 
one (DAOY) or two (UW228) Gray (Gy) irradiation after embedding in collagen. SIA was performed 
immediately after irradiation either in the absence or presence of 20 ng/mL HGF as indicated. Right: 
frequency distributions of the dot plots shown. B) Quantification of the area under the curve (AUC) of the 
frequency distributions with a cut-off of higher than 250 from the spheroid center. Mean and SEM of three 
(DAOY) or two (UW228) or one (UW228 + HGF) independent experiments are shown.  
 
Fig. 4 
MAP4K4 promotes endocytic uptake. A) Still images of time lapse movies of DAOY cells transfected with 
vectors expressing mM4K4 wild-type or mM4K4D152N (k/d) kinase dead mutant. LA-mCherry in red, EGFP-
mM4K4 in green. Inverted grey scale images show actin and MAP4K4. B) Left: same as in A) in DAOY cells 
treated with DMSO or MAP4K4 inhibitor C29, LA-EGFP in grey scale. Arrows point to trafficking vesicles. 
Right: IFA analysis of cells exposed to 70 kDa DS red dextran for 30 min. C) 70 kDa DS red dextran uptake 
in DAOY cells -/+ HGF 20 ng/mL. Upper: IFA showing representative images of DAOY cells 50 min after 
dextran exposure. Lower: quantification of HGF-dependent dextran uptake. D) 70 kDa DS red dextran uptake 
in DAOY cells treated with either DMSO, EIPA or C29. Left: representative images of dextran uptake -/+ 
C29. Green: F-actin, blue: DNA, Red: Dextran. Right: quantification of uptake 30 min after dextran addition. E 




& F) Quantification of TMR Dextran internalization after transient downregulation of MAP4K4 using siRNA 
(E) or overexpression of hM4K4 wt or hM4K4K54R kinase-dead MAP4K4 (F) -/+ HGF. Quantifications 
presented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (1way Anova). 
 
Fig. 5. 
MAP4K4 promotes integrin signaling. A) Quantification of activated ITGB1 in DAOY cells plated on Coll I -
/+ Dyngo 4a (Dy4a) or C29 or after MAP4K4 downregulation by siRNA. Representative confocal cross-
sections at level of Rab7 are shown. Green: F-actin, blue: activated ITGB1, red: Rab7. Bar graphs depict 
quantification of activated ITGB1 on Rab7-positive endosomes upon dynamin (Dyngo (McCluskey, Daniel et 
al. 2013)) or MAP4K4 (C29) inhibition or after transient depletion of MAP4K with siRNA. Mean and SEM of 
pooled data from 2 (compounds C29 and Dyngo 4a) and 3 (siM4K4) independent experiments are shown B) 
Left: representative images of activated ITGB1 in lamellipodia of DAOY cells invading Coll I matrix in siScr 
(siC) or siMAP4K4 cells. Right: quantification of activated ITGB1 in lamellipodia. At least 10 lamellipodia 
were analyzed per condition (See Fig. S4). C) Dot plot (left) and frequency distribution (right) of blocking anti-
ITGB1 or control ab effect on Coll I invasion in SIA and in response to HGF (20 ng/mL). D) Immunoblot and 
quantification of FAK phosphorylation in Coll I-embedded DAOY sgC and sgM4K4 cells. 
 
Fig. 6 
MAP4K4 promotes internalization and activation of cMet. A & B) Top: IB analysis of c-Met, Erk1/2 and 
FAK phosphorylation in response to HGF stimulation in the absence or presence of 10 µM Dyngo 4a. (A) or 
MAP4K4 depletion (B). Bottom: XY line plots of integrated pixel densities of phospho bands from 3 
experiments against time in min after HGF stimulation. C) Upper: confocal IFA of PLL adhering DMSO or 
Dyngo 4a-treated cells. pc-Met before (0 min) and after raising temperature from 0° to 37°C in the absence 
or presence of HGF. Insets show 4x magnification of spots. Bottom: bar diagram of single cell analyses of 
spots/cell, spot size and spots * size (n=13, mean and SD). D) As C) but either sgC or sgM4K4_2 cells were 
used. E) Left: biotinylation assay in sgC or sgM4K4_2 cells -/+ HGF. Right: quantification of internalized 
biotinylated c-Met relative to total c-Met. *p < 0.05, **p < 0.01, ***p < 0.001 (1way Anova). 
 
Supplementary Information: 
Figure S1:  
A) qRT-PCR quantification of mRNA expression levels of MAP4K4 in different MB lines and in HEK293T 
cells. B) qRT-PCR quantification of the MAP4K1-5, MAP3K1 and MAP3K6. Normalization using GAPDH 
expression levels in DAOY cells. C) qRT-PCR quantification of siRNA effects on target MAP4Ks and 
MAP4K1-5, MAP3K1 and MAP3K6. individual siRNA transient downregulation in DAOY cells.  
 
Figure S2:  
Frequency distribution curves (distance plotted against cell counts) derived from the spheroid invasion assay 
dot plots shown in 2E, right panel. MAP4K4 was depleted with two different shRNAs and SIA was performed 
in the absence or presence of growth factor (HGF: 20 ng/mL, EGF: 30 ng/mL, IGF: 20 ng/mL, bFGF: 100 
ng/mL) in DAOY MB cells.  
 
Figure S3:  
Irradiation promotes cell invasion in a MAP4K4-dependent manner in Medulloblastoma. Quantification 
of the Area under curve of frequency distributions of SIA with DAOY (Top) and UW228 (Bottom) cells after 
different irradiation dosages (0, 1, 2, 4 Gy). MAP4K4 was depleted by shRNA and SIA was performed in the 
absence of presence of HGF (20 ng/ml). The cut-off was defined as above 90% of the control non-irradiated 
cell population. Data are the mean and SEM of three independent experiments. 
 
Figure S4 
MAP4K4 promotes HGF-induced integrin activation in lamellipodia. Confocal microscopy images 
showing activated ß1 integrin (anti-activated ITGB1, 12G10 antibody) in lamellipodia of collagen-embedded 




DAOY sgScr and sgMAP4K4 cells without or with HGF (20 ng/ml) stimulation for 24h. Blue: Activated ß1 
integrin. Green: Actin. 
 
Figure S5 
Scheme depicting MAP4K4 implication of integrin α51ß1 and c-Met receptor turnover and activation for 
establishment of the pro-metastatic phenotype. 
  






Our data indicate that the up-regulation of MAP4K4 in MB controls relevant aspects of the metastatic 
behavior of the tumor cells by promoting productive turnover of integrin ß1 and the RTK c-Met in response to 
growth factor stimulation. GF-induced receptor downstream signaling and invasive motility of the tumor cells 
depend on the expression and activity of MAP4K4. We propose that the mechanisms underlying these 
MAP4K4 functions are linked at the level of endocytic turnover and vesicle trafficking. This novel activity of 
the tumor-associated MAP4K4 identified a potentially druggable mechanism to restrict tumor cell migration 
and invasion by interfering with the endocytic processing of adhesion and growth factor singaling. 
We detected both increased MAP4K4 mRNA as well as protein levels in tumors compared to the 
normal cerebellum controls. Interestingly, increased MAP4K4 staining was also detected in tumor cells of the 
Ptch-p53null mouse model invading the healthy tissues (Fig. 1). Thus, similar to other solid tumors such as 
glioblastoma, pancreatic ductal adenocarcinoma, lung cancer and gastric cancer, MAP4K4 is overexpressed 
in the cerebellar tumor tissue. High MAP4K4 mRNA expression was also detected in glioma, which confirms 
the intriguingly increased brain tumor-specific MAP4K4 expression levels noted a while ago (Wright, MCB 
2003). Although MAP4K4 expression in tissue-infiltrating cells of Ptch-p53null MB indicated the potential 
contribution of MAP4K4 to tumor cell invasion, functional analysis will be necessary to clarify the potential 
impact of MAP4K4 on tissue infiltration in this model. The increased MAP4K4 expression in at least 30% of 
the 68 human MB tissue samples analyzed indicates the potential diagnostic relevance of MAP4K4 for the 
clinic. However, to use anti-MAP4K4 IHC analysis as a diagnostic tool, the biological significance of MAP4K4 













In the present study, we have examined the function of the Ser/Thr MAP4K4 in the context of 
Medulloblastoma (MB) dissemination. We have shown that MAP4K4 expression is upregulated in 
Medulloblastoma tumors compared to normal healthy tissues. Furthermore, we have developed appropriate 
biological tools to analyze MAP4K4 function in Medulloblastoma (MB). These tools enabled us to reveal that 
MAP4K4 comprises an essential mediator of actin dynamics as well as endocytic uptake in MB cells and that 
MAP4K4-dependent processes promote pro-invasive functions in MB. 
 
5.1 MAP4K4 is overexpressed in Medulloblastoma 
 
Previous studies had demonstrated MAP4K4 involvement in tumorigenesis, mainly through 
observations that MAP4K4 levels were enhanced in different types of cancers and more importantly, in later, 
more aggressive tumor stages (Badea, Herlea et al. 2008; Liang, Wang et al. 2008; Hao, Chen et al. 2010; 
Liu, Cai et al. 2011; Qiu, Qian et al. 2012). Nevertheless, with MB being a highly metastatic tumor, MAP4K4 
function towards metastatic MB dissemination remained unclear. Thus, one of the first steps we undertook to 
explore whether MAP4K4 could be implicated in the context of MB invasive functions, was to examine 
MAP4K4 expression levels in MB tumors compared to samples from the normal cerebellum and normal brain 
regions. We detected both increased MAP4K4 mRNA as well as protein levels in tumors compared to the 
normal cerebellum controls (Fig. 1&B, Manuscript 2). Interestingly, increased MAP4K4 staining was also 
detected in tumor cells of the Ptch-p53null mouse model invading the healthy tissues (Fig. 1C, Manuscript 2). 
Thus similar to other solid tumors such as glioblastoma, pancreatic ductal adenocarcinoma, lung cancer and 
gastric cancer, MAP4K4 is overexpressed in the cerebellar tumor tissue. Interestingly, high MAP4K4 mRNA 
expressoin was also detected in glioma, which confirms the high brain tumor-specifc MAP4K4 expression 
levels noted a while ago (Wright, Wang et al. 2003). Although the MAP4K4 expression in tissue-infiltrating 
cells of Ptch-p53null MB indicated the potential contribution of MAP4K4 to tumor cell invasion, functional 
analysis will be necessary to clarify the potential impact of MAP4K4 on tissue infiltration. The increased 
MAP4K4 expression in at least 30% of the 68 human MB tissue samples analyzed indicates the potential 
diagnostic relevance of MAP4K4 for the clinic. However, to use anti-MAP4K4 IHC analysis indeed as a 
diagnostic tool, the biological significance of MAP4K4 function in MB pathogenesis and its association with 
clinical parameters needs to be clarified.  
 
5.2 Generation of tools to study MAP4K4 function 
 
MAP4K4 functions were linked to cytoskeletal rearrangements, cell shape and migration control, cell 
transformation and metastasis in neurons (Teuliere, Gally et al. 2011), adenocarcinoma cells (Baumgartner, 
Sillman et al. 2006), glioma (Loftus, Yang et al. 2013), epithelial (Lewellyn, Cetera et al. 2013) and 
endothelial cells (Haas, Bala et al. 2013), keratinocytes (Haas, Bala et al. 2013) and macrophages (Ma and 
Baumgartner 2014). To define MAP4K4 functions in Medulloblastoma cells, we initially reduced MAP4K4 
expression using different stable and transient RNA interference methods.  
Interference with siRNA led to our initial observations that MAP4K4 promotes MB cell motility. 
However, since siRNA effects are temporary and may confer ‘’off target’ effects, I proceeded towards the 
generation of stable cell lines with doxycycline-inducible expression of short hairpin RNA targeting MAP4K4. 
The use of these cell lines obviously offered significant advantages in terms of the duration of the effects, 
however downregulation using shRNA still resulted in only a partial downregulatoin of MAP4K4 (knock-down) 
and certain levels of kinase activity were still maintained.  
Therefore, to completely abrogate MAP4K4 functions I next established the CRISPR/Cas9 (clustered 
regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) system for MAP4K4 in MB. 
The CRISPR/Cas9 system was introduced into mammalian organisms four years ago (Cong, Ran et al. 
2013) and has become an effective tool for various genome editing purposes. CRISPR/Cas9 system can 
induce both gain- and loss-of-function mutations, and it causes less off-target effects than conventional RNAi 
methods. Although we observed a more complete reduction of MAP4K4 protein expression in 




CRISPR/CAS9-targeted MAP4K4 MB cells, residual MAP4K4 was still detected, which may be the 
consequence of mono-allelic knock-down of MAP4K4 only.  
As an alternative approach to the genetic depletion of MAP4K4, I also used stable ectopic 
overexpression of a kinase-inactive MAP4K4 (MAP4K4-K/D) mutant. To explore the effect of increasing 
MAP4K4 expression, I also established stable MB cell lines overexpressing MAP4K4. The stable lines 
expressed MAP4K4 at a level approximately 5-fold higher than the endogenous kinase. Although MAP4K4-
K/D expression phenocopied some of the effects such as decreased endocytic up-take, it was unable to act 
as a dominant-negative on others (HGF-induced collagen invasion). This discrepancy could be due to a 
kinase-independent scaffolding function of MAP4K4 for migration control or due to ineffective competition 
with the endogenous MAP4K4 molecules. Interestingly, ectopic expression of MAP4K4-wt resulted in 
increased basal dissemination levels, similar to those observed after HGF stimulation. This indicates that 
increasing MAP4K4 abundance above endogenous levels causes growth factor-independent activation of 
pro-migratory signaling and identifies MAP4K4 as a putative oncogene in Medulloblastoma. 
We also compared effects of MAP4K4 depletion to the pharmacological inhibition of MAP4K4 using 
C29, an experimental ATP-competitive MAP4K4 inhibitor developed by Genentech. In most assays, 
pharmacological inactivation of MAP4K4 using C29 produced more pronounced effects than the genetic 
depletion approaches. This may be in part due to the only partial efficacy of the targeting approaches. 
Nevertheless, off-target effects of C29 towards other kinases such as for example Mink1 cannot be excluded 
(Crawford, Ndubaku et al. 2014). 
 
5.3 MAP4K4 promotes MB cell motility 
 
Others and our group have revealed a striking association of c-Met receptor expression with the SHH 
MB subgroup (Onvani, Terakawa et al. 2012; Ramaswamy, Remke et al. 2013). Our group also detected 
increased c-Met expression in DAOY and UW228 cells, which are considered SHH-like MB cell lines 
(Onvani, Terakawa et al. 2012; Gotschel, Berg et al. 2013) and which are the main cell model of the present 
study.  
Cell motility and invasion experiments in our group had previously established the functional relevance 
of HGF-c-Met signaling as promoter of MB single cell migration on flat surfaces and inside three-dimensional 
collagen matrix. These observations complied with previous findings that have reported HGF induction of 3D 
cell motility in ductal adenocarcinoma, human mammary fibroblasts as well as endometrial carcinoma (Park, 
Ryu et al. 2003; Doyle, Carvajal et al. 2015; Spina, De Pasquale et al. 2015). 
In an number of cell migration experiments, I found that depletion of MAP4K4 using either siRNA or 
shRNA prevented HGF-induced pro-invasive activities. One of these experiments was the cell scattering 
assay. HGF, or scatter factor, is characterized by its ability to promote cell scattering (Naldini, Weidner et al. 
1991). Cell scattering is a process defined by the detachment of single cells from epithelial cell colonies and 
their dispersion (scattering). The detached cells exhibit a motile phenotype, continue to migrate, leading thus 
to a ''scatter'' phenomenon. The scattering of epithelial cells confers characteristics of the EMT phenotype, 
such as the loss of epithelial cell-cell junctions and the acquisition of a motile mesenchymal phenotype. 
Hence, cell-scattering assays have been used for studying EMT phenotype, as well as for detecting factors 
able to induce migratory cell behavior. In the present study, we used the principle of the cell scattering assay, 
to confirm MAP4K4 involvement in HGF-induced MB cell motility regulation. In line with our previous findings, 
we noticed that induced MAP4K4 depletion markedly reduced cell scattering (Fig. 5 & E, manuscript 1). 
Although the mechanism targeted by MAP4K4 for HGF-induced cell scattering is not known yet, this finding 
confirms that MAP4K4 mediates HGF-c-Met signaling and leads to increased MB cell migration in 2D in 
response to HGF, which consists one of the novel findings of the present study. Other RTKs can also 
activate MAP4K4 and trigger cell migration (Yao, Zhou et al. 1999; Yan, Nehrke et al. 2001; Baumgartner, 
Sillman et al. 2006). Consistent with the possibility that MAP4K4 acts downstream of activated RTKs, we 
found that MAP4K4 is mediating pro-migratory signaling downstream of EGF, IGF and bFGF (Fig. 2E, 
manuscript 2), which we all found to trigger migration and collagen invasion in MB (Kumar, Pillong et al. 
2015). However, since MAP4K4-depletion using shRNA only partially blocked bFGF-induced migration, it is 




highly likely that in MB cells MAP4K4-dependent and –independent pathways donwstream of RTKs are 
engaged for migration control and that the relative contribution may depend on the RTK and its immediate 
downstream effectors.  
 
Cell migration is a complex and dynamic process and is required for a number of basic cellular 
functions, such as morphogenesis, tissue regeneration, and cancer progression. Our study on MB cell 
migration in collagen gels demonstrated that MB cells migrate in the mesenchymal mode (Fig. 6, manuscript 
1; Fig. S2 (Kumar, Pillong et al. 2015)). Unlike other cancer cells, we could so far not detected 
rounded/amoeboid motility in MB. Although MAP4K4 ablation does not prevent mesenchymal cell 
morphology, it caused a marked reduction in F-actin in lamellipodia (Fig. 6, manuscript 2). Since these 
protrusions are necessary for effective movement of cells inside 3D matrices (Jacquemet, Hamidi et al. 
2015), we concluded that one function of MAP4K4 towards migration and invasion control is to facilitate their 
establishment. MAP4K4 can promote F-actin dynamics and lamellipodia formation by activating the Arp2/3 
complex (LeClaire, Rana et al. 2015) and proteins of the Ezrin, Radixin, Moesin family (Baumgartner, Sillman 
et al. 2006; Vitorino, Yeung et al. 2015). To initiate tumor cell motility, MB cells interact with typical 
components of the leptomeningeal extracellular matrix (ECM), such as fibronectin, collagen I and collagen IV 
(Wikstrand, Friedman et al. 1991; Liang, Diehn et al. 2008). Thus, it is also conceivable that the accelerated 
turnover of β1 integrin-mediated focal adhesions triggered by MAP4K4 recently reported (Yue and Wu 2014; 
Vitorino, Yeung et al. 2015) is necessary for MB cell invasion. Consistently, using an antibody raised against 
activated β1 integrin, we observed increased levels of activated β1 integrin in lamellipodia of HGF-stimulated 
MB cells invading collagen matrix compared to unstimulated control cells. In sgMAP4K4 cells, this increase 
was ablated, suggesting that MAP4K4 controls β1 integrin activation in a spatially controlled manner. 
However, it will need to be determined whether decreased integrin activation in the absence of MAP4K4 is 
the consequence of altered turnover as reported by Yue et al. and Vitorino et al. (Yue and Wu 2014; Vitorino, 
Yeung et al. 2015).  
Taken together, our migration and invasion analyis indicates that the phenomenon of early, rapid and 
extensive CNS dissemination of MB (Wikstrand, Friedman et al. 1991; Fiorilli, Partridge et al. 2008; Nalla, 
Asuthkar et al. 2010) could be mediated – at least in part - by MAP4K4 stimulation of promigratory cell 
functions. Our study furthermore indicates that these could involve - besides the activation of F-actin 
dynamics reported previously – the accelerated turnover and concomittant activation of RTKs and integrin 
receptors. Serous chemoattractants, which can abundantly be found within CSF or blood plasma (Rubin, 
Kung et al. 2003; Dudu, Able et al. 2012) are likely to positively influence the migratory capabilities of the MB 




5.4 MAP4K4 promotes irradiation-induced cell migration 
 
Apart from the intrinsic promoters of cell migration, treatment-related factors such as photon ionizing 
radiation (IR), have also been reported to increase MB tumor cell motility. IR has been found to enhance cell 
migration in sarcoma (Ogata, Teshima et al. 2005), colorectal cancer (Goetze, Scholz et al. 2007), and 
glioma (Wild-Bode, Weller et al. 2001). In medulloblastoma, preclinical studies have demonstrated increased 
tumor cell invasiveness through upregulation of urokinase plasminogen activator receptor (uPAR) signaling 
(Nalla, Asuthkar et al. 2010; Asuthkar, Gondi et al. 2012). In D283 and UW228 medulloblastoma cells, single 
photon doses of 6 Gy promoted uPAR-dependent Wnt/β-catenin-signaling and consequently increased the 
neurosphere-forming ability (Asuthkar, Gondi et al. 2012). Moreover, single photon doses of 7 Gy induced 
expression of α3 , α5 and β1 integrins, leading to enhanced wound healing migration in D283 and DAOY 
cells (Nalla, Asuthkar et al. 2010). To date, little data has focused on dose-dependent alterations in 
medulloblastoma cell motility, and none has addressed the potential impact of carbon ion IR. 
Since IR contribution to MB cell dissemination remained controversial, we determined IR effects on 
migration and invasion in DAOY and UW228 MB cell lines. Somewhat counterintuitively, we found that IR 




indeed mediated cell migration in both cell lines. More importantly, this effect was prominent in low IR 
dosages such as 1 - 2 Gy, which corresponds to a single therapeutic radiation dose. Since we had identified 
MAP4K4 as a critical molecule in MB cell motility regulation, we proceeded to explore its implication in IR-
induced cell migration in MB. Therefore we irradiated control as well as MAP4K4-depleted cells and 
compared the resultant dissemination levels. Interestingly, MAP4K4 decreased IR-induced cell dissemination 
levels in both cell lines, not only in untreated but also HGF-stimulated cells, suggesting that MAP4K4 is a key 
regulator of IR-induced cell motility. Taken together, the above findings underscore the relevance of MAP4K4 
in the context of MB cell dissemination.  
The main mechanism through which conventional radiation therapy targets cancer cells is DNA 
damage, including DNA dimers, oxidative base damage, intra- and inter-strand crosslinks, and single and 
double-strand breaks (DSBs). In order to repair the DNA damage, a cell has developed mechanisms for DNA 
damage sensing, that activate signal transduction pathways, which in turn orchestrate multiple cellular 
functions for successful damage repair (Wilson 2004). The finding that irradiation causes an increased 
migratory behavior suggests that besides DNA damage, other activating alterations may occur. More 
specifically, considering that MAP4K4 promoted IR-induced MB cell migration upon irradiation, one possible 
explanation could be that irradiation results in DNA alterations that increase the expression and/or secretion 
of HGF. This could cause increased c-Met signaling whereupon MAP4K4 could mediate cell migration. 
However, we could not detect increased HGF secretion after irradiation nor any alterations in the expression 
of c-Met or integrins (data not shown). Therefore, further experiments to test HGF expression and function in 
irradiated versus non-irradiated cells are required to clarify the mechanisms underlying MAP4K4 control of 
IR-iduced migration in MB.  
Cumulatively, the above observations corroborate previous results that had reported increased MB 
dissemination after irradiation (Nalla, Asuthkar et al. 2010) and seed the soil for questions regarding the 
potential objectionable effects on the clinical applications of craniospinal irradiation in Medulloblastoma. Our 
identification of MAP4K4 as a putative regulator of IR-induced cell migration further highlight its significance 
as a therapeutic target.  
 
5.5 Unravelling the mechanisms of MAP4K4-mediated functions 
 
Numerous studies have described MAP4K4 role in development (Su, Treisman et al. 1998; Xue, Wang 
et al. 2001), insulin sensitivity (Su, Treisman et al. 1998; Xue, Wang et al. 2001), systemic inflammation 
(Aouadi, Tesz et al. 2009), pathogen-dependent oncogenic progression (Haas, Bala et al. 2013; Ma and 
Baumgartner 2014), vascular inflammation (Flach, Skoura et al. 2015) and cancer (Badea, Herlea et al. 
2008; Liang, Wang et al. 2008; Hao, Chen et al. 2010; Liu, Cai et al. 2011; Qiu, Qian et al. 2012). However, 
the mechanisms as well as the signaling cascades that involve MAP4K4 during Medulloblastoma 
progression still remain unclear. 
Towards the elucidation of the molecular mechanisms through which MAP4K4 exerts its functions in 
Medulloblastoma, we were initially based on our observations regarding the phenotype of MB cells 
overexpressiong MAP4K4 wt or K/D mutant. In particular, we noticed that the cells overexpressing MAP4K4 
wt presented increased cortical F-actin turnover compared to the cells overexpressing the MAP4K4 K/D. 
Moreover, the rate of vesicle trafficking as well as the number of the recycled vesicles in the MAP4K4 wt 
cells appeared to be markedly increased (Fig. 27 & Fig. 5C manuscript 1). Therefore, we concluded that 
MAP4K4 overexpression coincides with increased cortical F-actin turnover and increased vesicle trafficking. 
Hence we hypothesized that MAP4K4 could be involved in the regulation of F-actin dependent endocytic 
processes such as macropinocytosis (Commisso, Davidson et al. 2013). 
 
5.5.1 Regulation of endocytosis 
 
To test this hypothesis we subsequently proceeded on testing the capability of MB cells to internalize 
large Dextran paricles (70 kDa Dextran – an established marker of macropinocytosis (Nakase, Hirose et al. 
2009) upon pharmacological or genetic blockage of MAP4K4. Since macropinocytosis is generally 




considered as a growth factor-dependent process (Haigler, Mckanna et al. 1979; Racoosin and Swanson 
1989), we stimulated the cells with HGF. We found that the internalization of large dextran particles was 
decreased in MB cells with impaired MAP4K4 function, thus confirming our hypothesis that MAP4K4 is 
involved in the regulation of macropinocytosis. 
Endocytic pathways including macropinocytosis have been linked in many studies to cell migration 
(Hattula, Furuhjelm et al. 2006; Beaumont, Hamilton et al. 2011; Rainero, Caswell et al. 2012; Nguyen, 
Grimm et al. 2017). Endocytosis plays key role during cell polarization, EMT transition and the formation of 
pro-migrating protrusions such as invadopodia and filopodia (Caswell, Spence et al. 2007; Poincloux, 
Lizarraga et al. 2009). One mechanism by which endocytosis controls cell migration is by trafficking 
adhesion molecules such as integrins, which is associated with the formation, turnover and recycling of focal 
adhesions and cell migration (reviewed in chapter 1.5.8 and 1.6.5).  
 
5.5.2 Integrin turnover 
 
Interestingly, MAP4K4 was also found to indirectly promote focal adhesion disassembly and integrin 
internalization (Yue and Wu 2014). Its D. meanogaster homologue (Misshapen) was identified as a key 
player during the morphogenesis of the Drosophila egg chamber by decreasing integrin levels at the basal 
surface, which facilitated detachment of each cell’s trailing edge thus promoting migration (Lewellyn, Cetera 
et al. 2013). Yet another mechanism of MAP4K4-mediated focal adhesion disassembly was identified by 
Vitorino and colleagues, who showed that MAP4K4-ERM function in endothelial cells causes focal adhesion 
destablilization, which is necessary for efficient plasma membrane retraction during endothelial cell migration 
(Vitorino, Yeung et al. 2015).  
We selected to study beta 1 integrin, not only because it was recently associated wih MAP4K4, but 
also because the dimers α2β1 and α1β1 consist the main receptors for type 1 collagen (Jokinen, Dadu et al. 
2004), implying a crucial role for beta 1 integrin during cell invasion in collagen I, which has been used for 
the 3D cell motility assays and the integrin replating assays. We found that MAP4K4 depletion or inhibition 
with C29 caused reduced accumulation of activated integrin β1 on endosomes in 2D. Similar results were 
acquired upon endocytosis inhibition using Dyngo 4a, suggesting that MAP4K4 capability to promote integrin 
internalization and signaling on endosomes depends on endocytosis. Integrins can transmit signals from 
endosomal locations during internalization, which promotes FAK phosphorylation and anoikis resistance, 
anchorage-independence and metastasis (Alanko, Mai et al. 2015). The same study reported MAP4K4 as a 
putative regulator of integrin β1 on endosomal membranes, suggesting that endosomes act as platforms that 
support integrin signaling away from the plasma membrane. Our data on MAP4K4 mediated activation of 
integrins in endosomal compartments adds additional functional relevance to the proposed model of 
endosomal signaling. Consistent with a regulatory role of MAP4K4, we also detected reduced FAK 
phosphorylation in MAP4K4-depleted cells migrating inside collagen gels, further corroborating the critical 
role of MAP4K4 for functional integrin signaling during migration and invasion.  
Interestingly, integrin activation consists a crucial factor for effcient 3D cell migration in collagen 
matrices (Mierke, Frey et al. 2010; Doyle, Carvajal et al. 2015). Using both an siRNA-mediated depletion 
approach and β1 integrin blocking antibody, we deomonstrate that β1 integrin function is essential for HGF-
induced migration and invasion of MB cells in collagen as well. Hence, we subsequently attempted to test 
whether MAP4K4, being a mediator of β1 integrin turnover, would affect integrin activation in 3D. 
Remarkably, stimulation of collagen-embedded DAOY cells with HGF led to the accumulation of activated β1 
integrin in cellular structures necessary for invasion (Fig. 5B, manuscript 2).  
During tumor cell migration in 3D microenvironments, activated α5β1 recycling promotes the extension 
of invasive pseudopodial structures, leading to increased invasiveness of the type associated with metastatic 
cancers (Caswell and Norman 2008; Muller, Caswell et al. 2009). Moreover, HGF and integrin cascades 
cooperate synergistically to induce FAK activation in an adhesion-dependent manner, leading to enhanced 
cell adhesion and motility (Beviglia and Kramer 1999). In our 3D assays we noticed the accumulation of 
activated β1 integrin in cellular migrating protrusions especially upon HGF stimulation. However, this 
phenotype was abbrogated upon MAP4K4 depletion using the CRISPR/Cas9 system (Fig. 5B, manuscript 
2), indicating that MAP4K4-dependent invasion in collagen relies on its ability to spatially coordinate 




activated β1 integrin. MAP4K4 appears to affect downstream integrin signaling as well, since immunoblot 
analysis revealed lower phopspho FAK (Tyr 397) levels in MAP4K4 depleted cells (Fig. 5E, manuscript 2). 
Furthermore, this finding corroborates the findings from Alanko and colleagues supporting that active FAK 
(Tyr 397) on endosomes results from integrin-ECM downstream signaling (Alanko, Mai et al. 2015).  
 
5.5.3 c-Met turnover 
 
Endosomes serve as signaling platforms not only for integrins but also for RTKs including c-Met 
(Masui, Castro et al. 1993). In fact, HGF stimulation can lead to clathrin-dependent internalization of c-Met, 
which leads to c-Met signaling form endosomal compartments and subsequent HGF-induced cell migration 
(Kermorgant and Scourzic 2005; Kermorgant and Parker 2005). c-Met has been shown to undergo Cbl–
Grb2-dependent recycling causing thus aberrant activation of GTPase Rac1 and enhancing cell migration, 
anchorage-independent cell growth and in vivo tumorigenesis (Joffre, Barrow et al. 2011). Moreover, the 
integrin binding partner, RCP, was identified as a promoter of c-Met recycling in cells expressing oncogenic 
mutant p53 (Muller, Caswell et al. 2009). Depletion of RCP in mutant p53-expressing cells decreased the 
recycling of c-Met back to the plasma membrane, thereby attenuating ERK1/2 signaling and decreasing cell 
invasion and cell scattering. Moreover, in invasive, basal-like human breast cancer cell models, c-Met 
sustains Rac1 signaling, triggers membrane ruffling, cell migration and invasion (Menard, Parker et al. 2014). 
These data suggest that the imbalance between recycling and degradation in favour of continuous 
endosomal c-Met trafficking contributes to the maintenance of the activated state of c-Met, leading to pro-
malignant signaling. 
Based on the above observations, and since we have demonstrated that MAP4K4 promotes HGF-
induced cell dissemination, we hypothesized that MAP4K4 mediates MB cell migration and invasion by 
promoting actin dynamics and turnover of c-Met receptors. We found that c-Met activation is impaired upon 
endocytosis inhibition and that MAP4K4 depletion phenocopies the reduced HGF-induced c-Met activation 
and phosphorylation of further downstream targets, suggesting that MAP4K4 mediates c-Met activation 
through endocytosis. These findings confirm previous observations pointing endocytosis as a mechanism of 




In summary, the findings provided in the present doctoral thesis emphasize MAP4K4 role in the 
regulation of Medulloblastoma dissemination. We provide evidence supporting MAP4K4 upregulated 
expression in Medulloblastoma tumors as well as its positive role towards Medulloblastoma dissemination. 
MAP4K4 controls actin dynamics and cytoskeletal rearrangements and facilitates cell migration. Additionally, 
MAP4K4 pro-migratory function was observed in response to IR, suggesting a potential contribution of 
MAP4K4 to IR-resistance of Medulloblastoma cells. Mechanistically, our data support a novel role for 
MAP4K4, whereby its control of cell migration is attributed to its function to regulate receptor endocytic 
turnover.  
We propose a model whereby MAP4K4 upregulated expression enhances integrin signaling and RTK 
endocytic turnover. Endocytosed receptors will subsequently increase the activation of downstream targets 
which will eventually lead to enhanced cell dissemination. Increased dissemination levels could be caused 
on the one hand due to the increased integrin turnover that is responsible for FA disassembly and the 
generation of new FAs towards the leading edge. On the other hand increased integrin endosomal signaling 
provides enhanced survival and proliferative capabilities which allow such disseminating tumor cells to grow 
in new, foreign microenvironments. Importantly, it has been shown that aberrant recycling, activation and/or 
cell surface presentation of integrins can markedly alter the invasive behaviour of cancer cells. For instance, 
ανβ6 integrin increased recycling has been shown to promote oral cancer progression (Ramsay, Keppler et 
al. 2007). Furthermore, it has been demonstrated that inhibition of ανβ3 integrin promotes invasive cell 
migration by enhancing endosomal recycling of α5β1 integrin under the control of the Rab11 effector Rab 
coupling protein (RCP) (Rainero, Caswell et al. 2012). Interestingly, aberrant integrin signaling has also been 




associated with mutated p53 expression. It is generally known that mutant p53 expression can promote 
invasion, loss of directionality of migration, and metastatic behavior (Vogelstein, Lane et al. 2000). Notably, 
these activities of p53 reflect enhanced integrin and epidermal growth factor receptor (EGFR) trafficking, 
which depends on Rab-coupling protein (RCP) and results in constitutive activation of EGFR/integrin 
signaling.  
Another aspect of MAP4K4-mediated pro-invasive aspects includes the endocytosis of c-Met. Our 
findings suggest that MAP4K4 could mediate HGF-induced cell motility through the constant endocytosis of 
c-Met receptor. Aberrant c-Met endocytosis and recycling has been identified as a pro-invasive mechanism 
(Joffre, Barrow et al. 2011). Therefore, although further experiments need to be performed in order to list the 
endocytic pathways that are dependent on MAP4K4, our data suggest its role as a promoter of endocytosis 
and that this function is able to elicit a migratory behavior of cancer cells. This migratory behavior can be 
generated through the formation of actin-rich migratory cell protrusions at the leading edge of the migrating 
cells and contribute to the penetration of 3D matrices.  
Furthermore, this endocytosis-associated pro-migratory function of MAP4K4 could be responsible for 
the abovely described IR-induced MB cell dissemination, either through increased integrin expression and 
endosomal signaling, or upregulated c-Met recycling, though further experiments will be needed to address 
this hypothesis. 
Cumulatively, in the present study we introduce MAP4K4 regulatory role in membrane receptor 
turnover as a prominent cause of Medulloblastoma cell infiltration. MAP4K4 can be pharmacologically 
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Σὰ βγεῖς στὸν πηγαιµὸ γιὰ τὴν Ἰθάκη, 
νὰ εὔχεσαι νά ῾ναι µακρὺς ὁ δρόµος, 
γεµάτος περιπέτειες, γεµάτος γνώσεις. 
  
Τοὺς Λαιστρυγόνας καὶ τοὺς Κύκλωπας, 
τὸν θυµωµένο Ποσειδῶνα µὴ φοβᾶσαι, 
τέτοια στὸν δρόµο σου ποτέ σου δὲν θὰ βρεῖς, 
ἂν µέν᾿ ἡ σκέψις σου ὑψηλή, ἂν ἐκλεκτὴ 
συγκίνησις τὸ πνεῦµα καὶ τὸ σῶµα σου ἀγγίζει. 
  
Τοὺς Λαιστρυγόνας καὶ τοὺς Κύκλωπας, 
τὸν ἄγριο Ποσειδῶνα δὲν θὰ συναντήσεις, 
ἂν δὲν τοὺς κουβανεῖς µὲς στὴν ψυχή σου, 
ἂν ἡ ψυχή σου δὲν τοὺς στήνει ἐµπρός σου. 
  
Νὰ εὔχεσαι νά ῾ναι µακρὺς ὁ δρόµος. 
Πολλὰ τὰ καλοκαιρινὰ πρωινὰ νὰ εἶναι 
ποῦ µὲ τί εὐχαρίστηση, µὲ τί χαρὰ 
θὰ µπαίνεις σὲ λιµένας πρωτοειδωµένους. 
  
Νὰ σταµατήσεις σ᾿ ἐµπορεῖα Φοινικικά, 
καὶ τὲς καλὲς πραγµάτειες ν᾿ ἀποκτήσεις, 
σεντέφια καὶ κοράλλια, κεχριµπάρια κ᾿ ἔβενους, 
καὶ ἡδονικὰ µυρωδικὰ κάθε λογῆς, 
ὅσο µπορεῖς πιὸ ἄφθονα ἡδονικὰ µυρωδικά. 
  
Σὲ πόλεις Αἰγυπτιακὲς πολλὲς νὰ πᾷς, 
νὰ µάθεις καὶ νὰ µάθεις ἀπ᾿ τοὺς σπουδασµένους. 
Πάντα στὸ νοῦ σου νά ῾χεις τὴν Ἰθάκη. 
Τὸ φθάσιµον ἐκεῖ εἶν᾿ ὁ προορισµός σου. 
  
Ἀλλὰ µὴ βιάζεις τὸ ταξίδι διόλου. 
Καλλίτερα χρόνια πολλὰ νὰ διαρκέσει. 
Καὶ γέρος πιὰ ν᾿ ἀράξεις στὸ νησί, 
πλούσιος µὲ ὅσα κέρδισες στὸν δρόµο, 
µὴ προσδοκώντας πλούτη νὰ σὲ δώσει ἡ Ἰθάκη. 
  
Ἡ Ἰθάκη σ᾿ ἔδωσε τ᾿ ὡραῖο ταξίδι. 
Χωρὶς αὐτὴν δὲν θά ῾βγαινες στὸν δρόµο. 
Ἄλλα δὲν ἔχει νὰ σὲ δώσει πιά. 
  
Κι ἂν πτωχικὴ τὴν βρεῖς, ἡ Ἰθάκη δὲν σὲ γέλασε. 
Ἔτσι σοφὸς ποὺ ἔγινες, µὲ τόση πεῖρα, 
ἤδη θὰ τὸ κατάλαβες οἱ Ἰθάκες τὶ σηµαίνουν. 
 























Once you set out for Ithaka 
hope your road to be long, 
full of adventures, full of knowledge. 
  
Don't be afraid of the Laistrygonians and the Cyclops, 
the angry Poseidon 
you'll never find them on your way 
if you keep your thoughts high, 
if rare excitement touches your spirit and your body. 
  
You won't meet the Laistrygonians and the Cyclops, 
the wild Poseidon 
unless you bring them along inside your soul, 
unless your soul puts them in front of you. 
  
Hope your road to be long 
may there be many summer mornings 
when you'll enter with pleasure, with joy, 
the harbours you've seen for the first time 
  
Stop in Phoenician trading stations 
and get the good wares 
pearls and corals, ambers and ebony, 
and sensual herbs of every kind 
as many sensual herbs as you can 
  
Go to many Egyptian cities 
to study and learn from the educated ones 
keep Ithaka always in your mind 
your arrival there is your destiny 
  
But don't rush the journey at all 
it better lasts for many years, 
and then when you're old to stay on the island, 
wealthy with all you've gained on the way 
without expecting Ithaka to make you rich. 
  
Ithaka gave you the beautiful journey. 
without her you wouldn't have set out 
there's nothing else to give you anymore 
  
And if you find her poor, Ithaka hasn't fooled you. 
now that you became wise with so much experience 
you should have already understood what Ithakas mean 
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  Professional	  working	  proficiency	  
French:	  Limited	  working	  proficiency	  




§ The	  Ser/Thr	  Kinase	  MAP4K4	  Controls	  Pro-­‐Metastatic	  Cell	  Functions.	  
0789415629	  •	  dimitratripol@gmail.com	  •	  www.linkedin.com/in/dimitra-­‐tripolitsioti	  
 
3	  
Dimitra	  Tripolitsioti,	  Michael	  A	  Grotzer,	  Martin	  Baumgartner	  (Carcinogenesis	  &	  
Mutagenesis,	  in	  press).	  
§ A	  novel	  approach	  to	  investigate	  cellular	  and	  molecular	  determinants	  of	  
brain	  tissue	  infiltration	  in	  medulloblastoma.	  
Anuja	  Neve,	  Karthiga	  Santhana	  Kumar,	  Dimitra	  Tripolitsioti,	  Michael	  A	  Grotzer,	  Martin	  
Baumgartner	  (Scientific	  Reports,	  Nature	  Publishing	  Group,	  in	  press).	  
§ The	  Ser/Thr	  kinase	  MAP4K4	  drives	  c-­‐Met-­‐induced	  motility	  and	  
invasiveness	  in	  a	  cell-­‐based	  model	  of	  SHH	  medulloblastoma.	  
Karthiga	  Santhana	  Kumar,	  Dimitra	  Tripolitsioti,	  Min	  Ma,	  Jasmin	  Grählert,	  Katja	  B	  Egli,	  




§ EMBO,	  2016	  in	  Cavtat,	  Croatia	  	  




Oral	  Presentations:	  	  
§ Jan	  2017,	  Jan	  2015:	  Cytomeet,	  Bern,	  Switzerland	   	  
§ May	  2016,	  Nov	  2014:	  Kolloquium	  of	  applied	  cancer	  research,	  Zürich,	  
Switzerland	  
Poster	  Presentations:	  	  
§ Jan	  2017,	  Jan	  2015:	  C.B.	  Brupbacher	  symposium,	  Zürich,	  Switzerland	  




§ Travel	  Grant	  from	  the	  Molecular	  Life	  Sciences	  PhD	  program	  for	  EMBO	  
2016,	  700	  CHF	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